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CHAPTER 1 — INTRODUCTION 
1.1 Overviews and Objectives     
Cancer is one of the most deadly disease in both men and women throughout the US.[1, 2]  
An estimated 1.7 million new cases will be diagnosed in 2014, and 600 thousand patients are 
expected to die of cancer.[1, 2]  Among many malignant tumors, lung cancer is of great relevance 
as it is the leading cause of cancer death. Lung cancers cause more death cases than three most 
common cancers combined (prostate, breast and colon) (cases of death: 160,340 in 2012, 159,480 
in 2013).[1, 2]  Lung cancer is mainly divided into two groups: non-small cell lung cancer 
(NSCLC, 85-90%) and small cell lung cancer (SCLC, 10-15%) [3].  The largest type in NSCLC 
is adenocarcinoma (50-60%) which is pulmonary neoplasia of epithelial tissues that contains 
glandular origin and glandular characteristics.[4]  Common treatments of lung cancer include 
surgery, chemotherapy, radiotherapy and all combined.  Because of the challenges in early 
detection of lung cancer, it is usually diagnosed at later stages of the disease, and thus only a small 
number of patients are eligible for surgery.  Even in those cases where surgery is possible, the rate 
of recurrence is high.  Due to most of lung cancers are metastatic, surgical treatment in patients 
with metastatic lung cancer is also not usually recommended due to the generally poor respiratory 
and overall clinical profile of the patients.  Therefore, chemotherapy is widely used against primary 
and secondary lung cancers.  However, chemotherapeutic strategies have done limited roles to 
improve therapeutic outcomes for patients with lung cancer, who have a 5 year survival rate after 
initial prognosis of only 16.6%.[5]  One major challenge is the low concentration (2-4% of initial 
dose) of chemotherapeutics found in the lung cancer spots upon i.v. administration.[6-8]  Dose 
limiting toxicity for chemotherapeutics also limits lung cancer treatment.[9]  This problem is 
complicated as high i.v. dosages are usually required due the poor distribution profile of anti-
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cancer therapeutics to the lung tumor.[8]  Drug delivery systems of combined chemotherapeutics 
are promising means to overcome most of issues above such as targeted delivery of chemotherapy 
agents, dose level increase in neoplastic lesion, sustained drug release and protection of attached 
cargo from metabolism.[10-18]   
Chemotherapy agent, such as doxorubicin (DOX), plays a vital role in cancer treatment.  It 
is also used in conjunction with other treatments such as surgery, radiation therapy and 
hyperthermia therapy.[19]  However, hydrophobic nature of most of chemotherapy agents result 
in limited aqueous solubility and rapid elimination from blood circulation.  Common 
administration route of chemotherapeutics is intravenous injection which non-specificially 
distributes DOX to whole body.  Systemic distribution, however, does not just significantly reduce 
local concentration level at lesion, but damage healthy tissues.[20, 21]  The accumulation of DOX 
in the heart results in increased oxidative stress, down-regulated protein function, decreased 
cardiac gene expression, and up-regulated apoptosis of cardiomyocytes, which eventually leads to 
lethal cardiomyopathy.[22]  Synthetic polymeric nanocarriers (PNCs) have been widely used and 
validated in anticancer therapeutics delivery, since PNCs are able to protect its cargos from 
enzymatic degradation, improve pharmacokinetics/pharmacodynamics of therapeutics, promote 
sustainable drug release and reduce cytotoxicity to healthy tissues.[23-26]  Among these PNCs, 
dendrimer nanocarriers (DNCs) as drug vehicles or scaffolds is one of the most promising frontiers 
in designing anticancer therapeutics delivery system.[27]  In addition to those general strengths of 
PNCs, hyperbranched polyamidoamine (PAMAM) dendrimer has its own featured advantages as 
anticancer therapeutics carrier:[28, 29] (i) good water solubility that enhances water solubility of 
hydrophobic anticancer drugs and peptides; (ii) monodispersity and predictable molecular weight 
that ensures consistent pharmacokinetics and pharmacodynamics; (iii) high density of reactive 
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surface groups on dendrimer that empowers dendrimer to enhance therapeutics payload and carry 
diverse chemical moieties for different purposes at one time;[30-32] (iv) high membrane-
penetrating potential that enhances the paracellular transport and intracellular uptake of anticancer 
therapeutics.[33, 34]  
Lungs have a few advantages over invasive and other non-invasive administration routes: 
(i) large surface area. It is estimated that there are 300 million of alveolar cells in human lungs, 
which thus leads to 80-90 m2 surface area for gas exchange in lungs.[35]  Alveolar sacs consist of 
only one epithelial monolayer, thus facilitating the rapid translocation of molecules from lungs to 
systemic circulation; (ii) reduced enzymatic degradation.  Some drugs (e.g. imipramine,[36] 
propranolol,[37] and midazolam[38]) can be inactivated by first-pass metabolism which occurs in 
digestive system and liver.  Drug delivery to lungs is one of alternative routes of medication 
administration that avoids first-pass effect; (iii) high local concentration.  Drug delivery to the 
lungs is especially promising in treating pulmonary disorders such as lung cancer, chronic 
obstructive pulmonary disease (COPD), and cystic fibrosis (CF), since high local drug 
concentration, rapid therapeutics action and minimization of systemic adsorption allowing for 
decreased side effects.  Therefore, oral inhalation (OI), an attractive non-invasive route of 
delivering small molecules and macromolecular therapeutics, has drawn more and more attention 
as it can reach different pulmonary regions and even systemic tissues.[39, 40]  Nebulizers, 
pressurized metered-dose inhalers (pMDIs), and dry powder inhalers (DPIs) are three major 
categories.[41, 42]  pMDIs are a well-developed aerosol technology and widely accepted by 
patients due to its portability, straightforwardness in use and enhanced lung deposition of inhaled 
therapeutics.  pMDIs consist of 60% aerosol products in market.   However, most of drugs are not 
soluble in propellant-based pMDIs.  The surfactants and/or co-solvents are required to disperse 
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small drugs.  The difficulty in the development of the surfactants restricts the application of pMDIs.  
Additionally, environmentally unfriendly propellant also limits the use of pMDIs to some 
extent.[43]  
Based on the challenges and opportunities discussed earlier, we propose strategies for 
treating lung cancers to (i) design polymer-bound DOX conjugates to promote spatial and temporal 
release—thus decreasing the plasma concentration of free DOX; (ii) modulate the transport of 
DOX across pulmonary epithelium with nanocarrier surface chemistry manipulation; (iii) enhance 
the local concentration of DOX in lung tumors upon pulmonary administration, potentially 
improving therapeutic efficacy and decreasing systemic exposure of DOX; (iv) develop oral 
inhalation (OI) formulations (pMDIs) for the local delivery to the lung tissue.  Such strategies are 
expected to improve the survival rate and quality of life of the ca. 225,000 people diagnosed with 
lung cancer per year.[2]   
Within the context, the objectives of this dissertation are:  
Objective #1. Investigate effect of PEGylation and route of administration on systemic 
and lung regional biodistribution of dendrimer nanocarriers.  Chemotherapy is widely used 
in the fight against primary lung cancers and lung metastasis.[6, 44-46]  However, there are several 
limitations in using chemotherapeutics to treat lung cancers.  One major challenge is the low 
chemotherapeutic concentration found in the lung tumor upon intravenous (i.v.) administration.[6, 
7]  It is estimated that only a few percent (ca. 2-4%) of the total dose administered i.v. reaches the 
lung tumor.[8]  Dose limiting toxicity is another major issue in the chemotherapeutic treatment of 
lung cancers.[9]  This problem is compounded as high i.v. dosages are usually required due to the 
poor distribution profile of chemotherapeutics.[8]  Nanocarriers have the potential to improve the 
biodistribution and pharmacokinetic profiles of various therapeutics including anti-cancer 
5 
 
drugs.[47-50]  Dendrimers are particularly relevant nanocarrier systems as they have a large 
number of surface groups amenable to the conjugation of therapeutic molecules and other ligands 
that allow for different purposes.  Direct delivery of drug to the lungs has attracted much attention 
due to enhanced local drug concentration, fast drug action, and low enzymatic degradation in the 
lungs.  However, a few extracellular barriers that potentially decrease the efficiency of pulmonary 
delivery includes bifurcating airways, mucociliary escalator, and alveolar macrophage 
phagocytosis.  A  few studies have focused on the systemic biodistribution of nanocarriers upon 
pulmonary administration,[39] including gold nanoparticles,[51] PEGylated polylysine 
dendrimers,[52] PEGylated poly(ethylene imine),[53] diethylaminopropylamine-poly (vinyl 
alcohol)-poly (lactide-co-glycolide) copolymer [54] and polystyrene nanoparticles.[55]  
Meanwhile, PEGylation of PAMAM dendrimer on surface has shown to significantly prolong the 
residence of nanocarriers in blood circulation and potentially accumulate nanocarriers in solid 
tumors upon i.v. administration.  However, the systemic and local biodistribution of PAMAM 
dendrimer nanocarriers administered via pulmonary route is still unclear.  Therefore, the 
elucidation of systemic and lung regional biodistribution of PEGylated PAMAM dendrimers is the 
prerequisite of assessing pulmonary delivery as route of administration for lung cancers.  Bare 
PAMAM dendrimers and fully PEGylated dendrimers were synthesized and characterized.  The 
dendrimer nanocarriers were then delivered to the lungs via pulmonary route.  The 
pharmacokinetics and systemic biodistribution of both dendrimers were characterized by ex-vivo 
imaging and quantified by extracting PAMAM dendrimers from tissues.  Lung regional 
distribution in different cell populations were investigated by specific cell-tagged flow cytometry.  
As compared, the same dendrimers were injected intravenously to mice and the same experiments 
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are performed.  Detailed studies regarding the systemic and local biodistribution will be further 
described in the following chapters. 
Objective #2 Design PAMAM dendrimer conjugates with temporal and spatial 
release of doxorubicin for lung cancer treatment.  Doxorubicin (DOX) is one of the most 
effective anti-cancer therapeutics available in the clinic today for treating a variety of cancers 
including lung tumors.[56, 57]  The applicability of DOX is limited, however, partly due to its 
cardiac toxicity and myelosuppression.[21]  The free DOX in bloodstream that gradually 
accumulates in the heart results in increased oxidative stress, down-regulated protein function, 
decreased cardiac gene expression, and up-regulated apoptosis of cardiomyocytes, which 
eventually leads to lethal cardiomyopathy.[22]  To address this issue, we designed a nanocarrier-
based strategy to promote the maximization of intracellular delivery of DOX to lung tumor cells, 
and at the same time minimization of systemic exposure of DOX.  PAMAM dendrimers are 
particularly interesting nanocarrier drug delivery systems as they are highly monodispersed 
(predictable pharmacokinetics/biodistribution) and can be easily functionalized with therapeutic 
agents through linkages that allow for temporal and spatial control of drug release.  Therefore, 
DOX was conjugated to PAMAM dendrimers with a pH-responsive linker.  The linker is only 
cleavable at mild acidic environment (e.g. lysosomal pH), but stable at extracellular/physiological 
pH condition.  The DOX released in acidic subcellular compartments are then migrated to nuclei 
to inhibit nuclear DNA synthesis.  PEG was also attached to PAMAM-DOX conjugates to prolong 
the residence of the conjugate in blood circulation and improve biodistribution.  The potency of 
acid-labile PAMAM-DOX conjugates against lung tumors were tested on in vitro and in vivo 
models, respectively.  The details regarding the design of acid-labile PAMAM-DOX conjugates, 
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and studies of in vitro and in vivo potency of these conjugates against lung cancers were described 
in the following chapters.  
Objective #3: Develop pMDI formulations for non-invasive pulmonary delivery of 
acid-labile PAMAM-DOX conjugates.  Since OI has demonstrated its advantages over systemic 
administration in treating pulmonary disorders.  However, the use of pMDI formulations 
containing polymeric nanocarriers is still relatively unexploited mainly due to strong aggregation 
of PNCs in propellant.  To address the issue, co-solvents and/or surfactants are added to improve 
dispersibility of PNCs.  However, the less volatile/nonvolatile co-solvents and surfactants may 
reduce aerosol performance, although drug solubility can be improved.  We attached PEG chains 
to dendrimer-DOX on surface for improving the dispersibility of dendrimer conjugates in 
propellant-based pMDI formulation.  Ether bond of PEG has been shown to strongly interact with 
HFA propellant, aiding the solvation of drug particles in propellant.[58]  The effect of PEG density 
and DOX payload was on the stability formulation and aerosol performance were tested.  The 
addition of biodegradable and biocompatible surfactant were further added to modulate lung 
deposition of the pMDI formulation for the delivery to various lung regions.   
In Chapter 1, we presented the literature review about polymeric nanocarriers for 
chemotherapeutics delivery, extra and intracellular barriers to pulmonary delivery of 
chemotherapeutics, and pMDIs for drug delivery via OI administration. 
In Chapter 2, we studied the effect of surface PEGylation and routes of administration on 
systemic and local biodistribution of PAMAM dendrimers.  Generation 3, amine-terminated 
PAMAM dendrimer was labeled with Cy3 probes.  The surface of the dendrimers was modified 
with high grafting density of polyethylene glycol 1000Da (PEG1000).  The PEGylation can 
significantly change the surface chemistry and surface charge, which modulates the interaction of 
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dendrimers with extracellular and intracellular barriers in vivo.  The Cy3-labeled dendrimer and 
PEGylated dendrimer were delivered to the lungs via pharyngeal aspiration (PA) and also through 
tail intravenous injection (IV).  The plasma concentration of dendrimer as a function of time was 
studied.  Major tissues were excised and then imaged for Cy3 fluorescence.  To quantify the 
biodistribution, dendrimers were extracted from tissue homogenates.  Furthermore, cellular uptake 
of dendrimer and PEGylated dendrimers were evaluated based on four major lung cellular 
populations — myeloid, epithelial, endothelial and ciliated cells.  The selected cell populations 
were tagged with corresponding primary/secondary antibodies and then analyzed with flow 
cytometry.  The chapter is based on the manuscript Zhong Q., Merkel O, Reineke J, da Rocha 
S.R.P.  The Effect of the Route of Administration and PEGylation of Poly(amidoamine) 
Dendrimers on their Systemic and Lung Cellular Biodistribution. To be submitted to Molecular 
Pharmaceutics, 2015.  
In Chapter 3, we discussed the development of PEGylated, acid-labile PAMAM-DOX 
conjugates and their propellant-based aerosol formulations.  A series of PEGylated 
poly(amidoamine) dendrimer nanocarriers with acid-labile DOX conjugates were synthesized, and 
characterized with 1H NMR for chemical composition, MALDI-TOF for molecular weight, light 
scattering for hydrodynamic diameters and surface charge.  We employed a two-step PEGylation 
strategy to increase the payload of the hydrophobic DOX, while reaching high PEGylation degree 
which is expected to improve in vivo pharmacokinetics and biodistribution.  We investigated the 
impact of pH (neutral and acidic pH), PEGylation density (low, medium and high) and number of 
DOX conjugates (low and medium) on the release of DOX from the dendrimer nanocarrier, the 
kinetics of carrier uptake, intracellular release kinetics of DOX from the nanocarrier, and toxicity 
in an alveolar adenocarcinoma cell line (A549).  These dendrimer-DOX conjugates were then 
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formulated into HFA-based inhalers, forming a pseudo solution formulations which are confirmed 
by light scattering.  The effect of PEG density and DOX payload on the stability were assessed by 
visualizing the dispersity as a function of time.  The aerosol performance of these formulations 
were assessed by an in vitro lung model — Andersen Cascade Impactor (ACI).  The chapter is 
based on the manuscript: Zhong Q., da Rocha S.R.P. Poly(amidoamine) Dendrimer-Doxorubicin 
Conjugates: In vitro characteristics and Pseudo-Solution Formulation in Pressurized Metered-
Dose Inhalers. Submitted to Molecular Pharmaceutics, 2015 
The modification of amine-terminated PAMAM dendrimers with PEG provides several 
advantages to the dendrimers.  Some  of  them  include,  lower  cytotoxic  potential, enhancement  
of  mucosal  transport  and  increased  circulation  time.   Chapter 4 studied the effect of PEGylation 
degree and DOX payload on their ability to modulate transport of PAMAM-DOX conjugates 
across polarized pulmonary Calu-3 monolayers.  The role of paracellular pathways in 
transepithelial transport of dendrimer-DOX conjugates was also investigated.  The PEGylated 
PAMAM-DOX conjugates have been readily formulated in HFA-based formulation with the aid 
of a trace of ethanol in Chapter 3.  We developed another facile co-solvent free method to prepare 
pMDI formulation containing PEGylated dendrimer-DOX conjugates.  The lung deposition 
position of the aerosol formulations can be modulated by the addition of biodegradable and 
biocompatible triblock copolymer.  The aerosol performance of these formulations containing 
dendrimer conjugates and triblock copolymers were assessed by an in vitro lung model — 
Andersen Cascade Impactor (ACI).  The chapter is based on the manuscript: Zhong Q., Humia B., 
Punjabi A., da Rocha S.R.P.  Design of Dendrimer-Doxorubicn Conjugates for Transport 
Modulation across in vitro Pulmonary Epithelium and Their Solution Formulation in Pressurized-
Metered Dose Inhalers. To be submitted to Molecular Pharmaceutics, 2015 
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In Chapter 5, we assessed the potency of acid-labile dendrimer-DOX conjugates upon 
pulmonary delivery with a mouse lung tumor model.  Poly(amidoamine) dendrimer (PAMAM) 
with doxorubicin (DOX) conjugated via a pH-labile spacer was synthesized for controlled 
intracellular release.  We investigated pH impact (pH 4.5 = lysosomal pH and pH 7.4 = 
physiological/extracellular pH) on the DOX release from the dendrimer, and cellular uptake 
kinetics and cell kill with B16F10 melanoma cells.  The in vivo lung tumor model was developed 
by injecting B16F10 melanoma intravenously through tail vein of mouse. 3 doses of therapeutics 
with 20 μg per dose and one dose every other day were given to tumor-bearing mice through 
pharyngeal aspiration (pulmonary administration), as well as intravenous injection (i.v.) as 
compared.  The lung tumor burdens at terminal point were evaluated by counting the number of 
black nodules per lung.  The in vivo systemic distribution of the PAMAM-DOX conjugate was 
also quantified by extracting DOX from tissue homogenates.  The focus were especially placed on 
the retention of PAMAM-DOX conjugates in the lungs and accumulation of DOX in heart tissues 
as a function of time.  The chapter is based on the manuscript: Zhong Q., Reineke J., da Rocha 
S.R.P. Conjugation to Poly(amidoamine) Dendrimers and Pulmonary Delivery Enhances the 
Antitumor Activity of Doxorubicin in Lung Metastasis.  To be submitted to Journal of Controlled 
Release, 2015.  
 In Chapter 6, we discussed the conclusions drawn from this work and future research 
suggestions. 
1.2 Literature review  
1.2.1 Inadequate biodistribution of chemotherapeutics upon i.v. administration   
As high enough (therapeutic) doses at the lung tumor site usually cannot be reached without 
inducing substantial systemic toxicity.[6]  For example, the maximum concentration of CIS 
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administered i.v is limited by strong renal toxicity, which may lead to acute renal failure,[59] while 
i.v. DOX presents high cardiotoxicity, which may lead to congestive heart failure and death. [60]  
The concentration of DOX reaching the lung tumor upon i.v. administration has been determined 
to be as low as 2% of the total dose. [8]  This low concentration of chemotherapeutic at the tumor 
site also contributes to the development of MDR, as cells cancer cells that survive due to low 
dosages, may become resistant.[61]  Local delivery of chemotherapeutics to the lung tissue is a 
promising alternative to i.v. administration in the treatment in lung cancer.    
Direct lung administration of therapeutic agents to the lungs via OI therapy offers several 
potential advantages, including the delivery of lower dosages compared to i.v., which will lead to 
reduced systemic side effects, as well as enhancing tumor exposure by improving the retention of 
the therapeutic agents.[62]  Clinical trials show that anti-cancer therapeutics delivered to lung 
cancer patients as aerosol before surgery appear only in trace concentrations in plasma, and that 
the drug concentration can be as high as 15x in tumor compared to normal lung tissue.[63]  Pre-
clinical studies show that the relative concentration of chemotherapeutics in the lungs after 
pulmonary administration can be 26 fold higher than that after i.v. administration.[64]  Inhaled 
DOX formulated in lipid vesicles and delivered as aerosol from nebulizers show no dose limiting 
toxicity.[65]  The toxicity profile of inhaled DOX in patients with metastatic lung cancer shows 
pulmonary dose limiting toxicity, but no systemic toxicity.[65]  Ongoing clinical trials on 
inhalation chemotherapy for the treatment of primary or metastatic lung cancer with both DOX 
also demonstrate the potential of local lung delivery.[66]  
1.2.2 Pulmonary extracellular barriers to delivery of therapeutics to/through the lungs 
Respiratory airway consists of nose, pharynx, larynx, trachea, bronchi, bronchioles, and 
alveoli sacs.  Since 17th generation of bronchioles, alveoli appear in the wall of respiratory airways 
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and by 20th generation the entire walls ware composed of alveoli —— alveoli ducts.  The bronchi 
and bronchioles narrow as the generation increases.  Finally, alveoli ducts ends in blind sacs at 
23rd generation.[67]  As the surface area of alveoli is estimated 80-90 m2, lungs are a potentially 
excellent place to deliver biopharmaceuticals for treating both local and systemic disorders.  
However, some extracellular barriers restrict efficient pulmonary delivery and deposition in deep 
lungs, including hyperbranched lung architecture, clearance processes (mucociliary defense) and 
macrophage-mediated immune response.  The deposition of inhaled particle in lungs is assessed 
by aerodynamic diameter.  It is defined as a g
a
d d 

 , where ρ is mass density of the particle, 
ρa is unit density (1 g/cm3) and dg is geometric diameter.[68]  The particle with da bigger than 10 
µm is deposited on bronchial region away from bronchioles and alveolar area, while the particle 
less than 1 µm is highly exhalable.  Therefore, 1-5 µm is found optimal size for particle to reach 
respiratory airways and peripheral lungs.[69]  However, most of PNCs used for drug delivery is 
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smaller than 1 µm, hence PNCs formulated into micron-sized particle is necessary for efficient 
deposition on respiratory airways and entry into lungs.  
The respiratory airways from nose to terminal bronchioles are covered by mucus layer 
which is composed of mucin glycoproteins, cells, bacteria, lipids, salts, proteins and cell debris.[70, 
71] The miscellaneous components act together to form a nanoscopically heterogeneous 
environment to prevent the transport of foreign particulate across respiratory airways.[72]  The 
PNCs to cross mucus layer are hindered by (i) size-dependent diffusion.  It is reported that average 
pore size for particle penetration was to be 100 nm;[73-75] (ii) strong electrostatic interaction with 
positively and negatively charged components.  Therefore, the PNCs must be shielded by 
hydrophilic and neutral macromolecules; (iii) rapid mucociliary clearance.  The luminal mucus 
Figure 1.1 Diagram of the human lungs and particle deposition 
based on size.[57] 
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layer of respiratory tract is renewed every 10 to 20 min, leading to efficient clearance of invading 
particles.[76]  
1.2.3 Pressurized metered-dose inhalers (pMDIs) as oral inhalation for pulmonary delivery 
In lung cancer treatment, current route to administer DOX is i.v. injection which results in 
non-specific systemic distribution.  The non-specific whole body distribution lowers dose level at 
pulmonary cancerous lesion, but increases side effect to normal tissues.  In contrast, oral inhalation 
is a promising non-invasive approach to efficiently deliver anticancer therapeutics to the lungs, 
since it may retain high drug dose in pulmonary area and thus lowers side effect.[77]  OI technique 
can be broken into three major categories: nebulizer, pressurized metered-dose inhalers (pMDI), 
and dry powder inhalers (DPI).[41, 42]  Generally, nebulizers can produce small particles (2-5 µm) 
that penetrate airways, deposit on deep lungs easily, and deliver large doses of aerosol with little 
requirement of patient skills.  Inconvenience in handling and considerable sedimentation of 
particles on oral cavity, larynx, and trachea result in large waste of delivered drugs.[43]  pMDIs 
are a well-developed aerosol technology and widely accepted by patients due to its portability, 
straightforwardness in use and enhanced lung deposition of inhaled therapeutics.  pMDIs 
formulations can be divided into two types: solution formulation and suspension formulation.  The 
drugs completely dissolved in the propellant can be formulated into a solution formulation,[78, 79] 
while the drugs practically insoluble is dispersed in the propellant to make a suspension 
formulation and create a heterogeneous system.[80-82]  Compared to suspension formulation, the 
solution formulation of pMDIs can give rise to a homogenous formulation without shaking prior 
to use, a larger fine particle dosage [83] and finer residual aerosol.[84]  However, many drugs and 
PNCs are not readily soluble in propellants, limiting the amount of drugs that can be used in pMDIs 
formulations.  Cosolvents and surfactants, such as PEG, Span 20, Tween 80 and Pluronic block 
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polymer, are widely added to help increase the solubility of the insoluble drugs.[78, 85]  However, 
aerosol characteristics may be attenuated by the addition of surfactants and/or cosolvents as they 
evaporate more slowly in atomized droplets.  Therefore, the dispersion of drug crystals in 
propellant and difficulties in screening of surfactants and co-solvents significantly limit the use of 
pMDIs.  Additionally, the transition from ozone-depleting propellant such as chlorofluorocarbon 
(CFC) to more environment-friendly substitutes such as hydrofluoroalkanes (HFA) can cause 
complicated issues due to the strong effect of thermodynamic properties of propellants on 
solubility of drug crystal and PNCs [86].      
1.2.4 Doxorubicin as leading anticancer therapeutics in lung cancer treatment   
Doxorubicin (DOX) is an anticancer chemotherapeutics that was first isolated from 
Streptomyces peucetius in 1967.[87]  Today DOX is a leading therapeutic in clinical oncology, 
having a broad range of activity against both solid and “liquid” tumors.[88]  DOX is used in the 
treatment of several cancers, including breast, ovarian, lung, sarcoma, acute lymphoblastic and 
myeloid leukemia.[89]  DOX is also used in pediatric oncology.[90, 91]  Since the discovery of 
DOX, thousands of other anthracyclines have been screened for their anticancer properties, but 
only few have emerged as clinically relevant.[92]  The lasting relevance of DOX in the fight 
against malignant tumors is also demonstrated by the fact that DOX shows up in over 1,500 clinical 
trials currently listed in the US NIH registry.[93]  There are two proposed mechanisms in which 
DOX works: (i) inhibition of topoisomerase-II-mediated DNA repair by intercalating DNA; (ii) 
generation of free radicals that rupture cellular and subcellular membrane structure.[94, 95]  It was 
reported that the transport of DOX across cellular membrane was through simple diffusion due to 
electrostatic binding to anionic phospholipid on membrane and direct insertion of hydrophobic 
chromophore into lipid layer.[95-97]  While nuclear DNA is the most studied DOX, DOX has also 
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shown to have mitochondrial activity and this action has been shown to promote apoptosis, even 
in MDR cells.[98-100]  However, the entire mechanism of how DOX interacts with various 
processes in the mitochondria is not yet known.[101, 102]  Short term incubation of DOX with 
cancerous cells brought about rapid changes in mitochondrial function including changes in 
mitochondrial redox potentials towards an increased oxidative state, depolarization of the inner 
mitochondrial membrane, increased matrix calcium levels, and increased mitochondrial ROS 
production.[103]  Long-term effects include an inhibition of respiration, ATP depletion, and 
increased production of proteins association with cell cycle arrest and cell death.[103]  DOX’s 
ability to intercalate with DNA may affect the integrity of mitochondrial DNA, which could also 
contribute to a decrease in electron transport chain complexes. 
1.2.5 Polymeric nanocarriers (PNCs) for targeted intracellular DOX delivery  
DOX is an anticancer therapeutics widely used in cancer chemotherapy.  DOX is 
administered intravenously in the form of its hydrochloride salt.  Since DOX administered via i.v 
route is distributed non-specifically in the body, affecting both tumor tissues and healthy tissues.  
Such non-specific distribution leads to insufficient dose in tumor and severe toxicity to normal 
tissues.  More importantly, the damage of DOX to heart tissue can cause life-threatening cardiac 
toxicity.  To improve therapeutic efficacy of DOX, several drug delivery systems based upon 
polymer nanoparticles,[104-109] liposomes,[71, 109, 110] monoclonal antibodies,[111] polymer 
conjugates, [34, 112-116] and polymer micelles[117] have been extensively employed.  DOX is 
either physically encapsulated in or covalently bound to polymeric matrices.  Polymer-based DOX 
delivery systems, by using both passive and active targeting strategies, can enhance extracellular 
or intracellular concentration of DOX in tumor cells whereas avoiding toxicity to normal tissues.  
The encapsulation of DOX into liposomes, polymer micelles and polymeric nanoparticles is an 
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effective strategy to increase DOX payload, enhance cellular uptake, and improve 
pharmacokinetics.  The  biodistrubtion of liposomal DOX and DOX-entrapped PNCs have shown 
higher dose level in tumor and inhibition of tumor growth due to EPR effect [118] and specific 
targeting.[119]  However, they are still flawed on inconsistent drug payload, weak particle stability 
and limited controllability of drug release.  Therefore, an alternative strategy where DOX is 
conjugated to polymer via a labile linkage has been developed.  The protruding advantage of the 
conjugate is to achieve reliable sustained drug release.  In analogous to DOX-entrapped PNCs, 
EPR effect and active targeting strategy facilitate polymer-DOX conjugates to accumulate in 
tumor vasculature and are internalized to tumor cells by endocytosis (receptor-mediated, 
adsorptive, and fluid phase endocytosis).  Subsequently, the polymer-DOX conjugates end up in 
acidic endosome (pH 6.0-5.0)/lysosome (pH 5.0-4.5) [120, 121] where DOX is released from 
polymer by non-specific pH-controlled hydrolysis [23, 113, 122] or specific enzymolysis [123, 
124] shown in Figure 1.  Of the labile bonds, cis-aconitic spacer,[115, 125] hydrazone,[115, 126] 
Figure 1.2 Schematic representation of intracellular release of 
Polymer-DOX conjugates (e.g. polyamidoamine-PAMAM).  
The conjugates are internalized by endocytosis into endosomes 
and then end up in lysosomes. DOX is released from polymer-
DOX conjugates with pH-sensitive linkers broken as pH drops 
to 5.0-4.5 in lysosomes. Released DOX subsequently moves out 
of lysosome towards nucleus.   
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and Gly-Phe-Lys-Gly peptide sequence [127, 128] have been mostly used for preparation of 
polymer-DOX conjugates.[129]  These linkers are sensitive to lysosomal pH or enzymes while are 
maintained stable at extracellular environment.  Furthermore, the polymer-DOX conjugate also 
showed higher cytotoxcity against cancer cells than bare DOX in vivo experiment.[130, 131]  
Therefore, the selective intracellular release of DOX can be accomplished by polymer-DOX 
conjugates with pH-sensitive or enzyme-degradable linkers.  
1.2.6 PEGylation of PNCs help overcome pulmonary extracellular barriers and improve 
biodistribution 
Apart from controlled intracellular release and effective tumor selectivity, other challenges 
of PNCs-based drug delivery systems include limited hydrophilicity, short blood circulation 
residence, and strong serum protein binding and particle aggregation.  The modification of PNCs 
with biocompatible and hydrophilic polymer is an effective strategy to solve those challenges.  One 
of the most widely accepted polymers for this modification is polyethylene glycol (PEG) which 
has been approved by Food and Drug Administration (FDA).[132]  It bears an array of attributes: 
neutral molecule, very low toxicity, excellent solubility in aqueous solution, non-immunogenicity, 
and no detrimental influence on protein conformation or enzymes activities.[133]  PEGylation of 
PNCs-DOX has been widely studied at both in vitro and in vivo level.  The overall charges on  
PNCs surface can be significantly masked after PEGyaltion such as PLA–PEG,[134] PAMAM-
PEG,[34] and polylysine-PEG nanoparticles,[52] leading to weak serum protein binding and 
decreased cytotoxicity and immunogenicity.  Furthermore, PEGylated PNCs showed prolonged 
blood circulation residence, thus resulting in improved pharmacokinetics and less drug 
administration frequency. [113, 135, 136]  However, PEGylated nanocarriers are also known to be 
less efficiently taken up by the cells.[137]  Therefore, a balance between overall charges of PNCs, 
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size of PEG chains, and PEG density must be modulated in order to maximize the potency of 
anticancer therapeutics.   
1.2.7 Development of in vivo lung cancer murine model 
The in vivo preclinical evaluation of new chemotherapeutics for cancer therapy requires 
relevant and appropriate animal models mainly including subcutaneous and orthotopic xenograft 
tumor models.  Each model has its advantages and disadvantages.  Subcutaneous xenografts are 
very convenient way to implant tumor cells, and the consequent tumors are palpable and easy to 
quantify the tumor growth.   However, orthotopic xenograft models provide an accurate 
representation of tumor microenvironment as cells are implanted directly into the organ in which 
the disease originates.  This allows for a reliable prediction of toxicity and understanding of 
microenvironment-dependent responses to selected therapies, thereby leading to more reliable 
translation to clinical cases.[138]  The most practical orthotopic lung tumor models involves the 
endobronchial inoculation of A549 and H460 cell lines into athymic NCr nu/nu mice.[139]  
Despite the benefits of orthotopic models, the development of these models are quite time-
consuming and challenging as cells typically conducted endobronchially, requiring precision and 
practice.  Additionally, once tumors start proliferation, it is more difficult to handle and quantify 
their growth than in traditional xenograft models.  Besides primary lung cancers, pulmonary 
metastasis model is the other widely used model for evaluating therapy in many tumors.  
Essentially, all tumors upon intravenous injection can be found in the lungs and the resulting 
pulmonary metastatic nodules are technically viewed as an independent primary tumor rather than 
a metastasis.[140]  B16 melanoma is transplantable tumor that originated from C57BL/6 mice.  
The strain F10 of B16 melanoma (B16-F10) characterized by its robust ability to colonize in the 
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lungs has been widely used to develop pulmonary metastasis upon intravenous injection of 
melanoma cells.[141-143]   
1.3 Relevance and Innovation 
This work is greatly relevant and innovative in a few aspects. Since DOX is one of the most 
important chemotherapy for various lung cancers, the design of advanced DOX delivery system 
and its efficient delivery to lungs via OI are very attractive.  This is the first time for (i) the 
elucidation of systemic and local biodistribution of PAMAM dendrimers via pulmonary delivery 
and effect of PEGylation on these aspects; (ii) development of a novel strategy for lung cancer 
treatment, which combines pulmonary delivery with PEGylated PAMAM dendrimer with DOX 
conjugated via an acid-labile linker.  The developed strategy can significantly increase local dose 
of DOX in the lungs, while reduce the accumulation of DOX in heart tissues; (iii) polymer 
nanocarrier drug delivery system is formulated into propellant-based inhalers, forming a pseudo 
solution aerosol formulation.  This research will contribute to designing novel dendrimer 
therapeutics delivery system that may be employed in the treatment of lung cancer, as well as 
provide a potential platform for other pulmonary disease treatment such as tuberculosis, and 
asthma. Finally, the research is also valuable on subsequent formulation in inexpensive inhalation 
devices. 
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CHAPTER 2 — The Effect of the Route of Administration and PEGylation 
of Poly(amidoamine) Dendrimers on their Systemic and Lung Cellular 
Biodistribution  
2.1 Introduction 
Pulmonary administration is an attractive and effective route for the non-invasive delivery 
of small molecule drugs and biomacromolecules for the treatment of lung disorders such as asthma, 
chronic obstructive pulmonary disease (COPD) and cystic fibrosis.[144-149]  Oral inhalation (O.I.) 
also has several notable advantages when compared to intravenous (I.V.) and other non-invasive 
administration routes (e.g. nasal and oral) with respect to the systemic delivery of therapeutics 
through the lungs that arise due to the large total surface area for drug absorption, the avoidance 
of first-pass metabolism and the potentially rapid therapeutic onset.[35, 150] 
In spite of the many potential advantages in the local or systemic delivery of drugs to and 
through the lungs, there is a notably small number of commercial O.I. products, and only very few 
classes of drugs are formulated as O.I..  Those include adrenocorticoid steroids (e.g. 
beclomethasone), bronchodilators (e.g. isoproterenol, metaproterenol, albuterol), antiallergics (e.g. 
cromoglicinic acid), and inhalable insulin for diabetes (Afrezza®).[151]  
There are, therefore, many opportunities for further development in the pulmonary drug 
delivery market.  Advances in the formulation of portable aerosol systems and the ability to 
develop innovative nanotechnologies capable of modulating the interaction between the 
therapeutic agents and the local physiological environment [39, 51, 52, 55, 152-154] are both 
expected to support and accelerate the development of O.I. formulations.  New formulations have 
a broad application range such as the many therapeutics that are under clinical trials for local and 
systemic delivery to/through the lungs.[57, 155-159] 
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Dendrimers represent a promising class of nanocarrier systems for the delivery of small 
molecule therapeutics and biomacromolecules.[113, 160-163]  Dendrimers are hyperbranched 
polymers that are highly monodisperse and possess a high density of functionalizable surface 
groups.[31, 164, 165]  A particular class of dendrimers, those with a polyamidoamine (PAMAM) 
architecture, has received a lot of attention in the literature, particularly those with amine-
terminated (NH2) surface groups. These dendrimers can be obtained and functionalized with 
therapeutics and other ligands and have the ability to efficiently gain access to the intracellular 
milieu.[166]  Toxicity [167] and rapid clearance [168, 169] of unmodified NH2 PAMAM 
dendrimers have somewhat reduced the excitement towards these carriers.  However, surface 
modification of such dendrimers with polyethylene glycol (PEG), also called PEGylation, has been 
shown to be one effective strategy in the development of dendrimer nanocarriers with reduced 
toxicity,[167] improved pharmacokinetic (PK) profiles,[168, 169] and improved aqueous 
solubility. The latter becomes a major issue upon conjugation of hydrophobic therapeutics such as 
doxorubicin to such nanocarriers.[170, 171] 
The tissue distribution and PK of PEGylated PAMAM dendrimers have been extensively 
studied in vivo upon I.V. administration, and the results suggest significantly decreased 
toxicity,[172] prolonged systemic circulation,[172, 173] and effective accumulation in target 
tissues through passive [34] and active targeting strategies.[174]  Meanwhile, a  few studies have 
focused on the systemic biodistribution of nanocarriers upon pulmonary administration,[39]   
including gold nanoparticles,[51] PEGylated polylysine dendrimers,[52] PEGylated poly(ethylene 
imine),[53] diethylaminopropylamine-poly (vinyl alcohol)-poly (lactide-co-glycolide) copolymer 
[54] and polystyrene nanoparticles.[55]  However, few attempts have been made on the systemic 
distribution of PAMAM dendrimers and their PEGylated counterparts upon pulmonary 
23 
 
administration.  Additionally, the distribution of PAMAM dendrimers amongst different cell types 
of the lung upon pulmonary administration has not been reported yet.  Such results are of great 
relevance for the ability to passively target various tissues by simply tuning the chemistry of the 
nanocarriers.  This knowledge will help guide the design of such nanocarriers for targeting 
different diseases both in terms of systemic distribution and lung cellular distribution.  For example, 
knowledge on the distribution to lymph nodes may help us design improved vaccine delivery 
systems,[175] while alveolar macrophage targeting may provide us a way to develop new 
strategies for the treatment of pulmonary tuberculosis.[176, 177]  
The goal of this work is to investigate the systemic and local biodistribution of amine-
terminated PAMAM dendrimers upon lung delivery, and the effect of PEGylation on their 
distribution profile.  We have selected generation 3, amine-terminated PAMAM (G3NH2) and 
1000Da PEG (G3NH2-PEG1000) for this study.  The pharmacokinetic parameters of the bare 
dendrimer and highly PEGylated dendrimer were investigated in vivo, upon lung delivery and 
benchmarked against the profiles obtained upon I.V. administration.  The systemic biodistribution 
was qualitatively determined by ex vivo imaging, and quantitative characterization was achieved 
by tissue extraction of the dendrimer conjugates.  The local distribution of dendrimer conjugates 
in different pulmonary cell populations was quantified using cell tagging and flow cytometry.  The 
results help us understand how the chemistry of such carrier systems may be used to target different 
tissues and cell populations, and thus serve as a guide for the design of new dendrimer-based 
carriers for the spatially and temporally controlled delivery of a variety of therapeutics for the 
treatment of lung and systemic disorders upon O.I. administration. 
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2.2 Materials.  
Generation 3, amine-terminated, poly(amindo amine) (PAMAM) dendrimers (G3NH2), 
with 32 -NH2 surface groups and theoretical molecular weight of 6909 was purchased from 
Dendritech, Inc (Midland, MI).  Cyanine 3 (Cy3) NHS ester was purchased from Lumiprobe 
Corporation (Hallandale Beach, FL).  Polyethylene glycol 1000Da (PEG1000) succinimidyl ester 
(PEG1000-SC) was purchased from NANOCS Inc (New York, NY).  Paraformaldehyde solution 
4% in PBS, saponin, dispase, and 10 kU heparin sodium salt from porcine intestinal mucosa were 
purchased from Sigma-Aldrich (St Louis, MO).  Sodium phosphate (dibasic, anhydrous) and 
sodium phosphate (monobasic, monohydrate) were purchased from EMD Chemicals, Inc 
(Gibbstown, NJ).  Deuterium oxide (D2O, D: 99.9%) was purchased from Cambridge Isotope 
Laboratories (Andover, MA).  Rat anti-mouse CD16/CD32 monoclonal antibody (Fc blocker) was 
provided by Thermo Fisher (Waltham, MA).  PerCP-Cy5.5 labeled anti-CD45 (30-F11) and PE-
labeled anti-CD31 were purchased from EBioscience (San Diego, CA).  A primary anti-
prosurfactant protein C antibody (pro-SPC) (1:100) and a primary anti-tubulin antibody (1:100) 
were obtained from abcam (Cambridge, United Kindom).  Alexa Fluor®647 F(ab’)2 goat anti-
mouse IgG  secondary antibody (1:100) and pacific blue F(ab’)2 goat anti-mouse IgG secondary 
antibody (1:100) were purchased from Life Technologies (Grand Island, NY).  Falcon cell strainers 
with mesh size 100 µm were obtained from Thermo Fisher Scientific (Waltham, MA).  Ultrapure 
deionized water (DI H2O) was obtained with the Barnstead NANOpure DIamond System (D11911) 
from Thermo Fisher Scientific (Waltham, MA).  Amicon® Ultra 15 centrifugal filters 
(MWCO=3kDa) were purchased from EMD Millipore (Billerica, MA).  Thin layer 
chromatography (TLC) Silica gel 60 F254 plastic sheet was purchased from Merck KGaA 
(Darmstadt, Germany).  All reagents were used as received unless otherwise specified. 
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2.3 Methods 
2.3.1 Cy3 labeling of PAMAM dendrimer (G3NH2-Cy3) 
G3NH2 (27.2 mg, 3.94 µmol) was dissolved in 3.0 ml phosphate buffer solution (0.2 M, 
pH 8.4).  A 0.5 ml dimethylsulfoxide (DMSO) of Cy3 NHS ester (7.29 mg, 12.35 µmol) was added 
dropwise to the above aqueous buffer.  The reaction mixture was stirred for 2h at 4oC and another 
4h at room temperature.  The unreacted Cy3 was removed using centrifugal filter device 
(MWCO=3kDa) until TLC showed no free Cy3 in the product.  The product was lyophilized and 
then stored at 4oC for further use.  The resulting structure of the G3NH2-Cy3 (number of Cy3 
conjugated to the dendrimer) was determined using proton nuclear magnetic resonance (1H NMR) 
and mass-assisted laser desorption/ionization-time of flight (MALDI-TOF).  1H NMR (DMSO_d6, 
ppm) spectra and peak assignment and MALDI spectra are provided in the Figure S1 of 
Supplemental Information in Appendix 1.  The ratio of Cy3 to dendrimer was also determined 
using UV spectrometry.  The UV spectra of Cy3-labeled dendrimer were recorded using Varian 
Cary® 50 UV-Vis spectrometer (Santa Clara, CA).  The concentration of Cy3 was calculated using 
Beer-Lambert law A = ɛbc to quantify the ratio, where molar absorbtivity ɛ at 555 nm is 150,000 
L∙mol-1∙cm-1, path length of quartz cuvette b is 1 cm, and c is concentration of sample with mol∙L-
1 as unit.  The result was compared with the data from 1H NMR and MALDI. 
2.3.2 Synthesis of PEGylated PAMAM dendrimers (G3NH2-PEG1000-Cy3) 
The resulting Cy3-labeled G3NH2 (15.2 mg, 1.84 µmol) was dissolved in 3.0 ml phosphate 
buffer (0.2 M pH 8.0).  A 1 ml anhydrous p-dioxane of PEG1000-SC (56.2 mg, 55.2 µmol) was 
added to the above aqueous buffer.  The reaction was stirred for 2h at 0oC, and another 4h at room 
temperature.  The unreacted PEG1000 was removed using a centrifugal filter device (MWCO = 
3kDa).  The resulting PEGylated dendrimer (G3NH2-PEG1000-Cy3) was lyophilized and then 
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stored at 4oC for further use.  1H NMR (DMSO_d6, ppm) spectra and peak assignment, and 
MALDI spectra are provided in the Supplemental Information in Appendix 1. 
2.3.3 Size and Surface Charge of the Conjugates. 
conjugates were measured using a Malvern NanoCS Zetasizer (Malvern Instruments; 
Worcestershire, UK).  The sample (1.0 mg/ml) was dissolved in DI H2O.  The aqueous suspension 
was equilibrated for 120 s before measurement, and the Mitoschi model was used as scattering 
calculated using the built-in software. 
2.3.4 Pulmonary administration of the dendrimer conjugates 
Pulmonary delivery of the bare and PEGylated Cy3-labeled dendrimers was performed 
using the pharyngeal aspiration (P.A.) technique.[55]  Briefly, male balb/c mice (25 g, 10-12 weeks 
old) were deeply anesthetized with 2.5% v/v isoflurance/oxygen and then placed on a tilted board 
in a supine position.  The tongue was held gently in extension while a 50 µl saline solution of 
G3NH2-PEG1000-Cy3 (4.09 mg/ml) or G3NH2-Cy3 (1.03 mg/ml) conjugate – same total G3NH2 
concentration - was gradually dripped in the pharynx region with a micro syringe.  The tongue was 
continuously held until after a few breaths.  As the whole solution was administered, the mice were 
left under anesthesia for 5 min and returned to the cage for monitoring of rapid recovery.  The P.A. 
technique has comparable effectiveness to intratracheal instillation, while less invasive, and also 
allows for the delivery of high dosages.[178]   
2.3.5 Pharmacokinetics (PK) of the administered dendrimer conjugates 
After the administration of dendrimer conjugates, blood samples were collected at 
predetermined time points (0.25, 0.5, 1, 3.25 and 6.5 h).  A volume of 80 µl of blood collected 
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from tail vein was mixed with 20 µl of heparin saline (10 U/ml).  The mixture was centrifuged at 
5000 rpm for 45 s, and the plasma obtained was pulsed into a flat bottom 96-well plate for Cy3 
fluorescence determination using BioTek Synergy HT multi-code microplate reader (Winooski, 
VA, US).   
2.3.6 Systemic biodistribution of the administered dendrimer conjugates 
The mice were sacrificed 6.5 h after the administration of the conjugates.  This time point 
is based on our previous experience where we measured the PK profile for G3NH2 in the same 
model by using the same route.[168]  The various tissues were excised and washed with saline, 
including axillary lymph nodes (ALN), bronchial lymph nodes (BLN), cervical lymph nodes 
(CLN), mesenteric lymph nodes (MLN), thymus, brain, heart, liver, lungs, kidneys, stomach and 
spleen.  The residual saline was wiped off using a filter paper, and the excised tissues were 
immediately used for analysis.  We bench-marked our studies by delivering the same dose of 
dendrimer conjugates I.V. through the tail vein.  These mice were sacrificed, harvested and 
samples analyzed in the same manner as the pulmonary study groups. 
2.3.7 Ex-vivo imaging of excised tissues 
The excised tissues were visualized using a Carestream In Vivo Xtreme (Rochester, NY, 
US) imaging system (Excitation/Emission: 555/571 nm).  The exposure time was set to 30 s.  
Visible light and Cy3 fluorescence images were taken and overlaid using the manufacturer's 
software. 
2.3.8 Quantification of dendrimer conjugates in tissues 
The excised tissues were fully homogenized using a Cole-Parmer LabGEN 7 Series 
Homogenizer (Vernon Hills, IL) in a 3 ml aqueous solution of 3 N sodium hydroxide (NaOH) and 
the dendrimer conjugates were then extracted for 72 h at room temperature in darkness.  The 
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extracted dendrimer conjugates were collected by centrifugation (14,000 g, 10 min) at 4°C.  The 
amount of dendrimer conjugates in each tissue was quantified according to established calibration 
curves in the corresponding tissue.  Briefly, the tissue was spiked with a known amount of G3NH2-
Cy3 or G3NH2-24PEG1000-Cy3 and the extracted as described above.  The fluorescence intensity 
was plotted as a function of the amount of G3NH2-Cy3 or G3NH2-24PEG1000-Cy3.[179]    
2.3.9 Single cell staining for pulmonary cellular biodistribution of the nanocarriers 
Pulmonary myeloid cells, alveolar epithelial cells, endothelial cells and ciliated airway 
epithelial cells were stained by probe-labeled antibodies and then analyzed with flow cytometry 
following a reported method with modifications (See Supplemental Information in Appendix 
1).[180]  Briefly, the excised lungs were ground gently and incubated with dispase and DNase to 
break extracellular matrix.  The resulting homogenate was filtered with 100 µm nylon cell strainers.  
The obtained cells were fixed with 4% paraformaldehyde solution and then incubated with 0.15% 
saponin buffer for permeabilization at 4oC.  Subsequently, the cells were incubated with Fc-blocker 
for 20 min and then stained with the probe-labeled antibodies against CD45, CD31, pro-SPC and 
β-tubulin for another 25 min at 4oC in darkness.  The stained cells were analyzed with a BD 
Bioscience BD LSR II Analyzer (San Jose, CA, US).  Data analysis was performed with 
TREESTAR FlowJo software (Ashland, OR, US).  Cells were sorted in two ways: those that 
contained and those that did not contain internalized dendrimer conjugates.  Secondly, from those 
that contained dendrimer conjugates, the fraction of myeloid (CD45), (alveolar) epithelial (pro-
SPC), endothelial (CD31) and ciliated (β-tubulin) cells was determined.  Studies were performed 
for both G3NH2-Cy3 and G3NH2-PEG1000-Cy3 conjugates, so that the effect of chemistry could 
also be assessed. 
2.3.10 Statistical analysis 
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Graphpad Prism 5 was used to perform the statistical analysis.  Data were compared using 
Student’s t test.  Means were considered statistically significantly different with a *p value <0.05. 
2.4 Results and discussion 
2.4.1 Synthesis of PEGylated dendrimer conjugates  
Compound 
MW 
(Da) 
m  n 
HD±s.d (nm) ζ±s.d (mV) 
MALDI NMR  MALDI NMR UV 
G3NH2 (as received) 6900 0 0  0 0 0 +3.8±1.3 +18.8±5.0 
G3NH2 8285 0 0  3.1 3.3 2.8 +5.1±1.4 +24.5±6.9 
G3NH2-24PEG1000 33312 24.5 23.9  3.1 3.3 2.8 +9.9±3.6 -3.7±5.0 
 
Figure 2.1 Schematic diagram of the synthesis of the Cy3-labled, PEGylated dendrimer 
conjugates. The Cy3 terminology is dropped in the results and discussion part. For 
simplicity, the conjugates are referred to G3NH2 and G3NH2-mPEG1000, where m is the 
number of PEG 1000Da graft moieties – the number of Cy3 is the same for all conjugates.  
r.t. = room temperature 
Table 2.1 Characterization of the Cy3-labeled, PEGylated dendrimer conjugates (G3NH2 and 
G3NH2-24PEG1000).  Molecular weight (MW), number of PEG grafts (m), size 
(hydrodynamic diameter, HD), and zeta potential (ζ) as determined by MALDI, 1H NMR, UV 
spectrometry and light scattering (LS). 
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Both Cy3 labeling and PEGylation were performed using a primary amine/NHS ester 
chemistry, resulting in the formation of an alkyl amide bond in each case, which is a bond known 
to be stable under both in vitro and in vivo conditions.[181]  The synthetic route is shown in Figure 
2.1.  The first step in the preparation of the conjugates was to label G3NH2 with Cy3 before 
PEGylation to guarantee the same number of Cy3 molecules on both the non-PEGylated and 
PEGylated dendrimers.  The 1H NMR with peak assignments and the MALDI spectra are shown 
in the Supporting Information in Appendix 1.  The NMR peaks at 7.614-7.163 ppm, 6.476 ppm, 
1.509 ppm, and 1.353 ppm indicate successful conjugation of Cy3 to G3NH2.  Similarly, the 
molecular weight shift in MALDI from 6900 Da to 8285 Da after Cy3 tagging, also confirm the 
successful conjugation of Cy3.  The UV spectrometry is also used to quantify the ratio of 
conjugated Cy3 to dendrimer due to the Cy3 absorption at 555 nm.  As shown in Table 2.1, an 
average of ca. 3 Cy3 molecules was conjugated per dendrimer as determined (in close agreement) 
by 1H NMR (3.3), MALDI (3.1) and UV spectrometry (2.8). 
Subsequently, dendrimers with a high PEG density were prepared by reacting G3NH2-Cy3 
with PEG1000 succinimidyl ester.  The 1H NMR peak at 4.02 ppm revealed the successful 
conjugation of PEG1000 to dendrimer-Cy3 with an amide bond.  1H NMR and MALDI were also 
used for quantification of PEG1000 density, revealing an average of 23.9 and 24.6 
PEG1000/dendrimer, respectively. 
The size and surface charge of bare dendrimer and PEGylated dendrimer conjugates were 
determined by light scattering (LS).  Compared to the bare dendrimer, the size of G3NH2-Cy3 
increased only slightly to 5.1 nm, while at high PEG density the HD of the dendrimer increased 
dramatically, to nearly 10 nm.  This increase may be attributed to the stretching of the densely 
packed layer of PEG1000.[182]  The surface charge of G3NH2-3Cy3 was seen to be even more 
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cationic than the bare dendrimer due to the introduction of tertiary amines of Cy3, which have a 
stronger electron donating capacity.  Even though a primary amine from the dendrimer was used 
up in the conjugation of each Cy3 molecule, two tertiary amines were brought into the conjugate 
per Cy3.  In contrast, the surface charge of the dendrimer was reversed upon PEGylation, resulting 
 good agreement with a 
previous report.[168]  These two carriers are thus different in two very important ways: their 
surface charge (one is positive and the other negative/neutral) and their size (PEGylated dendrimer 
is twice as big as non-PEGylated).  The PEGylation of the nanocarriers is expected to prolong their 
residence in systemic circulation and reduce nanocarrier toxicity.[168, 169, 183]  The surface 
charge of the conjugates and their size is also expected to impact their transport across the 
extracellular/apical barriers of the lung tissue,[39, 41, 168, 184] whose gap junctions are in the 
order of 3 nm.[185, 186]  
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Figure 2.2 Plasma concentration (Cp) as a function of time after administration of 
G3NH2 and G3NH2-24PEG1000 via (a) pharyngeal aspiration (P.A.) and (b) 
intravenous injection (I.V.) (n=3 per group).  The statistical analysis was performed 
between G3NH2 and G3NH2-24PEG1000 with Student’s t-test (*p < 0.05, **p < 0.01, 
and ***p < 0.001).  
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For simplicity, in the following discussion “Cy3” will no longer be mentioned when 
describing the conjugate structures – the conjugates will be referred to simply as G3NH2 or 
G3NH2-PEG1000.   
2.4.2 Plasma concentration profiles of dendrimer conjugates administered via pulmonary 
and I.V. routes. 
The plasma concentration-time profiles of the bare dendrimer (G3NH2) and highly 
PEGylated dendrimer (G3NH2-PEG1000) following pulmonary (P.A.) and intra-venous (I.V.) 
administration are summarized in Figure 2.2. 
The plasma concentration of dendrimer conjugates delivered via the pulmonary route 
(Figure 2.2a) is seen to increase soon after administration.  For G3NH2-24PEG1000, it levels off 
at 3.25 h post administration (plasma concentration not statistically different at 3.25 h and 6.5 h), 
while for G3NH2, a peak is reached at 3.25 h (plasma concentration at 6.5h significantly lower 
than at 3.25 h).  The plasma concentration of the PEGylated dendrimer was 6-fold higher than that 
of the bare dendrimer (peak concentration: 0.6±0.2 µg/ml vs 3.8±0.4 µg/ml or 2.1±0.6% vs 
13.2±1.7% of overall dose).  The plasma concentration of the G3NH2 conjugates administered I.V. 
decreased quickly, reaching 1.1±0.3 µg/ml (3.8% of overall dose) at 6.5 h post administration as 
can be seen in Figure 2.2b.  However, the plasma concentration of the highly PEGylated dendrimer 
G3NH2-24PEG1000 decreased only slightly within the same time remaining at 76% of the 
delivered dose.  At 6.5 h the plasma concentration of the PEGylated dendrimer is 19.5-fold higher 
than that of bare dendrimer (21.6±1.5 µg/ml vs 1.1±0.3 µg/ml).  A similar plasma concentration-
time profile was also found for PEGylated polylysine dendrimers of 11kDa, 22kDa and 78kDa, 
upon delivered to the lungs via intratracheal instillation.[52] 
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The effect of PEGylation on plasma concentration is in line with previous results for 
PAMAM dendrimers and other polymeric nanoparticles.[34, 173, 187]  The plasma concentration 
and in vivo biodistribution of the dendrimer conjugates is mainly affected by its absorption, 
distribution, metabolism and elimination.[169]  Surface charge, size and surface functionality of 
the dendrimer conjugates determine their interaction with serum proteins and blood cells, uptake 
into target and non-target organs, and potential routes of elimination.  It has been demonstrated 
that PEGylation can neutralize surface charge of cationic polymers [125, 174] and reduce the 
binding affinity of proteins to nanocarriers,[188-191] which attenuates plasma protein adsorption, 
opsonization, phagocytosis and stimulation of immune cells.[30, 172, 191, 192]  Therefore, the 
blood circulatory residence of PEGylated dendrimers was significantly prolonged. 
In contrast to I.V. administration, dendrimer conjugates administered via pulmonary route 
need to cross several extracellular barriers to enter the local/systemic blood circulation.  These 
extracellular barriers include the fast-renewing mucus gel layer and ciliated epithelial cells on the 
airways, resident alveolar macrophages, lung surfactant and the alveolar epithelial cells in the deep 
lungs.  The significantly different plasma concentration profiles for G3NH2 and G3NH2-
24PEG1000 suggest that their charge and/or size have a significant impact on how they interact 
with the extracellular barriers before they reach systemic circulation.  We have previously 
observed that even though dendrimers are much smaller than the mucus mesh size (ca. 100 nm),[72] 
they may be retained in the mucus layer depending on their charge.  Cationic dendrimers interact 
with the mucus environment much more strongly, and thus take longer to traverse the mucus layer 
compared to neutral/negatively charged PEGylated dendrimers.[72, 168]  The increase in size of 
the PEGylated conjugates may in principle also have an effect as the tight junctions of the epithelial 
barriers strongly modulate the transport of molecules as a function of time – for example, 
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macromolecular therapeutics with sizes < 40-50kDa (HD: 5-6 nm nm) are known to be peak in 
systemic circulation in a matter of minutes,[179] while those larger molecules  peak in systemic 
circulation upon lung delivery over periods of hours, days, or weeks.[67]  However, in vitro results 
show that even highly PEGylated dendrimers can interact with the tight junctions of the pulmonary 
epithelium, and thus modulate their way across, reducing the impact of their size,[168] at least 
within the size range being investigated and discussed here. 
The impact of the dendrimer size can perhaps more strongly affect the route of elimination 
upon reaching systemic circulation.  The HD of the non-PEGylated dendrimer (5.1 ± 1.4 nm) is 
smaller than the size limit (ca. 6 nm) in which nanoparticles are quickly eliminated from blood 
circulation, and it can thus be eliminated by the kidneys (glomerular filtration),[193] while those 
nanocarriers larger than 6 nm, as for example G3NH2-24PEG1000 (HD = 10.9±3.6 nm), cannot 
be eliminated by kidneys, but accumulate in liver and spleen through the mononuclear phagocyte 
system (MPS), which is a relatively slow process.[49, 194]  However, the hydrophilicity imparted 
by the PEGylation reduces or delays MPS processing [190, 195] and prolongs systemic 
circulation.[168]  Thus, once the dendrimers are absorbed systemically, the PEGylation prevents 
glomerular filtration (due to their size) and also reduces MPS processing (due to their 
hydrophilicity). 
2.4.3 Systemic biodistribution of the dendrimer conjugates delivered via the pulmonary 
and intra-venous (I.V.) routes. 
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The effect of the administration route and PEGylation on the systemic distribution of 
dendrimer conjugates was investigated in this work.  Mice were sacrificed 6.5 h after P.A. or I.V. 
administration, and the major organs were excised, including lymph nodes, thymus, heart, lungs, 
stomach, spleen, liver and kidneys.  Ex vivo imaging was used to qualitatively assess the 
biodistribution of the dendrimer conjugates in these tissues.  The results, using representative 
tissues, are summarized in Figure 2.3.  
Quantitative assessment of the concentration of the conjugates was performed by 
fluorescence spectroscopy by recovering the tagged dendrimers from the various tissues as 
discussed in Materials and Methods.  The results, in terms of % of (total) Dose, as a function of 
route of administration and conjugate chemistry are summarized Figure 2.4.  The results are also 
Blank
G3NH2
(I.V.)
G3NH2-24PEG1000
(I.V.)
G3NH2-24PEG1000
(P.A.)
G3NH2
(P.A.)
ALN    BLN     CLN       MLN    Thymus    Lungs   Heart  Spleen Stomach Brain  Kidneys  Liver
Figure 2.3 Ex vivo biodistribution of G3NH2 and G3NH2-24PEG1000 
delivered via pharyngeal aspiration (P.A.) or I.V., determined 6.5 h after 
administration (n=3 per group).  ALN: axillary lymph nodes; BLN: 
bronchial lymph nodes; CLN: cervical lymph nodes; MLN: mesenteric 
lymph nodes.  The tissues that are enlarged for better visualization in the 
figure are ALN, BLN, CLN and MLN.  Liver is shrunk instead for better 
visualization.  The inset is the scale bar of fluorescne intensity. 
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summarized in terms of the mass dendrimer / mass tissue – they are shown in Figure S4 - 
Supplemental Information in Appendix 1. 
The results demonstrate that administration route (compare Figure 2.4a and 2.4b) and 
chemistry of the conjugates (comparing G3NH2 and G3NH2-24PEG1000 in Figure 2.4a and 
Figure 2.4(b) have a significant impact on the dendrimer biodistribution.  The impact of the 
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Figure 2.4 In vivo biodistribution of G3NH2 and G3NH2-24PEG1000 delivered via (a) 
pharyngeal aspiration (P.A.) and (b) I.V., 6.5 hours after administration (n=3 per group).  
The insets highlight the biodistribution of the conjugates in the different lymph nodes; 
when they are all combined, they are represented in the main figure as LN.  ALN: axillary 
lymph nodes; BLN: bronchial lymph nodes; CLN: cervical lymph nodes; MLN: mesenteric 
lymph nodes.  The statistical analysis was performed between G3NH2 and G3NH2-
24PEG100  with Student’s t-test (*p<0.05, **p<0.01, and ***p<0.001). 
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conjugate chemistry, however, is observed to be much less pronounced following I.V. delivery 
when compared to P.A. administration.  It can also be observed that the amount of conjugate found 
in the lungs is much higher when they are administered via. P.A. than compared to I.V. delivery, 
as expected.  While 83.4±7.3% of the injected dose for G3NH2 and 67.7±7.4% of injected dose 
for G3NH2-24PEG1000 are present in the lungs 6.5 h hours post P.A. administration, only 1.6 ± 
0.5 % G3NH2 and 0.9 ± 0.4 % G3NH2-24PEG1000 can be found in the lungs at the same time 
when administered I.V.  The lung retention upon P.A. delivery is also impacted by the chemistry 
of the nanocarriers.  The positively charged G3NH2 is retained longer in the lungs, while the 
PEGylated dendrimer translocates to systemic circulation and leaves the lungs to a higher extent.  
These results suggest the potential of the dendrimer nanocarriers for the targeting of lung diseases 
when combined with oral inhalation formulations as the chemistry of the conjugates can be used 
to modulate the transport of therapeutics across the pulmonary epithelium.  The potential in using 
such nanocarrier systems is supported by our recent results where we demonstrate that dendrimer 
nanocarriers can be formulated in portable oral inhalation devices,[184] and those can be used for 
the delivery of small molecules [146, 184] or biomacromolecules such as nucleic acids.[144, 163] 
We also observed that the dendrimers administered via P.A. show up in significant 
quantities in the lymph nodes (LN), while no accumulation is observed upon I.V. administration.  
In fact, on a mass/tissue basis (Figure S4), the mass of conjugates found in the LN upon P.A. is 
second only to the lungs.  It can also be observed that the chemistry of the conjugates plays a major 
role in terms of their biodistribution to the LNs upon P.A. delivery.  The PEGylated dendrimer 
appears in significantly greater concentrations in the bronchial lymph nodes (BLN) and cervical 
lymph nodes (CLN), and in the thymus as well compared to the non-PEGylated conjugates. 
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Charge effects on biodistribution have been reported for solid nanoparticles.[39, 194]  
Neutral (polystyrene-polyacrylate) and hydrophilic (PEG20kDa) organic nanoparticles smaller 
than 38 nm and with PEG ligands were rapidly translocated to mediastinal lymph nodes, while 
anionic and cationic charged nanoparticles readily adsorbed on endogeneous protein in the lungs.  
When polystyrene nanoparticles ranging from 50 to 900 nm are administered to the lungs, the 
highest nanoparticle deposition (35 – 50% of extrapulmonary distribution) was also detected in 
the lymph nodes 3 h after pulmonary administration.[55] 
These results point to a strategy for passively targeting the lymph nodes with dendrimers 
upon delivery via P.A., which may prove relevant for the development of various dendrimer-based 
therapies, including pulmonary vaccination (e.g. influenza,[196] tuberculosis,[145] HPV 
infection[197]) and diseases of the lymphatic system such as metastasis (e.g. breast cancers [198]). 
No obvious fluorescence was found in the major organs responsible for elimination of the 
dendrimers such as liver, spleen and kidneys at 6.5 h post administration when the conjugates were 
delivered via P.A..  In contrast, significant quantities of the conjugates are detected in liver, spleen 
and kidneys when the conjugates were administered intravenously.  In that case, greater 
concentrations of the non-PEGylated dendrimers are cleared/found in the kidneys (32.8±8.8%), 
spleen (5.3±2.5%) and liver (7.0±3.7%) when compared to the than PEGylated conjugates (2.7±1.2% 
in kidneys, 2.9±1.7% in liver, and 2.7±1.6% in spleen).  These results are in excellent agreement 
with the PK results discussed above.  In fact, the accumulation of bare dendrimer in the kidneys 
may be underestimated to some extent since previous studies showed PAMAM dendrimers can be 
detected in urine 2 h after I.V. injection.[199]  The distribution of dendrimer in both kidneys and 
liver/spleen revealed renal excretion and MPS are able to play roles in dendrimer elimination.  
Noticeably, the kidneys showed the greatest fluorescence in the case of bare dendrimer, 
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demonstrating that the bare dendrimer was mainly eliminated renally due to its small size (5.1 
nm).[49]  However, the PEGylated conjugates show no preferable accumulation site at 6.5 h. 
2.4.4 Lung cellular biodistribution of the dendrimer conjugates administered via 
pulmonary route. 
The internalization of the dendrimer conjugates in selected lung cell types upon P.A. was 
also assessed.  Four typical pulmonary cell populations were selected to be tagged during the flow 
cytometry experiments, namely myeloid, endothelial, alveolar epithelial and airway ciliated 
epithelial cells.  The characteristic receptors of these cells are CD45 on myeloid cells, CD31 on 
endothelial cells, lung pro-surfactant protein C (pro-SPC) on alveolar epithelial type II cells, and 
cilia layer on apical side of airway epithelial cells.  Cilium is a microtubule-based cytoskeleton 
that is constructed by β-tubulin in combination with α-tubulin.  Therefore, ciliated airway 
epithelium has much higher levels of β-tubulin than other cells do.  The flow cytometry results are 
summarized in Figure 2.5 – representative dot plots are shown in the Supplemental Information 
in Appendix 1– Figure S3. 
The flow cytometry results (inset in Figure 2.5) indicate that G3NH2 is found internalized 
in 32.8±3.6% of the pulmonary cells upon P.A. delivery, while the % of the cells that had 
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Figure 2.5 Lung cellular distribution studies upon lung 
delivery of the dendrimer conjugates.  Break down in terms 
of cell type (out of those cells that had internalized dendrimer 
conjugates) and dendrimer conjugate PEGylation.  Inset: % of 
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internalized G3NH2-24PEG1000 was 27.9±2.7%.  While no statistically significant difference was 
found when comparing the average for both groups, a lower percentage of internalization of the 
PEGylated dendrimer would be in agreement with the fact that PEGylation has been shown to 
decrease the rate and extent of internalization within this time frame - as shown in vitro,[168, 183].  
This observed trend also confirms that the PEGylated dendrimers seem to be transported into 
systemic circulation faster (PK results) and are found at a lower concentration in the lungs 
(biodistribution results). 
Myeloid cells, including monocytes, granulocytes, dendritic cells and macrophages, were 
observed to internalize the largest fraction of dendrimers when compared to all other cells.  While 
the specific cell subpopulation was not determined, these results suggest that such dendrimer 
conjugates would be able to target cells that are relevant in the treatment of medically important 
diseases such as tuberculosis,[145] and in vaccine delivery applications.[196]  It is also observed 
that the cell populations interact differently with the different chemistries.  For example, while 
37.2% of the cells that internalized G3NH2 were myeloid type, the preference of myeloid cells 
was lower towards G3NH2-24PEG1000.  As a matter of fact, the percentage of all cells (based on 
cell type) that had internalized G3NH2-24PEG1000 was lower than the percentage of cells that 
internalized G3NH2.  This was not true for endothelial cells, where 20.4% contained G3NH2-
24PEG1000, compared to only 6.0% for G3NH2.  These results support the view that the 
PEGylated dendrimers can more efficiently transport across the epithelial barrier of the pulmonary 
epithelium, and gain access to the endothelial layer, where they are internalized, while at the same 
being able to evade internalization by myeloid cells. 
In addition, the dendrimer nanocarriers can be also significantly internalized by alveolar 
epithelial cells (G3NH2 vs. G3NH2-24PEG1000 = 22.9±3.7% vs. 16.1±4.5% of those cells 
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internalizing dendrimer nanocarriers) and ciliated airway epithelium (G3NH2 vs. G3NH2-
24PEG1000 = 12.4±4.2% vs. 8.3±1.8% of those that internalized dendrimer).  These results show 
that highly positively charged bare dendrimers are entrapped by or interacts with the epithelial 
layer to a larger extent than their PEGylated counterparts.  The internalization of dendrimer 
nanocarriers by alveolar/airways epithelial cells implies its potential for drug delivery to the 
diseases that cause acute/chronic dysfunctional respiratory tract and lungs such as pneumonia 
(usually in alveolar sacs), and asthma (airways and lungs). 
Combined, the biodistribution, PK and lung cellular distribution results shown here provide 
us with clues that can help formulate a reasonable hypothesis as to why the dendrimer conjugates 
are so effectively drained into the lymph nodes upon P.A.  While big particles (> 500 nm) require 
the activation of antigen-presenting cells (e.g. dendritic cells, B cells) to be trafficked to lymph 
nodes,[55] dendrimer nanocarriers with hydrodynamic diameters < 10 nm tend to rapidly 
translocate across pulmonary epithelium from airway/alveolar luminal surface to septal 
interstitium, followed by rapid accumulation to lymph nodes.  This step doesn’t need to activate 
antigen-presenting cells (APCs).  It is believed that the passive pathway may play a major role in 
targeting dendrimer nanocarriers to lymph nodes.[200]  Although APCs would rather phagocytize 
large particles than small ones, the abundance of APCs in the respiratory tract and lungs can also 
effectively take up smaller carriers such as dendrimers.  The macrophages and dendritic cells 
activated by the phagocytosis of dendrimer nanocarriers migrate via lymph flow to 
tracheabronchial and bronchiolar lymph nodes including bronchial-associated lymphatic tissue 
(BALT), and are eventually carried into draining lymph nodes.[152, 201, 202]  In addition, the 
routing of dendrimer nanocarriers to lymph nodes is dictated by their surface chemistry. 
2.5 Conclusions 
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In this work we investigated the effect of the surface chemistry (PEGylated vs. non-
PEGylated) and the route of administration (pulmonary delivery vs. intravenous injection) on the 
systemic tissue biodistribution and local (lung) cellular distribution of G3NH2 dendrimers.  The 
results show that both have a strong impact on how the dendrimers interact with the physiological 
environment.  Biodistribution results show much greater accumulation of dendrimer nanocarriers 
in lungs and a variety of lymph nodes upon pulmonary delivery, for both PEGylated and non-
PEGylated dendrimers when compared to I.V. administration.  PEGylation is seen to further 
promote the passive targeting of dendrimers to lymph nodes upon pulmonary administration.  
Upon systemic delivery, PEGylation was seen to increase circulation times, as expected, with very 
little lung or lymph node accumulation.  PEGylation also helps modulated the uptake of 
dendrimers by different lung cell populations.  The results shown here suggest that both the 
pulmonary route of administration and dendrimer chemistry combined can be used to passively 
target tissues of great interest, and can thus be used as guiding principles in the development of 
dendrimer-based drug delivery strategies for medically relevant diseases including lung ailments, 
pulmonary vaccination, and malignant metastases among others. 
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found Appendix A.
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CHAPTER 3 — Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: In 
vitro characteristics and Pseudo-Solution Formulation in Pressurized Metered-
Dose Inhalers 
3.1 Introduction 
Cancer is the second most common cause of death in the United States.[2, 203]  An 
estimated 1.7 million new cases are diagnosed yearly, with ca. 600 thousand cancer deaths.[204]  
Among the many types of malignant tumors, lung cancers are of great relevance as they are the 
leading cause of cancer death among both men and women.[1, 205]  More people die of lung 
cancer than colorectal, breast, pancreatic, and prostate cancers combined.[2] 
Chemotherapy is widely used in the fight against primary lung cancers and lung 
metastasis.[6, 44-46]  However, there are several limitations in using chemotherapeutics to treat 
lung cancers.  One major challenge is the low chemotherapeutic concentration found in the lung 
tumor upon intravenous (i.v.) administration.[6, 7]  It is estimated that only a few percent (ca. 2-
4%) of the total dose administered i.v. reaches the lung tumor.[8]  Dose limiting toxicity is another 
major issue in the chemotherapeutic treatment of lung cancers.[9]  This problem is compounded 
as high i.v. dosages are usually required due to the poor distribution profile of 
chemotherapeutics.[8] 
Doxorubicin (DOX) is a leading therapeutic in clinical oncology, having a broad range of 
activity against both “liquid” and solid tumors,[88] including lung cancers.[6, 57, 206]  Since the 
discovery of DOX, thousands of other anthracyclines have been screened for their anticancer 
properties, but only few have emerged as clinically relevant.[92]  In spite of its immense 
acceptability, however, DOX causes a series of side effects, of particularly relevance being its 
toxicity to the cardiac tissue.[207-209]  While DOX-induced cardiomyopathy is clinically 
manageable, it is associated with 50% mortality in those patients that develop congestive heart 
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failure during treatment,[210, 211] thus limiting the range of applicability of this powerful 
therapeutic.  The ability to efficiently deliver DOX locally to the lungs, and to improve DOX’s 
biodistribution by minimizing its concentration in the cardiac tissue may, therefore, represent an 
important step forward in the use of such a relevant anti-cancer therapeutic in the treatment of lung 
cancers. 
Nanocarriers have the potential to improve the biodistribution and pharmacokinetic 
profiles of various therapeutics including anti-cancer drugs.[47-50]  Dendrimers are particularly 
relevant nanocarrier systems as they are highly monodisperse,[31] have a large number of surface 
groups amenable to the conjugation of therapeutic molecules and also other agents and ligands that 
allow for the enhancement of the properties of the nanocarriers such as increased aqueous 
solubility upon conjugation of hydrophobic therapeutics[30] (as is the case for DOX), and 
enhanced pharmacokinetic and biodistribution profiles,[169] as well as the tagging of imaging 
agents for theranostics,[199, 212] among others.  Particularly relevant to this work is the fact that 
we have also recently shown that the chemistry of generation 3, amine-terminated PAMAM 
dendrimers (G3NH2) can be used to modulate their interaction with the pulmonary epithelium both 
in vitro and in vivo,[168] and can thus be potentially used to improve therapeutic outcomes of 
DOX. 
Based on the challenges and opportunities discussed above, the goal of this work was to 
evaluate the interaction of PAMAM dendrimer-DOX conjugates with an in vitro lung cancer 
model, and to develop portable oral inhalation (OI) formulations for the local delivery of the DOX 
conjugates to the lungs.  More specifically, we propose to synthesize and characterize G3NH2-
DOX conjugates with an intracellular degradable linker and varying densities of PEG 1000Da, and 
to evaluate the kinetics of cellular internalization, intracellular DOX release and organelle 
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colocalization, and cell kill on A549 cells – a model of the alveolar epithelial human 
adenocarcinoma.  Moreover, we also propose to develop HFA-based pMDI formulations of the 
G3NH2-DOX conjugates with aerosol characteristics conducive to deep lung deposition of DOX. 
3.2 Materials 
Generation 3, amine-terminated, poly(amido amine) (PAMAM) dendrimer (G3NH2, 32 -
NH2 surface groups, theoretical molecular weight = 6909) was purchased from Dendritech, Inc 
(Miland, MI, USA).  PEG1000Da succinimidyl ester (PEG1K-SE) was purchased from NANOCS 
Inc (New York, NY, USA).  Doxorubicin hydrochloride salt (DOX) was purchased from LC 
Laboratories (Woburn, MA, USA).  Cis-aconityl anhydride, succinic anhydride, triethylamine 
(TEA), 2, 5-dihydoxybenzoic acid (2, 5-DHB), ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxylsuccinimide (NHS) were purchased from Sigma-Aldrich (St Louis, MO, 
USA).  3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was purchased 
from Life Technologies (Grand Island, NY, USA).  Deuterated dimethylsulfoxide (DMSO_d6) 
was purchased from Cambridge Isotope Laboratories (Andover, MA, USA).  Ultrapure deionized 
water (DI H2O, Ω=18.0-18.2) was sourced from a Barnstead NANOpure DIamond System 
(D11911), equipment purchased from Thermo Fisher Scientific (Waltham, MA, USA).  
1,1,1,2,3,3,3-heptafluoropropane (HFA227) with trade name Dupont™ FM-200® and 2H, 3H 
perfluoropentane (HPFP) with trade name Vertrel™ XF were purchased from Dupont 
(Wilmington, DE, USA).  A549 human lung cancer cell line was purchased from American Type 
Culture Collection (Manassas, VA, USA).  Spectra®Por dialysis membrane (MWCO = 3000Da) 
was purchased from Spectrum Laboratories, Inc (Rancho Dominguez, CA, USA).  Amicon® Ultra 
15 centrifugal filter device (MWCO = 3000Da) was purchased from EMD Millipore (Billerica, 
MA, USA).  Thin layer chromatography (TLC) Silica gel 60 F254 plastic sheet was purchased from 
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Merck KGaA (Darmstadt, Germany).  All reagents were used as received unless specified 
elsewhere. 
3.3 Methods 
3.3.1 Synthesis and characterization of acid-labile, PEGylated PAMAM-DOX conjugates 
(G3NH2-mPEG-nDOX).   
As shown in Figure 1, DOX was reacted with cis-aconityl anhydride in basic aqueous 
solution to obtain cis-aconityl DOX.  Acid-labile, PEGylated conjugates were synthesized via two 
different routes: Direct PEGylation or Two-step PEGylation.  In the Direct PEGylation approach, 
cis-aconityl DOX was first conjugated to G3NH2 using EDC/NHS chemistry.  PEG was 
subsequently conjugated to G3NH2-nDOX to obtain the final product G3NH2-mPEG-nDOX.  
Various PEG densities (m = 0, 9 and 21) were achieved by reacting different ratios of PEG-SE to 
G3NH2-nDOX.  The Two-step PEGylation strategy was required in order to achieve higher 
payloads of DOX (in this particular case for n = 7), as G3NH2-nDOX becomes too hydrophobic 
and crashes out of solution for n > 3.  In the Two-step PEGylation strategy, G3NH2 is first pre-
PEGylated at a low/medium PEG density.  Cis-aconityl DOX is subsequently conjugated (to a 
high/desired payload) to the pre-PEGylated dendrimer using EDC/NHS chemistry.  Finally, 
additional PEG is conjugated onto the pre-PEGylated dendrimer-DOX conjugates, so as to achieve 
the desired/final PEG density.  Proton nuclear magnetic resonance (1H NMR) was recorded using 
Mercury 400 spectrometer (Agilent Technologies, Inc.  Santa Clara, CA, USA).  The molecular 
weight (MW) of the various intermediates and final products was determined by electrospray 
ionization (ESI) mass spectrometry using a ZQ-Waters TERS/Micromass spectrometer (Waters 
Corporation. Milford, MA, USA) and matrix-assisted laser desorption ionization-time of flight 
(MALDI-TOF) using a Bruker Daltonics UltrafleXtreme mass spectrometer (Bruker Corporation. 
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Billerica, MA, USA).  Hydrodynamic diameter (HD) and zeta potential (ζ) were determined using 
Zetasizer Nano ZS (Malvern Instruments Ltd. Malvern, Worcestershire, UK).  Solvated diameter 
(SD) was also determined using the Zetasizer Nano ZS, but in that case in HPFP (non-aqueous 
solvent).  Detailed procedures for these measurements are described in Supplemental Information 
S1, and all synthetic details of the conjugates are also described in Supplemental Information S2 
in Appendix 2.   
3.3.2 Synthesis and characterization of non-labile, PEGylated PAMAM-DOX conjugates 
(G3NH2-mPEG-nDOXNL).   
The non-labile G3NH2-mPEG-nDOXNL conjugates were synthesized via the same 
strategy—direct PEGylation and two-step PEGylation—as described in Section 3.1.  The only one 
difference is that DOX was first reacted with succinic anhydride in non-aqueous solution.   
3.3.3 Culture of A549 Cells.   
Human lung alveolar adenocarcinoma epithelia cells (A549), passages 10 to 15, were 
plated in 75 cm2 cell culture flask at a density of 104 cells/mL, and cultured with Dulbecco’s 
Modified Eagle’s Medium (DMEM, Life Technologies) supplemented with 10% Fetal Bovine 
Serum (FBS, Atlanta Biologicals) and penicillin (100 U/ml)-streptomycin (100 µg/ml) (Pen-Strep. 
Life Technologies).  The cells were grown in Thermo Scientific™ CO2 incubator (Thermo Fisher 
Scientific) at 37 oC and 5% CO2.  The medium was exchanged every two days and the cells were 
split when they reached ca. 80% confluence. 
3.3.4 In vitro release of acid-labile G3NH2-mPEG-nDOX and acid-non-labile G3NH2-
mPEG-nDOXNL conjugates.   
In vitro release was determined at both pH 7.4 and 4.5, representing the extracellular physiological 
pH and the lysosomal pH, respectively.  A 2 mL of phosphate buffer saline (PBS, 1X, pH 7.4) or 
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citrate buffer (0.01 M, pH 4.5) containing free DOX or the conjugates (all with 0.38 µmol DOX 
or equiv.) was added to a dialysis membrane (MWCO = 3000Da), and the system immersed in 30 
mL PBS or citrate buffer.  The in vitro release studies were performed in MaxQ thermostatic water 
bath shaker (Thermo Fisher Scientific), preset to 37.0 ± 0.2 °C.  A 0.1 mL solution from outside 
the dialysis bag was sampled at predetermined time points, and the concentration of DOX 
determined using a Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek Instruments, Inc. 
Winnooski, VT, USA), at 490 nm.  The samples were returned after each time point.  These 
experiments were run in triplicate.  The cumulative release of DOX from G3NH2-mPEG-nDOX 
and G3NH2-mPEG-nDOXNL was plotted as a function of time. 
3.3.5 Cell kill of acid-labile G3NH2-mPEG-nDOX and acid-non-labile G3NH2-mPEG-
nDOXNL conjugates.   
The ability of DOX, G3NH2-mPEG, G3NH2-mPEG-nDOX, and G3NH2-mPEG-nDOXNL 
conjugates to kill A549 lung cancer cells was assessed using the MTT assay.  A series of 
concentrations were sterilized by filtering sample-laden DMEM (no phenol red) through 0.22 µm 
sterile syringe filter (VWR Internationals. Radnor, PA, USA).  1×104 cells/well (n=8 per 
concentration) were seeded in tissue culture treated 96-well plate (VWR Internationals) with 
DMEM (no phenol red).  The medium was removed after 24 h, and 100 µL of the sample-laden 
DMEM (no phenol red) was pulsed to each well.  The samples were incubated with cells for 72 h 
or 144 h.  The sample-laden medium was then removed from each well.  The cells were washed 
with PBS (1X, pH 7.4) twice.  100 µL of fresh DMEM (no phenol red) and 10 µL of MTT PBS 
solution (5 mg/ml) were added to each well.  After 4 h (37 oC, 5% CO2), 75 µL of medium was 
removed, and 60 µL DMSO was added into each well to dissolve formazan crystal.  The cells were 
allowed to sit in the incubator (37 oC, 5% CO2) for another 2 h.  Finally, the absorbance of each 
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well was recorded at 540 nm using Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek 
Instruments, Inc). 
3.3.6 Cellular internalization of acid-labile G3NH2-mPEG-nDOX conjugates by A549 cells.   
3×105 A549 cells/well were seeded in 24-well plates 24 h before the experiment.  A 0.5 mL sterile 
Hanks Balanced Salt Solution (HBSS, 1X, pH 7.4) of free DOX or G3NH2-mPEG-nDOX 
conjugates (0.1 µM DOX equivalent) was added to each well and then incubated with cells for 
different lengths of time (0.5, 1, 1.5, 2, 3, 4 and 5 h. n=3 per time point).  The cellular 
internalization was ceased at each time point by replacing sample-laden HBSS with cold blank 
HBSS.  The cells were detached with 0.2 mL 0.25% trypsin-0.53 mM EDTA solution (Life 
Technologies).  The detached cells were pelletized by centrifugation at 350 g.  The cell pellet was 
resuspended in 0.5 mL blank HBSS (4 oC) and immediately analyzed for DOX fluorescence using 
flow cytometry (BD LSR II Analyzer, BD Bioscience. San Jose, CA, USA).  At least 10,000 events 
were counted for statistical significance.  Median fluorescence intensity (MFI) was plotted as a 
function of time to evaluate the effect of dendrimer chemistry (PEG density and DOX payload) on 
cellular internalization. 
3.3.7 Intracellular release and nuclear colocalization of DOX from acid-labile G3NH2-
mPEG-nDOX conjugates.   
2×105 cells were seeded on a cover slide, which was placed in a 24-well plate.  After 24 h, a 0.5 
mL DMEM (no phenol red) solution of the acid-labile G3NH2-mPEG-nDOX conjugates (4 µM 
DOX equivalent) was incubated with the cells for 48 h.  The sample-containing medium was then 
thoroughly removed by washing the cells with PBS (1X, pH 7.4) three times.  Nuclei were then 
stained with Hoechst 33342 (Life Technologies) for 10 min and excess dye was thoroughly washed 
away with PBS three times.  The cells were fixed with 4% paraformaldehyde PBS solution (Sigma-
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Aldrich) at 4 °C for 20 min and then mounted for imaging.  The fixed cells were imaged with Zeiss 
LSM 780 Confocal Laser Scanning Microscope (Carl Zeiss Microscopy. Oberkrochen, Germany).  
To evaluate the intracellular release of DOX from acid-labile G3NH2-mPEG-nDOX conjugates as 
a function of time (and the free DOX control), the DOX or conjugate-laden medium was incubated 
with cells for different lengths of time (24, 48, 96 and 144 h, with n=3 per time point).  The 
Pearson’s correlation coefficient (PCC) was calculated as a function of time using the Leica LAS 
AF Lite software (Leica Microsystems. Buffalo Grove, IL, USA).  The results were compared with 
free DOX.  Colocalization of the non-labile conjugates was also qualitatively assessed by 
rendering the 3D confocal images of A549 cell incubated with the G3NH2-mPEG-nDOXNL 
conjugates, and stained with nuclear stain. 
3.3.8 Preparation and characterization of the pMDI formulations 
3.3.8.1 Physical stability of acid-labile G3NH2-mPEG-nDOX conjugate formulation in 
HFA227 propellant.   
A predetermined amount of G3NH2-mPEG-nDOX conjugates and anhydrous ethanol were 
weighed into pressure proof glass vial (West Pharmaceutical Services. Exton, PA, USA).  
Subsequently, the glass vial was crimped manually using 63 µL metering valves (Bespak. Norfolk, 
UK).  HFA227 propellant (4 mL) was added to the sealed glass vial with the help of a manual 
syringe pump (HiP 50-6-15) and a home-made high pressure filler.  The resulting formulation was 
placed in VWR P250D low energy sonication bath (VWR Internationals) for 30 min, which was 
set to 180 W and 0-5 oC.  The physical stability of the formulations was evaluated by visually 
monitoring the dispersion as a function of time after sonication. 
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3.3.8.2 Particle size measurement. 
The solvated diameters (SD) of G3NH2-mPEG-nDOX conjugates were determined using 
light scattering (LS).  Briefly, the aqueous solution of G3NH2-mPEG-nDOX conjugate was 
filtered with 0.22 µm syringe filter (VWR Internationals) and then lyophilized.  HPFP was also 
filtered with 0.22 µm syringe filter (VWR Internationals) to remove any impurities in solvent.  The 
purified G3NH2-mPEG-nDOX conjugate (0.2 mg DOX equivalent) was added to 1 mL HPFP with 
the help of anhydrous ethanol (0.37 % v/v).  The HPFP was added and then sonicated at 0-5 oC for 
30 min.  The SD of the conjugate in HPFP was determined using Zetasizer Nano ZS (Malvern 
Instruments).  The average SD and standard deviation (s.d.) were calculated based on at least three 
measurements. 
3.3.8.3 Aerosol performance of the pMDI formulations.   
The in vitro aerosol characteristics of G3NH2-mPEG-nDOX pMDI formulations were 
determined with Andersen Cascade Impactor (CroPharm, Inc. Milford, CT, USA) fitted with a 
USP induction port.  All measurement was operated at a flow rate of 28.3 L/min, 25 oC and 75% 
relative humidity.[163]  The pMDI formulations were prepared as described above and several 
shots were fired to waste.  Subsequently, 10 shots were released into an Anderson Cascade 
Impactor (ACI) with 10 s interval between shots.  The run was promptly stopped 10 s after the last 
shot.  The ACI was dissembled carefully.  Actuator, induction port, eight plates and filter 
membrane were thoroughly rinsed with 10 mL DI H2O each.  The concentration of the G3NH2-
mPEG-nDOX conjugates collected in the aqueous solutions was measured at 490 nm using Cary 
50 UV-Vis spectrometer (Agilent Technologies. Santa Clara, CA, USA).  The mass of the 
conjugates deposited on the actuator, induction port, and each plate were calculated relative to an 
established calibration curve.  The following aerosol parameters were calculated: respirable 
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fraction (RF), fine particle fraction (FPF), mass median aerodynamic diameter (MMAD), 
geometric standard deviation (GSD) and recovery.  The RF is defined as the ratio of mass of 
particles collected on Stage 0 to filter to the mass of particles released into the ACI.  The FPF is 
defined as the ratio of mass of particles on Stage 3 to filter, to the mass of particles on Induction 
port to Filter.  The MMAD represents the median of the distribution of airborne particle mass with 
respect to aerodynamic diameter.  MMAD is usually reported along with the GSD, which 
characterizes the variability of the particle size distribution.  GSD is defined as the square root of 
the ratio of 84.13% over 15.87% particle size distribution.  Further details on the calculation of 
MMAD and GSD has been previously reported.[80]  The recovery is calculated by dividing 
collected dose (mass of particles in actuator, induction port, stage 0-7 and filter) by theoretical 
dose (concentration × volume per puff × puff number).   
3.4 Results and Discussion 
3.4.1 Synthesis and characterization of acid-labile G3NH2-mPEG-nDOX and non-labile 
G3NH2-mPEG-nDOXNL conjugates.   
DOX was conjugated to generation 3, amine-terminated PAMAM dendrimers (G3NH2) 
through an acid-labile cis-aconityl spacer.  After forming two amide bonds with DOX and G3NH2, 
cis-aconityl anhydride has one free carboxyl group (-COOH) left, which can readily catalyze the 
cleavage of its neighboring intra-molecular amide bond at acidic conditions (i.e. pH < 5), and thus 
release conjugated DOX – not the pro-drug but DOX itself.[213] 
Two synthetic strategies were developed for synthesis of PEGylated PAMAM dendrimers 
containing different DOX payloads: direct PEGylation for low DOX payloads, and two-step 
PEGylation for high DOX payloads, as shown in Figure 3.1. 
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In the direct PEGylation strategy, cis-aconityl DOX was first conjugated to G3NH2, 
followed by PEGylation.  However, the maximum payload that can be obtained before the 
conjugate becomes water insoluble is ca. 3.3 DOX.  Therefore, an alternative strategy is required 
in order to prepare G3NH2-DOX conjugates with higher DOX payloads.  The way we approached 
the problem was to first prepare G3NH2 with an initial loading of PEG1000, and only then 
conjugate the hydrophobic DOX.  For a pre-PEGylated G3NH2 with 7PEG1000, we observed that 
up to 8.8 DOX molecules can be conjugated before the nanoconstruct becomes water insoluble. 
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Figure 3.1 Synthesis of the PEGylated, generation 3, amine-terminated PAMAM dendrimer 
(G3NH2) conjugated with DOX.  DOX conjugated via an acid-labile linker: G3NH2-mPEG-nDOX; 
DOX conjugated via a non-labile linker: G3NH2-mPEG-nDOXNL. 
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Based on these observations, it seems that a further increase in DOX payload can be 
achieved by initially conjugating higher number density of PEG1000.  Using this approach, in 
order to achieve the final / desired PEG density (if greater than 7PEG100), a second round of 
PEGylation is needed.  This two-step PEGylation strategy is a viable approach to achieve both 
high degree of PEGylation and high DOX payload. 
We also attempted another strategy in which high PEGylation preceded DOX conjugation, 
so as to avoid a two PEGylation strategy.  However, only 4.4 DOX can be conjugated to G3NH2-
22PEG1000, leading to the failure to achieve high DOX payload.  A similar strategy in which 
PEGylation precedes DOX conjugation has been also reported in an earlier work.  High density of 
peripheral PEG, however, was not attempted (20 PEG out of 64 surface groups) in these reports.[34, 
125]  However, we will show later that in our work high PEGylation densities are required for the 
formulation of these nanoconstructs in pMDIs. 
In summary, the synthesis of PEGylated PAMAM with low DOX payload (i.e. 3-4 
DOX/G3NH2) can be performed independently of the sequence of DOX and PEG conjugation, 
while the conjugates with high DOX payload (> 7-9 DOXs/G3NH2) need to follow the conjugation 
sequence: 1st PEGylation  DOX conjugation  2nd PEGylation. 
As described for the acid-labile counterparts, the acid-non-labile conjugates with low and 
high payloads were synthesized via direct PEGylation or two-step PEGylation, with cis-aconityl 
spacer replaced by succinic linker.  The disappearance of free carboxyl group in succinic spacer 
renders the conjugates stable under both acidic and neutral conditions (G3NH2-mPEG-nDOXNL). 
The acid-labile G3NH2-mPEG-nDOX and non-labile G3NH2-mPEG-nDOXNL 
conjugates were characterized by 1H NMR, MALDI, and ESI.  The ESI (m/z) peaks at 700.2016 
([cis-aconityl DOX+H]+), 722.1509 ([cis-aconityl DOX+Na]+), and 738.1769 ([cis-aconityl 
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DOX+K]+) confirm the successful reaction between DOX and cis-aconityl anhydride, while 
666.1815 ([succinic DOX+Na]+) and 682.1591 ([succinic DOX+K]+) were assigned to succinic 
DOX (Supplemental Information in Appendix 2).  The 1H NMR peaks at 6.397 ppm (-CH=C- of 
Figure 3.2 Example of (a) 1H NMR spectra of PEGylated G3NH2 
dendrimer with acid-labile DOX conjugates (G3NH2-3DOX and 
G3NH2-21PEG-7DOX).  Inset: chemical structure of G3NH2-
mPEG-nDOX.  Spectral shifts for all compounds are provided in 
Supplemental Information S2 in Appendix 2, and (b) MALDI 
spectra of a PEGylated G3NH2 dendrimer with acid-labile DOX 
conjugates (G3NH2-21PEG-7DOX) and the intermediates 
synthesized via two-step PEGylation strategy. 
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aconityl spacer), 4.025 to 3.936 ppm (-CH2- in PEG) and characteristic peaks of DOX (see 
Supplemental Information in Appendix 2) indicate that DOX was successfully conjugated to 
dendrimer to form G3NH2-mPEG-nDOX – Figure 3.2a.  In Figure 3.2b we show an example of 
MW change of the conjugates prepared in the two-step approach (G3NH2-21PEG-7DOX), as 
monitored by MALDI-TOF.  Results for the all other materials are provided in Supplemental 
Information in Appendix 2. 
 
The PEG density, DOX payload, and MW of acid-labile G3NH2-mPEG-nDOX and acid-
non-labile G3NH2-mPEG-nDOXNL conjugates were quantified and are summarized in Table 3.1 
along with their hydrodynamic diameter (HD) and zeta potential (ζ). 
Table 3.1 Molecular weight (MW), number of PEG1000 grafts (m), number of doxorubicin 
(DOX) conjugates (n), hydrodynamic diameter (HD), and zeta potential (ζ) of the PEGylated, 
generation 3, amine-terminated PAMAM dendrimer (G3NH2) conjugates.  DOX conjugated 
via an acid-labile linker: G3NH2-mPEG-nDOX; DOX conjugated via a non-labile linker: 
G3NH2-mPEG-nDOXNL.  Results obtained by 
1H NMR, MALDI, and light scattering (LS) 
at 25oC.  s.d. = standard deviation. 
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A series of dendrimers linked with 3 DOX through a pH labile bond or stable bond (control) 
and varying PEG1000 density were prepared.  Another system with 7 DOX was also prepared to 
compare the effect of DOX loading.  The HD is seen to increas upon PEGylation and DOX 
conjugation, with sizes ranging from 4.0 to 11.3 nm.  At low DOX density, the HD is dominated 
by the PEG density, as all dendrimers with the same PEG density have similar HD, except for 
G3NH2-10PEG.  G3NH2-10PEG’s small HD may be related to the fact that PEG can more easily 
form strong bonds with the protonated terminal amine groups of G3NH2, and thus assume a more 
collapsed configuration.[182, 214]  The addition of 7DOX to the dendrimer with high PEG density 
seems to have an impact on the overall size, albeit not statistically significant. 
We can also observe that the ζ of the nanocarriers decreases from a large positive value for 
the conjugates with no PEG, to negatively charged at high PEG density – note here that this is the 
case in spite of the fact that not all surface groups have been modified with PEG, and thus 
protonated amines are still expected to be present.  This effect may be related to the fact that ether 
oxygen from PEG can strongly interact with the protonated surface amines, thus shielding the 
surface charge of the nanocarriers.[182, 215]  The presence of the extra carboxyl group of the acid-
labile DOX linker also helps decrease the overall charge of the dendrimer, as can be observed by 
comparing for example G3NH2 2-
high PEG densities.[168] 
Sizes and charges are some of the most relevant parameters in the design of nanocarriers 
for drug delivery applications, as these properties dictate how the dendrimer nanocarriers interact 
with the physiological environment, and thus their fate, including bioavailability, 
pharmacokinetics and pharmacodynamics.[30, 169]  The next step in our work was to evaluate the 
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success of the acid-labile DOX conjugation strategy, by determining the release at relevant 
physiological pHs. 
3.4.2 In vitro release of DOX from acid-labile G3NH2-mPEG-nDOX and non-labile 
G3NH2-mPEG-nDOXNL conjugates at extracellular physiological and lysosomal pH 
   
The DOX released from the acid-labile G3NH2-mPEG-nDOX conjugates and the effect of 
PEG density on the release of DOX were investigated at pH 7.4 (extracellular physiological pH) 
and 4.5 (lysosomal pH).  The release profiles were compared to that of the acid-non-labile G3NH2-
mPEG-nDOXNL conjugates and free DOX, the controls.  The results are summarized in Figure 
3.3. 
Figure 3.3  In vitro release profiles of DOX from the acid-labile (G3NH2-mPEG-nDOX) and 
non-labile (G3NH2-mPEG-nDOXNL) conjugates at (i) lysosomal pH = 4.5: (a) and (b); (ii) 
physiological pH = 7.4: (c) and (d), all at 37 oC. 
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As shown in Figure 3.3 (b and d), only very small amounts of conjugated DOX are released 
from the acid-non-labile G3NH2-mPEG-nDOXNL conjugates at either physiological or acidic pH 
conditions (<4%).  In contrast, the release of DOX from G3NH2-mPEG-nDOX is shown to be a 
strong function of pH.  While small (<9%) amounts of DOX are released from G3NH2-mPEG-
nDOX at pH 7.4, when G3NH2-mPEG-nDOX is in contact with an acidic medium, > 80-85% 
DOX is released from the acid-labile conjugates.  Based on the released profile of free DOX, we 
expect the losses of up to ca. 7% of DOX (lack of recovery) due to interactions of DOX with the 
dialysis bag and to a lesser extent due to photobleaching. 
The rate and total amount of DOX released from the acid-labile conjugates is also seen to 
be a function of the PEGylation density of G3NH2-mPEG-nDOX.  An increase is PEG density is 
seen to retard the release of DOX.  At 50 h, for example, the % release of DOX for G3NH2-21PEG-
3DOX is only 47.6%, while that for G3NH2-3DOX is 80.3%.  The effect of PEGylation can be 
explained by the increased steric hindrance for proton access to initiate the degradation of the acid-
labile linker and also by providing a prolonged diffusion of released hydrophobic DOX out of 
hydrophilic PEG coating layer.[214] 
In summary, the acid-labile PEGylated PAMAM-DOX conjugates showed the potential of 
being stable at extracellular physiological pH, while a sustained DOX release in conditions 
mimicking intracellular acidic compartments is achieved.  It was also shown that the release of 
DOX can be further modulated by tailoring the peripheral PEG density.  The crucial advantage 
from acid-labile linker is the potential to decrease the concentration of free DOX in plasma by 
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promoting drug release intracellularly, thus diminishing DOX potential toxicity in general and 
cardiotoxicity in particular, which may lead to congestive heart failure and death. 
3.4.3 Kill of lung adenocarcinoma cells with acid-labile G3NH2-mPEG-nDOX and non-
labile G3NH2-mPEG-nDOXNL conjugates.   
The cytotoxicity of the various DOX conjugates and controls, including free DOX, free 
dendrimer, and free dendrimer-PEG conjugates was assessed by MTT assay on A549 cells.  The 
Figure 3.4 Cell kill of (a) G3NH2 and PEGylated dendrimers (G3NH2-mPEG), (b) acid-
non-labile conjugates (G3NH2-mPEG-nDOXNL), and (c) acid-labile conjugates (G3NH2-
mPEG-nDOX), as determined by the MTT assay after 72 h incubation with A549 cells.  (d) 
Cell kill of acid-labile conjugates (G3NH2-mPEG-nDOX) determined by the MTT assay 
after 144 h incubation with A549 cells.  Free DOX is used as control.  Results denote mean 
± s.d. (n=8). 
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results are summarized in Figure 3.4.  Corresponding IC50 values are listed in Supplemental 
Information Table S1 in Appendix 2. 
Neither PAMAM (PEGylated or non-PEGylated) nor acid-non-labile G3NH2-mPEG-
nDOXNL showed strong toxicity against A549 cells within the concentration range and incubation 
time investigated – Figure 4a.  Their IC50 values could not be detected in the measured range.  The 
toxicity of bare G3NH2 was similar to that of G3NH2-3DOXNL (Figure 3.4b), demonstrating that 
the toxicity of the conjugates containing non-labile DOX was mainly induced by the peripheral 
NH2 groups of the dendrimers. 
In contrast, free DOX and acid-labile conjugates induced significant cell kill on alveolar 
cancer cells.  In Figure 3.4c it can be observed that the profiles for free DOX and acid-labile DOX 
are similar, but free DOX is seen to have higher activity at lower concentration.  This is to a large 
extent related to the fact that free DOX can quickly diffuse through the cell bilayer[104, 216] and 
reach the nucleus, while DOX from the nanocarriers only starts to be released after internalization 
and traffic to the lysosomes, where the liable bonds will be broken – allowing DOX to finally reach 
the nucleus.[217, 218]  After cleavage, the diffusion of DOX out of lysosome is also a time-
consuming process as the base form of weak bases (e.g. DOX) can readily diffuse across internal 
membrane of lysosome, while their cationic forms (major form of weak bases in lysosomes) 
diffuse very slowly across the membrane.[219]  This effect can be seen to be dominant, as the cell 
kill profiles for free DOX and conjugated DOX are seen to be much closer to each other at 144 h 
post exposure to the dendrimer-DOX conjugates.  Another possible reason for the reduced toxicity 
of conjugated DOX is related to the isomerization during the conjugation of cis-aconityl DOX to 
dendrimer (cis-aconityl to trans-aconityl DOX),[220] which may result in the failure of original 
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DOX release from the dendrimer conjugates – a pro-drug is released instead.  The reduced toxicity 
of polymer-bound DOX conjugates is consistent with previously published results.[34, 221] 
In summary, the conjugation of DOX to dendrimer nanocarriers promotes the control of its 
release, both temporally and also spatially (intracellular/low pH), and further control can be 
achieved upon PEGylation.  The cell kill curves reflect this temporal controlled release, with DOX 
toxicity of the conjugates progressively becoming more similar to free DOX profile, as the DOX-
dendrimer bonds are slowly broken down upon cellular internalization and transport of the carriers 
to acidic compartments, and finally diffusion of DOX to reach the nucleus.  The impact of 
PEGylation density on cell kill is small, and becomes negligible at long incubation times, a very 
favorable result as the interaction of the carriers in vivo can be controlled by changing the 
PEGylation density/surface characteristics of the nanocarriers, [222, 223] and so can its behavior 
in HFA-propellants used in pMDI formulation, as will be shown later.  
3.4.4 Cellular internalization of acid-labile G3NH2-mPEG-nDOX conjugates   
The kinetics of cellular internalization of the acid-labile G3NH2-mPEG-nDOX conjugates 
in A549 cells was evaluated by flow cytometry, by measuring the median fluorescence intensity 
Figure 3.5 Synthesis of the PEGylated, generation 3, amine-terminated PAMAM dendrimer (G3NH2) 
conjugated with DOX.  DOX conjugated via an acid-labile linker: G3NH2-mPEG-nDOX; DOX 
conjugated via a non-labile linker: G3NH2-mPEG-nDOXNL. 
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(MFI) of DOX internalized within the cells as a function of time, for a period of 5 h.  The results 
are summarized in Figure 3.5. 
It can be observed from Figure 3.5a that the rate and extent of internalization of DOX 
within 5h is enhanced upon conjugation to G3NH2.  The rate of internalization of DOX in G3NH2-
3DOX is 4.7 times greater than free DOX, and the total internalization is statistically different and 
about 1.6 times as high as free DOX at the end of 5 h.  The difference in extent of internalization 
of free DOX and conjugated DOX is seen to decrease as a function of time.  PEGylation is seen to 
decrease the rate and extent in cellular internalization of conjugated DOX – Figure 3.5a.  It is 
interesting to note, however, that at the highest PEG density (G3NH2-21PEG-3DOX), the rate and 
extent of internalization of conjugated DOX is not much different than free DOX, and the means 
(MFI and rate) are not statistically different at later time points when compared to the same 
conjugates.  
It has been reported that hydrophobic DOX is taken up through passive diffusion and that 
the diffusion rate is determined by the concentration gradient and interaction with the lipid 
bilayer.[216, 224]  Dendrimer nanocarriers are internalized through different endocytic pathways 
such as receptor-mediated endocytosis,[217, 225, 226] macropinocytosis,[226] and non-specific, 
adsorptive endocytosis.[225, 227, 228]  The difference in internalization rate of PAMAM-DOX 
conjugates can be attributed to changes in surface charge.  G3NH2-
readily adsorbed and quickly saturates the negative plasma membrane.[227]  As a consequence, 
rapid internalization and uptake plateau (1.5 h after incubation) are observed.  The uptake plateau 
may also reveal the equilibrium of internalization and exocytosis of those conjugates.  The non-
specific, adsorptive endocytosis is faster and less energy-dependent than other endocytic pathways 
due to its electrostatic interaction.[217]  
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density of PEG.  The interaction between the negatively charged G3NH2-mPEG-nDOX and the 
plasma membrane is thus attenuated, leading to a slowdown in internalization.  However, it is 
important to note that the long-term cytotoxicity studies suggest that high DOX internalization is 
achieved for all carrier systems, as similar IC50 concentrations are observed independent of the 
PEGylation density. 
We also investigated the impact of the DOX loading of the conjugates on the rate and extent 
of internalization of DOX.  The results from Figure 3.5b show that the rate and extent of 
internalization of the dendrimer with the higher payload (G3NH2-21PEG-7DOX) is not 
statistically different from that for the dendrimer with lower payload (G3NH2-21PEG-3DOX), 
indicating that PEGylation dominates the rate and extent of internalization at short times, which is 
reasonable considering that there are 21PEG and only 7/3DOX per dendrimer, and both impart 
negative charged characteristics to the dendrimer. 
In summary, conjugating DOX to dendrimer nanocarriers enhances their rate and extent of 
cellular uptake, at least at early times.  Cellular internalization of dendrimer-DOX conjugates can 
be further modulated by PEG density, while the DOX payload on the periphery of the conjugates 
does not affect uptake when at high PEG densities.  
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3.4.5 Intracellular release and colocalization of DOX from acid-labile G3NH2-mPEG-
nDOX conjugates   
The intracellular colocalization of free DOX, and DOX from the acid-labile G3NH2-3DOX 
and acid-non-labile G3NH2-3DOXNL conjugates in A549 cells was determined by confocal 
microscopy.  As shown in Figure 3.6a (“Overlay” column), the red fluorescence of DOX in the 
case of free DOX (first row) and of the DOX from the G3NH2-DOX conjugate (second row) was 
highly superposed with the blue staining of the nucleus (Hoechst 33342), revealing significant 
colocalization of DOX with the nuclei of A549 cells, the target organelle.  Perinuclear 
colocalization of DOX from G3NH2-DOX indicates that not all DOX had been released at that 
Figure 3.6 (a) Selected confocal images of A549 cells contacted with free DOX, acid-labile 
G3NH2-3DOX and acid-non-labile G3NH2-3DOXNL conjugates.  (b) Cross section of 3D 
rendered confocal image of acid-labile G3NH2-3DOX and acid-non-labile G3NH2-3DOXNL 
conjugates.  Image (a) and (b) were obtained 48 h after A549 cells were incubated with the 
samples.  Blue color represents nuclei, red color for DOX, and pink color for DOX co-localized 
with nuclei. 
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time.  No red fluorescence from DOX was observed in the nuclei for acid-non-labile G3NH2-
3DOXNL (third row). 
The 3D rendering of the confocal layers for G3NH2-3DOX and G3NH2-3DOXNL shown 
in Figure 3.6b further confirms the ability of the conjugates to gain intracellular access, to be 
trafficked through an acidic pathway, thus releasing the DOX conjugated through the acid labile 
bond to G3NH2, and finally to co-localize with the nucleus.  These results support the cell kill 
experiments shown in Figure 3.5.  We can also observe that DOX in G3NH2-3DOXNL does not 
gain access to the nucleus as is not released due to the presence of a pH stable bond between DOX 
and the dendrimer, and the fact that the dendrimer-DOX conjugate seems to be too large to 
passively cross the nuclear pores.  
These qualitative observations are complemented by quantitative results of the 
colocalization of DOX (red fluorescent pixels from the confocal slices) with the nucleus (blue 
fluorescent pixels) as a function of incubation time, upon determination of the Pearson’s 
Figure 3.7 Pearson’s Correlation Coefficient (PCC) of 
DOX free and from acid-labile G3NH2-mPEG-nDOX 
conjugates as a function of incubation time.  PCC was 
determined by confocal microscopy, and calculated based 
on the colocalization of blue-stained nuclei and red DOX.  
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Correlation Coefficient (PCC) for those fluorescent signals.  A PCC = 1 represents complete 
correlation, while a PCC = 0 represents no correlation.[229]  The PCC values for DOX:nucleus 
for G3NH2-mPEG-nDOX conjugates, and for free DOX (control) are summarized in Figure 3.7. 
The PCC of free DOX is seen to reach 0.87, which represents very high correlation, and 
this happens at early times - 24 h due to fast colocalization of free DOX within the nucleus.  The 
PCC is seen to level off after ca. 48 h.  The PCC for DOX:nucleus in the experiments with the 
acid-labile G3NH2-mPEG-nDOX conjugates is also seen to be very high at 0.7, indicating strong 
nuclear colocalization, with a maximum PCC happening at 144 h.  However, the maximum PPC 
for the conjugated DOX is smaller than that seen for free DOX.  This lower maximum PCC may 
be attributed to the isomerization of the conjugates and the fact that there are many potential 
endocytic pathways for internalization of the conjugates.  As cis-aconityl DOX is conjugated to 
PAMAM dendrimer, cis-aconityl spacer may isomerize to trans-aconityl form.[220]  The 
PAMAM-DOX conjugates with cis-aconityl spacer releases free DOX, whereas the counterparts 
with trans-aconityl spacer gives rise to aconityl DOX due to the cleavage of amide bond between 
G3NH2 and linker.  The aconityl DOX is not able to get into nucleus due to the loss of the NH2 
group, which is the driving force of DOX to reach the negatively charged DNA.[96]  In addition, 
the conjugates that are internalized by certain endocytic pathways that do not lead to the acidic 
lysosomes (i.e. caveolae-mediated endocytosis) will have a retarded rate of release for DOX.[230] 
The PCC curves are also impacted by PEGylation.  They are supported by the cellular 
internalization (Figure 3.5) and controlled release (Figure 3.3) results that show a slowdown in 
uptake and release as the PEG density increases.  The DOX loading is shown not to affect the PPC 
curves – see curves for G3NH2-21PEG-3DOX and G3NH2-21PEG-7DOX.  Finally, it is worth 
pointing out that the rate of increase in PCC with time is also slower in the case of the conjugates 
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– compared to free DOX, but it is not clear whether a plateau has been reached at the terminal 
point of the experiment, which may suggest that higher PCCs for DOX from the conjugates may 
be achieved. 
3.4.6 Physical stability of the acid-labile G3NH2-mPEG-nDOX conjugates in HFA 
Propellant.   
Once the efficacy of the DOX conjugation strategy was assessed in vitro, we developed a 
strategy to formulate dendrimer-DOX conjugates in pMDI formulations for local lung delivery.  
We are particularly interested in pMDIs due to the many advantages of such portable inhalers, 
including ease of use and the fact that they are the least expensive OI devices in the market 
today.[231-233] 
We started by investigating the impact of PEGylation and DOX loading on the 
dispersibility / pseudo-solubilization of the G3NH2-mPEG-nDOX conjugates in HFA277, one of 
the propellants approved by the FDA for formulation in pMDIs.[234]  The stability of the 
formulations was assessed by visually monitoring the dispersion of G3NH2-mPEG-nDOX 
conjugates in HFA227 as a function of time after sonication.[58]  In order to improve the 
solubilization/dispersion of the conjugates, a small amount of ethanol (EtOH) cosolvent was added.  
EtOH is an excipient commonly used in commercial pMDI products, usually at much higher 
concentrations - up to ca. 15% v/v in commercial formulations [235]  However, because the 
presence of large amounts of EtOH is known to negatively impact aerosol quality in pMDIs,[78, 
233, 236] we kept the EtOH concentration to a minimum.  The physical stability results of the 
formulations are summarized in Figure 3.8.  
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  We can observe that the dispersibility / pseudo-solubilization of the G3NH2-mPEG-nDOX 
conjugates is dramatically impacted by the presence of PEG1000.  As the PEG1000 density 
increases, so does the dispersibility of the conjugate, with the conjugate having 21PEG1000 
showing excellent dispersibility in HFA227.  Our previous ab initio calculations and chemical 
force microscopy results have revealed that ether-containing functionalities (e.g. -CH2CH2O-) can 
be well solvated in HFA propellants as the ether oxygen atom can strongly interact with the dipole 
of the propellant.[237]  The precise conformation of the PEG layer around the dendrimer when the 
system is dispersed in HFA propellant is still unclear.  However, we speculate that some of the 
segments of the PEG chain may protrude into the propellant, thus acting as a stabilizer as they 
strongly interact with HFA molecules (HFA-ether complexes),[237] whereas the rest of domains 
cover the dendrimer surface to form a compact architecture, so as to reduce attractive forces among 
the dendrimer nanocarriers.[182]  Therefore, it is likely that the conjugates in propellant HFA227 
take on a core-shell conformation in which PAMAM and DOX consist of the core and PEG chains 
are situated in the outer shell layer.  We also see that at high PEG1000 density the increased 
payload of HFA-phobic DOX does not affect the dispersibility of the conjugate in the propellant.  
Figure 3.8 Dispersion of acid-labile G3NH2-mPEG-nDOX in HFA227 propellant as a function of 
time after sonication.  Conditions were: 0.2 mg/mL DOX equivalent; 0.37% anhydrous ethanol (v/v 
relative to the propellant), at 25oC. 
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It is believed that 7 peripheral DOX molecules can be still thoroughly coated by an abundance of 
grafted PEG chains.  
In order to further clarify the nature of the pseudo-solutions/dispersions of the conjugates 
in HFA, we determined their solvated diameters (SD).  We use an HFA that is liquid at ambient 
conditions and a model liquid propellant  — 2H,3H perfluoropentane (HPFP).[81, 238]  The results 
are summarized in Table 3.2.   
At low/no PEG1000 density, the G3NH2-mPEG-nDOX conjugates formed large, micron-
sized aggregates, which indicates the lack of dispersibility in HFAs.  However, upon increasing 
density of PEG1000 to 21, no micron-sized aggregates can be found.  The SDs of the highly 
PEGylated conjugates were around 30-40 nm.  These sizes may represent aggregates of a few 
conjugates only, or even a single dendrimer conjugate whose SD in HPFP (26 nm for G3NH2-
21PEG-3DOX) turns out to be a few times larger than their HD (SD in water – 10 nm G3NH2-
21PEG-3DOX) - which are reported in Table 3.1. 
Conjugate 
SD ± s.d.  
Peak A Peak B 
G3NH2-3DOX 0.5 ± 0.1 µm (13.3%)  6.1 ± 2.8 µm 
G3NH2-9PEG-3DOX 0.7 ± 0.1 µm (15.1%)  4.2 ± 1.2 µm 
G3NH2-21PEG-3DOX 26.1 ± 7.8 nm (100%) n.p. 
G3NH2-21PEG-7DOX 38.3 ± 11.6 nm (100%) n.p. 
 
Table 3.2 Solvated diameter (SD) of the PEGylated (m), generation 3, 
amine-terminated PAMAM dendrimer (G3NH2) conjugates with DOX 
measured in the model propellant HPFP.  DOX conjugated via an acid-labile 
linker (G3NH2-mPEG-nDOX).  Results determined by light scattering (LS) 
at 25oC and 0.2 mg/mL DOX equivalent.  n.p. = not present; % in parenthesis 
= volume fraction within that diameter range. 
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3.4.7 Aerosol characteristics of pMDI formulations of acid-labile G3NH2-mPEG-nDOX 
conjugates.   
While good dispersibility was found for the PEGylated conjugates, the results discussed 
before do not address the aerosol quality of the resulting formulations.  Andersen Cascade 
Impactor (ACI) is widely used as an in vitro lung model to determine drug deposition in the lungs.  
The correlation of stages to anatomical pulmonary regions are summarized in Figure 3.9a.  Stage 
3 and higher represent the lower respiratory tract and deep lung deposition.  The effect of PEG 
density on the aerosol performance of pMDI formulations of G3NH2-mPEG-nDOX conjugates 
was evaluated and are summarized in Figure 3.9b and Table 3.3.  
 Formulations were prepared at the same conditions as in the physical stability studies 
discussed earlier - HFA227 propellant at 0.2 mg/mL DOX equivalent and 0.37% v/v EtOH.  It can 
be observed from Figure 9b that the fraction of DOX (in the conjugate) deposited on stages 3-F 
increase dramatically at the high PEG density (21PEG1000) compared to no PEG and 9PEG1000.  
The mass deposition on each stage is summarized in Supplementary Information Table S2 of 
Figure 3.9 (a) Structure diagram of an Andersen Cascade Impactor (ACI) and correlation of stages 
in ACI to anatomical regions of the lungs.  (b) Aerosol characteristics of the pMDI formulations 
containing acid-labile conjugates (G3NH2-mPEG-nDOX) in HFA227 propellant at 0.2 mg/mL DOX 
equivalent and 0.37% anhydrous ethanol v/v relative to propellant, as determined using ACI at 25 
oC.  AC, IP, 0-7 and F denote actuator, induction port, Stage 0-7 and filter, respectively. 
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Appendix B.  The mean mass aerodynamic diameter (MMAD), and the geometric standard 
deviation (GSD) of the formulations were determined from the ACI results and are summarized in 
Table 3.3, along with the respirable fraction (RF) and fine particle fraction (FPF), which represent 
respirable dose of the formulation and the dose deposited on low respiratory and deep lung area, 
respectively. 
While the MMAD for all conjugates fall within the optimum range (5.0-0.5µm), the GSD 
is much smaller for the highly PEGylated conjugates.  More importantly, the RF and FPF for the 
conjugates with 21PEG1000 (both low and high DOX payload) are much higher than those for 
G3NH2-3DOX and G3NH2-9PEG-3DOX, the conjugates that showed low dispersibility of the 
propellant.  The RF and FPF for G3NH2-21PEG-3DOX was found to be 82.0% and 78.1%, 
respectively.  For comparison, most of marketed formulations have RF<45%[239-241] of emitted 
dose and FPF<55%.[163]  The RF of the formulation is even higher than HFA-based solution 
formulations of small molecules (RF: ca. 60-80%) containing soluble excipients.[239, 242]  The 
recovery for the formulations containing G3NH2-21PEG-3DOX and G3NH2-21PEG-7DOX is 
much higher than that of the poorly dispersed counterparts.  We believe that the loss of the 
delivered dose of the formulation containing highly PEGylated conjugates is mainly from small 
particles with exhalable size range (aerodynamic diameter < 0.5 µm), whereas the strong 
aggregation of non-PEGylated/low PEGylated conjugates in propellant (big aggregates may not 
be puffed out) causes the relatively low recovery rate for those nanocarrier systems.   
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One interesting aspect of this study is the fact that pMDI formulations containing 
dendrimer conjugates with such small SD – thousand fold smaller than the optimum aerosol 
diameter - between 0.5to 5 µm,[243] are capable of generating corresponding aerosols with such 
exceptional quality. 
We propose here a mechanism to explain the results, a schematic diagram of which is 
shown in Figure 3.10.  In Figure 3.10a, the pseudo-solution of the G3NH2-mPEG-nDOX 
conjugates in HFA propellant is shown – this picture is supported by the SD and physical stability 
results discussed above.  Upon depressing the actuator, droplets containing G3NH2-mPEG-nDOX 
and propellant are formed.  As the HFA227 propellant evaporates – Figure 3.10b, the polymer 
concentration within the droplets increases and it eventually crosses the phase boundary illustrated 
in Figure 10c – from a single phase to a phase-separated system.  Micron-sized particles made of 
phase-separated G3NH2-mPEG-nDOX are formed with the appropriate aerosol diameter for deep 
lung deposition - Figure 3.10b (iii). 
Conjugates MMAD (µm) GSD (µm) RF (%) FPF (%) Recovery (%) 
G3NH2-3DOX 4.5 ± 1.9 6.6 ± 2.4 31.8 ± 3.9  16.1 ± 1.8 65.7 ± 6.4 
G3NH2-9PEG-3DOX 3.3 ± 0.8 3.9 ± 1.4 33.1 ± 5.9 29.7 ± 3.7 69.2 ± 7.1 
G3NH2-21PEG-3DOX 1.2 ± 0.1 1.9 ± 0.1 82.0 ± 4.8  78.1 ± 4.3  86.9 ± 4.7 
G3NH2-21PEG-7DOX 1.2 ± 0.1 1.6 ± 0.1 75.4 ± 3.0 70.8 ± 5.4 84.6 ± 5.5 
 
Table 3.3 Median mass aerodynamic diameter (MMAD), geometric standard deviation (GSD), 
respirable fraction (RF), fine particle fraction (FPF) and recovery (%) of the pMDI formulation 
containing the PEGylated (m), generation 3, amine-terminated PAMAM dendrimer (G3NH2) 
dendrimers conjugated with DOX via an acid-labile linker (G3NH2-mPEG-nDOX).  Aerosol 
results determined using the Andersen Cascade Impactor (ACI), at 25oC.  Formulation containing 
0.2 mg of DOX equivalent per mL of propellant and anhydrous ethanol at 0.37% v/v relative to the 
propellant.  Propellant is HFA227. 
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3.5 Conclusion 
In this work we demonstrated the ability of G3NH2-DOX conjugates to effectively kill 
A549 cells, an in vitro model of alveolar adenocarcinoma.  We also developed a novel strategy for 
the formulation of the conjugates in pMDIs, consisting in forming a pseudo-solution of the 
nanocarrier/polymer-drug conjugates in the propellant, which can be achieved upon surface 
modification of the nanocarrier with a moiety that has high affinity to HFA.  DOX was conjugated 
to G3NH2 through a pH sensitive bond, which was shown to be a suitable strategy to provide a 
Figure 3.10 Schematic diagram of the proposed 
mechanism for the formation of the micron size 
aerosol particles from the nanometer size 
conjugates.  (a) Acid-labile G3NH2-mPEG-nDOX 
are solvated as individual particles or 
nanoaggregates of a few molecules in liquid 
HFA227 in pMDI at its saturated pressure.  (b) As 
the aerosol forms, the conjugates are (i) initially 
fully solvated; (ii) as the propellant evaporates, the 
dendrimer solution phase separates, forming 
dendrimer nuclei that continue to increase in size to 
form particles until; (iii) the propellant completely 
evaporates.  (c) Phase separation as the 
concentration of dendrimer conjugates increases 
upon evaporation of propellant at ambient pressure. 
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sustained intracellular release, while being very stable at extracellular physiological conditions.  
We showed that the release profile of DOX at low pH can be further modulated by the number 
density of PEG conjugated onto the G3NH2 surface.  PEGylation is used to enhance the aqueous 
solubility of the conjugate at high DOX payloads, and also to promote the formation of the pseudo-
solution in the propellant HFA of pMDIs.  The impact of PEG is also observed on the rate and 
extent of internalization of the dendrimer-DOX conjugates in A549 cells at short times (up to 5h).  
Nuclear colocalization studies indicate that the dendrimer-DOX conjugates are not only taken up 
by A549 cells, but the DOX released colocalizes with its target organelle, the nucleus, very 
efficiently.  Interestingly, PEGylation does not affect the ability of the conjugates to kill the 
adenocarcinoma cells, as all conjugates show similar IC50’s at the same DOX equivalent loading 
at long incubation times.  Highly stable pseudo-solution of the G3NH2-nDOX conjugates were 
formed at high PEG densities, as the dipole of HFA can interact very strongly with the ether oxygen 
of the PEG layer covering the drug-dendrimer conjugate, and thus promote its pseudo-
solubilization.  The aerosol characteristics of the resulting pMDI formulations were shown to be 
exceptional, with respirable fractions as high as 82%.  The relevance of the aerosol study goes 
beyond the formulation of DOX, as other small molecule therapeutics have similar potential to be 
formulated in pMDIs as dendrimer-drug pseudo solutions using the strategy discussed here. 
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3.7 Supplemental information 
Description of synthesis and characterization of the acid-labile and acid-non-labile 
PEGylated dendrimer-DOX conjugates/structures including 1H NMR, ESI, MALDI-TOF and LS.  
The IC50 of free DOX and various PEGylated dendrimer-DOX conjugates and aerosol mass 
deposition in ACI of pMDI formulation containing dendrimer-DOX conjugates are also provided.  
This material is available in Appendix B.
79 
 
CHAPTER 4 — Design of Dendrimer-Doxorubicin Conjugates for 
Transport Modulation across in vitro Pulmonary Epithelium and their 
Solution Formulation in pMDIs 
4.1 Introduction 
Of all malignant tumors, lung cancers hold great relevance as it is the leading cause of 
cancer death for both men and women throughout the world.[2]  The mortality of lung cancer is 
higher than that of colorectal, breast and prostate cancers combined.  5-year survival rate of lung 
cancers after initial prognosis is only 16.6% since most of patients are diagnosed at late phase, thus 
limiting surgical treatment in the alleviation of lung cancers.[244]  Therefore, chemotherapy is 
widely used as a tool to treat lung cancers.  However, limited progress has been made by 
chemotherapy in the fight against lung cancers.  One of major challenges is low therapeutic 
concentration found in lung tumors upon systemic administration (e.g. intravenous and 
intraperitoneal injection).[8]  Therefore high dosage of drug with strong systemic adverse effects 
is required due to poor distribution to lung tumors.    
The lungs as a portal of entry for  regional [245, 246] and even systemic [247, 248] drug 
delivery is often characterized by enhanced bioavailability, which is to some extent associated with 
long drug retention, large respiratory surface area (ca. 100 m2),[249] low enzymatic degradation 
of drugs in lung tissues, fast action of drug, reduced systemic adverse effect, and thin cellular 
barriers for entry of drugs to blood circulation.[250]  Several anatomical barriers that entrap drugs 
administered through pulmonary route include bifurcated bronchi, epithelial layers with viscous 
mucus, fast-renewed mucociliary clearance, and alveolar macrophage.[251]  One major challenge 
in pulmonary drug delivery is limited transport across respiratory epithelial barriers, which 
attenuates drug distribution in lung tissues and even its entry to systemic circulation.  For example, 
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tight junction with small pore size (ca. 0.5-2 nm),[185] junctional protein complex that regulates 
paracellular transport,[185] and transmembrane drug transporters in charge of transcytosis.[186]   
Oral inhalation (OI) has showed its great promise not only for regional administration of 
therapeutics to the lungs, but also as a promising noninvasive route to systemic circulation through 
the lungs.[245, 252]  Pressurized-metered dose inhalers (pMDIs) have been seen the most 
promising OI technique due to its portability, ease of use and reliable dosage delivery.  However, 
the biggest challenge for pMDIs formulation is that few drugs are soluble, even with the aid of co-
solvents or surfactants, in propellants used for pMDIs.[78]  The addition of co-solvents and 
surfactants help solubilize and disperse drugs to in propellants, making a drug suspension that is a 
heterogeneous system.  In contrast, solution formulation gives rise to a homogenous system 
characterized by a larger fine particle dosage [83] and finer residual aerosol,[84] which leads to 
efficient delivery of drug to low respiratory tract and deep lung areas.  Additionally, the fraction 
of nonvolatile components added to both solution and suspension formulation can modulate 
aerosol performance of pMDI formulations.  
Doxorubicin (DOX), as a leading chemotherapeutics, has been widely used for treating 
many cancers including lung cancers. Fast clearance and severe cardiac toxicity, however, limit 
its application in some patient populations.  Dendrimer nanocarriers (DNCs) have been 
successfully explored for targeted and controlled delivery of DOX in cancer treatment.[33, 125, 
253]  Polyamidoamine (PAMAM) is a hyperbranched synthetic dendrimer with monodispersity, 
highly controlled size, and multivalent surface groups.[30, 31]  By attaching different ligands, the 
multifunctional surface groups of PAMAM dendrimer could be potentially used to (i) target tumor 
cells,[170] (ii) modulate cellular uptake,[254] (iii) facilitate transepithelial transport,[41, 42, 192] 
and (iv) deliver therapeutics to subcellular organelles.[170]  However, amine-terminated PAMAM 
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dendrimer showed generation-dependent toxicity and hemolysis.[255]  PEGylation has been an 
effective strategy to help DNCs improve pharmacokinetics,[173, 256] reduce toxicity,[170, 257] 
and escape mucus entrapping.[72]  Recent study showed an additional significant attribute of PEG 
as ligand for pulmonary administration: the modulation of  in vitro transepithelial transport of 
DNCs across airway epithelium and in vivo entry of DNCs to systemic circulation.[256] 
Based on those challenges and opportunities of pulmonary route for lung cancer treatment, 
the work was to design DNCs for controlled intracellular delivery of DOX that can modulate the 
transport across pulmonary epithelium, as well as to develop facile DNC-laden pMDI formulation 
with superior aerosol performance.  To achieve this goal, DOX was conjugated to generation 3 
amine-terminated PAMAM dendrimer with varying peripheral PEG density via an acid-labile cis-
aconityl spacer.  The effects of PEGylation degree and DOX payload on in vitro release, 
cytotoxicity, and transepithelial transport were investigated on airway epithelial cancer cell model 
(Calu-3).  The PEGylated PAMAM-DOX conjugates were directly formulated in portable pMDI 
with HFA227 propellant.  The effect of PEGylation degree on physical stability, particle size and 
aerosol characteristics was also evaluated with scanning electronic microscopy, dynamic light 
scattering and Andersen Cascade Impractor (ACI).  The deposition of the conjugates in different 
pulmonary regions was modulated by adjusting conjugate concentration in pMDI formulation.   
Broadly, this work is of great relevance because to our best knowledge it is for the first time that 
polymeric nanocarrier-based drug delivery system has been formulated into propellant-based 
solution pMDI formulation which holds aerosol performance superior to current marketable pMDI 
products and formulations in literatures.  
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4.2 Materials 
Generation 3 amine-terminated poly(amindo amine) (PAMAM) dendrimer (G3NH2, 32 -
NH2 surface groups, theoretical molecular weight = 6909) was purchased from Dendritech, Inc 
(Miland, MI, USA).  Doxorubicin hydrochloride salt (DOX) was purchased from LC Laboratories 
(Woburn, MA, USA).  Polyethylene glycol succinimidyl ester, 1000Da (PEG1000-SE) was 
purchased from NANOCS, Inc (New York, NY, USA).  Polyethylene glycol 1000Da (PEG1000), 
cis-aconityl anhydride, sodium hydroxide (NaOH), stannous octoate (95%), 4% para-
formaldehyde phosphate buffer saline and mucin from porcine stomach (type III, bound sialic acid 
0.5-1.5 %) were purchased from Sigma-Aldrich (St Louis, MO, USA).  D, L-lactide was a gift 
from Purac Biomaterials (Amsterdam, Netherland).  Pierce® BCA Protein Assay Kit was 
purchased from Thermo Fisher Scientific (Waltham, MA, USA).  Dulbecco’s Modified Eagle’s 
Medium (DMEM) and penicillin (10,000 U/mL)-streptomycin (10,000 µg/mL) were purchased 
from Life Technologies (Grand Island, NY, USA).  Fetal bovine serum (FBS) was purchased from 
Atlanta Biologicals, Inc (Flowery Branch, GA, USA).  Deuterated dimethlsulfoxide (DMSO_d6) 
was purchased from Cambridge Isotope Laboratories (Andover, MA, USA).  Ultrapure deionized 
water (DI H2O) was obtained from a Barnstead NANOpure DIamond System (D11911) from 
Thermo Fisher Scientific (Waltham, MA, USA).  Calu-3 human lung adenocarcinoma epithelial 
cell lines were purchased from American Cell Collection (Manassas, VA, USA).  Amicon® Ultra 
15 centrifugal filter device (MWCO = 3000Da) was purchased from EMD Millipore (Billerica, 
MA, USA).  Costar Transwell® Permeable Support (pore size: 0.4 µm; surface area = 0.33 cm2) 
was purchased from Corning Incorporated (Corning, NY, USA).  Thin layer chromatography (TLC) 
Silica gel 60 F254 plastic sheet was purchased from Merck KGaA (Darmstadt, Germany).  All 
reagents were used as received unless otherwise stated. 
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4.3 Methods 
4.3.1 Synthesis of acid-labile PEGylated PAMAM-DOX conjugates (G3NH2-mPEG-nDOX, m=0, 
9, 21, and n=3, 7).   
The synthesis of the acid-labile (cis-aconityl), PEGylated DOX-dendrimer conjugates used 
in this work has been discussed in detail in Chapter 2.  All the products were characterized with 
proton nuclear magnetic resonance (1H NMR), matrix-assisted laser desorption/ionization-time of 
flight (MALDI-TOF), and light scattering (LS). The characteristics of the various conjugates are 
summarized in Table 1. 
4.3.2 Cell kill ability of acid-labile G3NH2-mPEG-nDOX conjugates against Calu-3 cells. 
The ability of free DOX and G3NH2-mPEG-nDOX conjugates in killing the human lung 
adenocarcinoma Calu-3 cell was assessed using the MTT assay.  Approximately 1×104 cells/well 
(n=8 per concentration) were seeded in tissue culture treated 96-well plates (VWR Internationals.  
Radnor, PA, USA) with DMEM (no phenol red).  The medium was removed after 24h and 100 µl 
of the free or conjugated DOX solution in DMEM (no phenol red) was pulsed to each well.  The 
samples were incubated with the cells for 72h.  The sample-laden medium was then removed from 
each well.  The cells were washed with PBS (1X, pH 7.4) twice.  100 µl of fresh DMEM (no 
phenol red) and 10 µl of MTT PBS solution (5 mg/mL) were added to each well and incubated for 
4h (37 oC, 5% CO2).  Subsequently, 75 µl medium was removed from each well and 60 µl DMSO 
was added back into the wells to dissolve the formazan crystal.  The cells were incubated (37 oC, 
5% CO2) for another 2h.  Finally, the absorbance of formazan at 540 nm was recorded using a 
Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek Instruments, Inc.  Winooski, VT, USA).  
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4.3.3 In vitro transport of G3NH2-mPEG1000-nDOX conjugates across polarized Calu-3 
monolayers 
4.3.3.1 Cell growth on Transwell® inserts.   
Approximately 5×104 Calu-3 cells (passage 10-20) were seeded on the apical compartment 
of each insert, which was placed onto 24-well plates with 0.2 mL DMEM (20% FBS, 100 U/mL 
penicillin and 100 µg/mL streptomycin).  The basolateral compartment of each insert was filled 
with 0.6 mL DMEM (20% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin).  The cells 
were grown for 48h (37 oC, 5% CO2) and the medium was removed from the apical side at that 
time.  The cells were allowed to grow at the air-liquid interface (AIC).  The medium in the 
basolateral compartment was changed every 2 days.  The transepithelial electrical resistance 
(TEER) of the cell were monitored every day, to assess the formation of confluent and polarized 
monolayers.[256]  TEER measurements were performed with a chopstick electrodes (STX-2) and 
EVOM voltometer (World Precision Instruments.  Sarasota, FL, USA) as reported previously.[256]  
The actual monolayer TEER was obtained by subtracting the EVOM reading of a blank insert from 
that of cell-laden insert, and normalizing for the surface area of the insert (0.33 cm2). 
4.3.3.2 In vitro transepithelial transport.   
In vitro transport was conducted as the TEER of cell monolayer started leveling off at ca. 
450 Ω (ca. 11 days).  The TEER was measured prior to the addition of free DOX or G3NH2-
mPEG1000-nDOX conjugates.  HBSS (1X, pH 7.4) was added to apical (0.2 mL) and basolateral 
(0.6 mL) compartments of the insert and the TEER was again measured as described above.  The 
obtained TEER was used as that at t = 0h.  Subsequently, the inserts were moved to the next well 
and the blank HBSS in apical compartment was replaced with 0.2 mL HBSS with 50 nM (DOX 
equivalent) of free DOX or G3NH2-mPEG1000-nDOX conjugates (n=6 per sample).  The TEER 
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was measured after 1 h (the conjugate-laden HBSS in the apical compartment was used rather than 
blank HBSS) and the insert was then moved to a new well.  TEER measurement and insert 
movement were repeated.  The process was terminated at 5h post pulsing free DOX or the DOX 
conjugates.  A 0.1 mL HBSS solution was taken from each of the basolateral compartment to 
determine the DOX concentration (fluorescence, with Biotek Synergy 2 Multi-Mode Microplate 
Reader).  The transport from apical to basolateral side (AB) was represented by apparent 
permeability (Papp AB), calculated as 
0
app
F
P
A C


, where F is the flux or rate of change of 
cumulative mass transported from apical to basolateral direction, A is the area of the insert and C0 
is the initial concentration of free DOX or DOX in the conjugates.  Subsequently, the HBSS at the 
apical side of the monolayer was recovered to determine the remaining amount of DOX in the 
apical side of the chamber.  After that, 3 inserts from each sample (n=6) were used to monitor 
TEER recovery of the cell monolayer over time when free DOX or conjugated DOX was removed, 
while the other 3 inserts were used for determining the extent of internalization as described next.  
The cell monolayer was washed with fresh HBSS twice and 0.2 mL DMEM was added to apical 
side.  The TEER was measured at 24, 48 and 72 h after the terminal transport point. 
4.3.3.3 Internalization during in vitro transport.   
The cell monolayers on the other 3 wells were washed with 4 oC blank HBSS thrice.  The 
cell monolayer on each insert was detached by 0.2 mL 0.25% trypsin-EDTA solution and was then 
lysed overnight using 0.5 mL Triton-X100 aqueous solution (0.5% by weight).  The supernatant 
collected by centrifuging the lysate was measured for DOX fluorescence analysis.  The uptake of 
free DOX or conjugates was normalized to cellular protein content using BCA protein assay.   To 
perform a mass balance, the mass of the samples that were (i) internalized, (ii) transported in AB 
direction, or (iii) retained at apical side was summed up and compared to the total initial mass. 
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4.3.4 Transport of G3NH2-mPEG1000-nDOX conjugates across mucus   
The transport of the conjugates across an artificial mucus layer was also studied to 
deconvolute the impact of the mucus and that of the polarized cell layer on the transport of the 
nanocarriers.  The synthetic mucus gel was composed of mucin (23 mg/mL) and buffer (85 mM 
NaCl, 20 mM HEPES, pH 7.3).[256]  The mucus was shaken at 4 oC overnight.  A 30 µL mixture 
of free DOX or conjugates (50 nM DOX equivalent, n=3 per sample) and mucus gel (ca. 900 µm 
thick) was pulsed onto the apical side of each insert which were placed onto a 24-well plate.  The 
basolateral compartment was filled with 0.6 mL HBSS-HEPES (1X, pH 7.4, HEPES 0.1 mM).  
The insert was moved every hour to a new well and the transport assay was terminated at 5h.  The 
solution from the basolateral side (0.1 mL) was analyzed for DOX fluorescence to quantify the 
extent to which the free DOX or DOX from conjugates transport across the mucus layer. 
4.3.5 Preparation and Characterization of the pMDI Formulations 
4.3.5.1 Synthesis of the polylactide-PEG-polylactide (LAn-EOm-LAn) tri-block copolymer.   
The LAn-EOm-LAn tri-block copolymer was prepared as reported previously, with small 
modifications.[258]  Briefly, PEG1000Da (1 g, 1 mmol) was reacted with D, L-lactide (10 g, 0.183 
mol) with 0.1% wt/wt stannous octoate as catalyst.  The reaction was stirred under N2 atmosphere 
at 145oC for 1h.  The resulting copolymer was dissolved in 3 mL dichloromethane and then 
precipitated with 100 mL cold methanol.  The product was isolated by centrifugation and dried 
completely under reduced pressure.  The resulting LAn-EOm-LAn tri-block copolymer, where n 
and m are the number of repeat units, was characterized with 1H NMR and MALDI-TOF. 
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4.3.5.2 Preparation of pseudo-solution formulation containing G3NH2-21PEG1000-3DOX 
conjugate.   
G3NH2-21PEG1000-3DOX (0.2 mg DOX equivalent per mL HFA227) with varying 
concentrations of copolymer stabilizer LAn-EOm-LAn (0, 0.12 and 0.53 mM) were added into 
pressure proof glass vials (West Pharmaceutical Services. Exton, PA, USA).  The glass vials were 
placed onto a hot plate (60 oC) for a few seconds (Method A) or trace amounts of anhydrous ethanol 
(0.37% v/v relative to HFA227 propellant) was added to the conjugate and copolymer mixture 
(Method B).  The glass vial was immediately crimped manually using 63 µl metering valve 
(Bespak.  King’s Lynn, Norfolk, UK).  HFA227 propellant (4 mL) was filled to the sealed glass 
vial using a manual syringe pump (HiP 50-6-15) and a home-made high pressure filler.  The 
formulation was sonicated for 30 min at 0-5 oC in a sonicating bath (P250D, VWR International), 
set to 180 W.  
4.3.5.3 Solvated diameter (SD) of pseudo-solutions in HFAs.   
The SD of G3NH2-21PEG1000-3DOX conjugate was determined in 2H, 3H 
perfluoropentane (HPFP), a model for propellant HFA that is liquid at ambient conditions, using 
Nano ZS Zetasizer (Malvern Instrumetns Ltd.  Malvern, Worcestershire, UK).  Briefly, the 
aqueous solution of the conjugate was filtered with 0.22 µm syringe filter (VWR Internationals) 
and then lyophilized carefully.  G3NH2-21PEG1000-3DOX conjugate (0.2 mg DOX equivalent 
per mL HPFP) was dissolved in HPFP with the aid of anhydrous ethanol (0.30 % v/v relative to 
HPFP).  The HPFP was sonicated at 0-5 oC for 30 min.  Average size and standard deviation (s.d.) 
of over 14 repeats are reported here. 
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4.3.5.4 Aerosol performance of the pseudo-solution formulations.   
The aerosol characteristics of the formulations were determined with an Andersen Cascade 
Impactor (ACI, CroPharm, Inc. Milford, CT, USA) fitted with a USP induction port at a flow rate 
of 28.3 L/min, 25oC and 75% relative humidity.[82]  The pMDI formulations were prepared as 
described above.  Several shots were fired to waste.  Subsequently, 20 shots were released into the 
ACI with 10s interval between each shot.  Air flow was maintained 10s after the last shot.  The 
actuator, induction port, plate on each stage and nylon filter membrane were thoroughly rinsed 
with 10 mL acetone each.  3 mL sample-containing acetone solution was used for measuring UV 
absorption of DOX at 494 nm using Cary 50 UV-Vis spectrometer (Agilent Technologies.  Santa 
Clara, CA, USA).  The mass of the conjugate was determined according to an established 
calibration curve.  The measurements were performed in triplicate (n=3).  The respirable fraction, 
representing respirable dose of the formulation, was calculated following Equation 1.  Fine particle 
fraction, denoting the dose deposited on low respiratory and deep lung, was calculated following 
Equation 2.  Mass median aerodynamic diameter (median of the distribution of airborne particle 
mass with respect to aerodynamic diameter) and geometric standard deviation (variability of 
particle size distribution) were calculated as reported previously.[80]  
RF =
Stage 0  to  Filter   
Actuator+ Induction port + Stage 0  to Filter
   Eq. 1 
FPF =
Stage 3  to  Filter   
Induction port  to  Filter
      Eq. 2 
4.4 Results and discussion 
4.4.1 Physiochemical properties of acid-labile G3NH2-mPEG-nDOX conjugates   
The synthesis and characterization of the acid-labile G3NH2-mPEG-nDOX conjugates 
have been discussed in detail in Chapter 2.  Briefly, we synthesized acid-labile G3NH2-mPEG-
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nDOX conjugates with varying PEG density (low = 0, medium = 9 and high = 21) and DOX 
payload (low = 3 and medium = 7).  Two PEGylation strategies were developed for dendrimers 
containing different DOX payloads: direct PEGylation for low DOX payloads, and two-step 
PEGylation for high DOX payloads.  In direct PEGylation, DOX was conjugated to generation 3 
amine-terminated PAMAM dendrimer via an acid-cleavable cis-aconityl spacer.  The PAMAM-
DOX conjugates were then covalently attached with varying density of PEG1000Da.  For the 
dendrimer conjugates carrying high DOX payload, DOX was conjugated to the dendrimers that 
have been PEGylated aforehand (PAMAM-xPEG1000; x = average 7 PEG1000 per dendrimer), 
and followed by second PEGylation step to achieve high density of PEGylation.   
Both 1H NMR and MALDI-TOF demonstrated the successful conjugation of DOX and 
PEGylation.  The hydrodynamic diameters (HD) and zeta potentials of G3NH2-mPEG-nDOX 
conjugates measured with light scattering (LS).  That is, 4.0±2.3 nm and +6.3±3.5 mV for G3NH2-
3DOX, 6.9±3.2 nm and -2.1±4.3 mV for G3NH2-9PEG-3DOX, 9.6±4.9 nm and -6.6±2.7 mV for 
G3NH2-21PEG1000-3DOX, and 11.3±4.3 nm and -10.5±6.1 mV for G3NH2-9PEG-7DOX. The 
in vitro release of DOX from the conjugates determined at pH 7.4 and pH 4.5 showed DOX (80-
85%) is released from dendrimer conjugates only at acidic pH (lysosomal pH), while is stable at 
extracellular/physiological conditions (<8 % DOX is released).  Additionally, the rate at which 
DOX is released decreases as PEGylation degree increases.  Therefore, the intracellular release of 
DOX in reponse to pH drop potentially decrease the concentration of free DOX in plasma, thus 
reducing systemic adverse effects. 
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4.4.2 Cytotoxicity of acid-labile G3NH2-mPEG-nDOX conjugates   
The cytotoxicity of the various dendrimer-DOX conjugates and controls (free DOX) was 
assessed by MTT assay on Calu-3 cells.  As shown in Figure 4.1, free DOX and acid-labile 
conjugates induce significant cell kill on airway epithelial cells.  The cell kill profiles for free DOX 
and acid-labile dendrimer-DOX conjugates follow similar trend, but free DOX have greater 
potency at 72 h incubation (see both profiles and IC50 values).  As discussed in Chapter 2, we 
believe the cytotoxicity of the acid-labile conjugates could be comparable to that of free DOX as 
incubation time was prolonged and the impact of PEGylation was negligible at long incubation 
times.  The stronger time-dependent cell kill is mainly related to the sustained release of DOX 
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Figure 4.1 Viability of Calu-3 cells 72 h post incubation 
with varying concentrations of bare dendrimer, free DOX 
or acid-labile conjugates (G3NH2-mPEG1000-nDOX, with 
m = 0, 9, or 21 and n = 3 or 7), as determined by the MTT 
assay.  Results denoted as mean ± s.d. (n=6).  The inset of 
IC50 values of the free DOX (DOX) various conjugates at 
72 h incubation.  The IC50 values were obtained with non-
linear regression Log(inhibitor) vs. Response (variable 
slope). 
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from dendrimer conjugates and different cellular uptake pathways for free DOX and acid-labile 
DOX.    
4.4.3 In vitro transport of acid-labile G3NH2-mPEG-nDOX conjugates across polarized 
pulmonary epithelial monolayer 
Our recent work has shown surface chemistry of generation 3, amine-terminated PAMAM 
dendrimers (G3NH2) can be used to modulate their interaction with the pulmonary epithelium both 
in vitro and in vivo,[168] and thus be potentially used to improve permeability of DOX across 
pulmonary epithelial barriers.  In this work, we studied the effect of PEGylation degree and DOX 
payload on the transport of acid-labile G3NH2-mPEG-nDOX conjugates across epithelial 
monolayer with an in vitro Calu-3 cell monolayer model — upper airway cancer cell line.[184]  
The G3NH2-mPEG-nDOX conjugates are pulsed to apical side of cell monolayer and the amount 
of the conjugate collected at basolateral side are measured.  The results are plotted in Figure 4.2.  
It is observed that the dendrimers with medium (9 PEG) and high (21 PEG; *p<0.05 at 4.5 and 5.5 
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Figure 4.2 Apical to basolateral (AB) transport of 
free DOX and DOX from acid-labile G3NH2-
mPEG1000-nDOX conjugates across polarized Calu-
3 cell monolayers as a function of time (n=6).  
Statistical significance was calculated with respect to 
free DOX by one-way ANOVA Dunnett’s test 
(*p<0.05). 
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h with respect to free DOX) PEGylation degree transport more DOX from apical to basolateral 
side (A  B) of cell monolayer than free DOX, while non-PEGylated dendrimer transports less 
DOX in A  B direction.  Additionally, the amount of DOX collected at basolateral side increases 
as PEGylation degree increases.  The cumulative mass of DOX transported in A  B direction 
slightly increases as DOX payload increases, but no statistical significance is observed.  
We also calculate overall apparent A  B permeability (Papp A  B) of free DOX and 
G3NH2-mPEG-nDOX conjugates.  Papp A  B is a measure of ease with which substances are 
transported across epithelial layers.  Our results (Figure 4.3) show Papp A  B of free DOX is 
2.0×10-6 cm/s, which lies between G3NH2-3DOX and G3NH2-9PEG-3DOX.  Papp A  B values 
of highly PEGylated dendrimer-DOX conjugate are significantly higher than that of free DOX.  
Both Papp A  B and cumulative mass of DOX at receiving side demonstrate PEGylation and 
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Figure 4.3 Apparent permeability (Papp) of G3NH2-
mPEG1000-nDOX conjugates across Calu-3 cell 
monolayer (n=6).  Papp was determined at 5 h post 
incubation of the cell monolayer with the conjugates, 
with the transport being from the apical to basolateral 
(AB) side.  Statistical significance was calculated 
with respect to free DOX by one-way ANOVA 
Dunnett’s test (*p<0.05). 
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varying DOX payload could modulate the transepithelial transport of dendrimer-DOX conjugates 
across pulmonary epithelial layers.   
It has been reported that the DOX translocates across polarized epithelial monolayer is 
through transcellular pathway (e.g. transcytosis) in which DOX molecules are taken up by 
epithelial cells on apical side and then dropped off on basolateral side.[259, 260]  The transport of 
DOX through paracellular pathway hasn’t been reported in literature.  In contrast, dendrimer 
nanocarriers are able to cross epithelial barriers via paracellular route in conjunction with 
transcytosis.[42, 184, 218] and the rate of transport is affected by their size and surface chemistry.  
To understand the role of paracellular pathway in transepithelial transport of dendrimer-DOX 
conjugates, electrophysiological behavior of cell monolayer is evaluated by measuring the TEER 
value in the course of transport.  The TEER values are summarized in Figure 4.4.  Only a limited 
reduction (ca. 10%) is observed in the case of free DOX, demonstrating no obvious opening of 
intercellular tight junction proteins (e.g. actins and occludins) and good integrity of Calu-3 cell 
monolayer.  It thus corroborates the fact that paracellular pathway plays little/no role in the 
transepithelial transport of DOX across pulmonary epithelial layer.[259] On the other hand, it is 
evident that dendrimer-DOX conjugates have pronounced impact on TEER of Calu-3 cell 
monolayer (ca. up to 40-60% decrease in the course of transport experiment), indicating the 
significant opening of intercellular tight junction, which is a robust evidence of paracellular 
transport.[261]  Additionally, the TEER decreases as PEG density increases, demonstrating the 
highly PEGylated dendrimer can have stronger interaction with tight junctional proteins.  The 
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opening of tight junction This is in accordance with the findings in Bharatwaj’s work.[256]  The 
TEER values of Calu-3 monolayer are reversible upon removal of dendrimer-DOX conjugates 
from apical side.  As seen in Figure 4.4, all TEER values return to ca.  90% of their original values 
within 48 h.  The reversibility of the TEER values revealed Calu-3 cells are not damaged 
significantly as the G3NH2-mPEG-nDOX conjugates transport across.[41, 184].  Therefore, the 
combined results indicate PEG chains on dendrimer surface may promote the paracellular transport 
of dendrimer-DOX conjugate by interacting with intercellular tight junction and the interaction 
has no permanent damages on calu-3 monolayer.   
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On top of surface chemistry impact, the change on surface charge introduced by 
PEGylation should be considered.  As discussed earlier, non-PEGylated dendrimer-DOX 
conjugate (G3NH2-3DOX) were positively charged, whereas moderately (G3NH2-9PEG1000-
3DOX) and highly (G3NH2-21PEG1000-3DOX and G3NH2-21PEG1000-7DOX) PEGylated 
dendrimer-DOX conjugates are near-neutral or slightly negative.  The tight junctional opening by 
surface charge of dendrimers is ranked in the sequence: positive > negative > neutral.[41]  The 
sequence is obtained based on the transport study on intestinal epithelial models (e.g. Caco-2 cell 
line).  However, these intestinal cell monolayer models do not have mucus gel layer covered on 
apical side.  The mucus layers on the top of respiratory epithelial monolayer (e.g. Calu-3 cell line) 
are able to trap invading nanocarriers, especially positively charged and hydrophobic particulates.  
Mucus is viscoelastic gel layer covering the organs and tissues that expose to external environment, 
such as lungs, stomach and vagina.  Mucus gel is made up of crosslinked mucin fiber, lipids, salts, 
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proteins, nucleic acids and cellular debris.[72]  The thickness of respiratory mucus layer ranges 
from 5 to 55 µm.[262, 263]  The respiratory mucus can entrap inhaled particles and bacteria due 
to the presence of size-limiting pores, hydrophobic domains and polyvalent adhesion.  The 
particulate-entrapped mucus gel is the rapidly cleared by mucociliary escalator and fast renewed 
mucus.[72, 264] 
To study the retention of G3NH2-mPEG-nDOX conjugates by mucus layer, we use 
synthetic human mucin gel to mimic mucus layer on cell monolayer.  As shown in Figure 4.5, free 
DOX, G3NH2-21PEG1000-3DOX and G3NH2-21PEG1000-7DOX show similar capability to 
escape mucus trapping.  Dendrimer-DOX conjugates with low PEG density transport across mucus 
gel at a much smaller rate.  The similar trend is also reported our recent study and Schipper’s work 
investigating the transport of deacetylated chitosan across mucus-covered intestinal epithelial 
cells.[265]  G3NH2-3DOX is positively charged, while G3NH2-21PEG1000-3DOX and G3NH2-
21PEG1000-7DOX are negatively charged.  A large amount of anionic charges (e.g. carboxyl and 
sulfate groups) in glycosylated domains of mucin fibers can significantly immobilize cationic 
dendrimers (G3NH2-3DOX), while negatively charged dendrimers can relatively cross the mucus 
layer easily.[266-268] 
At the end of transport experiment, we also calculate amount of dendrimer conjugates left 
in apical side of cell monolayer and internalized into Calu-3 cells.  As seen in Figure 4.6, most of 
free DOX and dendrimer-DOX conjugates remain in apical side of cell monolayer (65-80% of 
added samples).  Approximately, 6.4% G3NH2-3DOX has been internalized by Calu-3 cells at 
terminal point (5.5 h), whereas PEGylated dendrimer-DOX conjugates have reduced 
internalization (4.4% for G3NH2-9PEG1000-3DOX, 3.2% for G3NH2-21PEG1000-3DOX, and 
2.5% for G3NH2-21PEG1000-7DOX).  These results in combination with cumulative mass 
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transported across cell monolayer allow us to perform an overall mass balance study.  
Approximately, an average of 85% of added samples can be recovered.  The 15% of the conjugates 
in loss may be attributed to a few factors including the presence of conjugates adhered to cell 
debris after lysis and the adsorption of conjugates to surfaces of the inserts.[256] 
In summary, the transport of DOX across pulmonary epithelial epithelium can be 
significantly enhanced upon its conjugation to dendrimers and PEGylation.  The significantly 
reduced TEER value and very limited internalization of dendrimer conjugates reveal that 
paracellular pathways play a vital role in the transport of PEGylated dendrimer-DOX across 
pulmonary epithelium.  
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4.4.4 Pseudo solution pMDI formulations of acid-labile G3NH2-mPEG-nDOX conjugates 
In Chapter 2, we have reported that the pseudo solution formulation of acid-labile G3NH2-
mPEG-nDOX conjugates in pMDIs can be readily prepared with a trace of cosolvent (ethanol).  
The physical stability and aerosol characteristics of the pMDI formulations improve significantly 
as the PEG density increases.  In this work, a facile cosolvent-free preparation for the pMDI 
formulation was also developed (Method A).  We selected the G3NH2-21PEG1000-3DOX as 
model conjugate.  A predetermined amount of conjugates (0.2 mg DOX per mL HFA227 
propellant) was added to pressure proof glass vial and then slightly melted at ca. 60 oC for a few 
seconds.  Propellant HFA227 was subsequently added to the conjugates.  The molten PEGylated 
dendrimer conjugates are found well solvated by propellant even without sonication.  The pMDI 
formulation of G3NH2-21PEG1000-3DOX was also prepared with cosolvent method reported 
earlier (Method B).  The solvation diameters (SDs) of the pMDI formulations prepared by both 
methods are determined using light scattering (LS).  We use an HFA that is liquid at ambient 
conditions and a model liquid propellant — 2H, 3H perfluoropentane (HPFP).[81, 238] The 
measurement showed SDs of the formulation from Method A and Method B are similar: 27.3±8.5 
nm vs. 26.1±7.8 nm, revealing that Method A can also prepare PEGylated dendrimer-DOX 
conjugates into pseudo solution pMDI formaution.  The size may represent aggregates of a few 
conjugates only, or even a single dendrimer conjugate whose SD in HPFP (26-28 nm for G3NH2-
21PEG1000-3DOX) turns out to be less than 3 times larger than their HD (SD in water – 10 nm 
G3NH2-21PEG1000-3DOX).    
To further understand thermal properties of G3NH2-m21PEG1000-nDOX conjugate, 
differential scanning calorimetry (DSC) was used to monitor their molten behaviors and the results 
were plotted in Figure 4.7 (a).  The melting point (mp) of G3NH2-21PEG1000-3DOX is 45.72 
oC, 
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which is similar to that of PEG (mp of pure PEG: 46.72 oC).  Since G3NH2 dendrimer is an 
amorphous polymer without melting point, PEG chains on surface are mainly responsible for 
melting behavior of the conjugate.  It is believed that the molten PEG chains covering on dendrimer 
surface facilitate the solvation of the conjugates (acting as cosolvent).   
4.4.5 Impact of heating process on aerosol performance of pseudo solution pMDI 
formulation  
The aerosol characteristics are key to a pMDI formulation.  Andersen Cascade Impactor 
(ACI) is widely used as an in vitro model to determine drug deposition in the lungs.  Lung 
deposition of the formulations by Method A and B are summarized in Figure 4.7 (b).  The mass 
deposition on each stage is summarized in Supplementary Information Table S1.  The 
formulations prepared by Method A and B showed similar the deposition fraction of the conjugates 
on ACI, mainly on from Stage 4 to 7 which corresponds to deep lung regions.  Respirable fraction 
(RF), fine particle fraction (FPF), mass median aerodynamic diameter (MMAD), geometric 
standard deviation (GSD) and recovery are calculated according to the deposition data and listed 
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Figure 4.7 (a) erosol characteristics of the pMDI formulations containing the acid-labile 
G3NH2-21PEG1000-3DOX conjugates.  Method A = formulation prepared by heating the 
conjugate or conjugate and polymer mixture before addition of propellant; Method B = anhydrous 
ethanol (EtOH) at 0.37% v/v relative to HFA227 propellant was added to the formulation as co-
solvent.  (b) Differential scanning calorimetry (DSC) thermograms of PEG1000 and acid-labile 
G3NH2-21PEG1000-3DOX conjugates. 
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in Table 4.1.  The RF and FPF are two major parameters to assess the efficiency of the pMDI 
formulation for pulmonary delivery.[82]  RF (85.2±5.8%) and FPF (81.9±4.5%) of the formulation 
from Method A are slightly greater than those of Method B (RF: 82.0±4.8%; FPF: 78.1±4.3%), 
but no statistical significance is found.  The FPFs obtained from both methods are much higher 
than those of commercial HFA-based suspension pMDIs (30-55% on average)[81, 269] and HFA-
based solution formulations (60-80% on average).[239, 242]  Additionally, the MMAD and GSD 
are similar for both methods, falling within the optimum range of aerodynamic diameters (5.0-
0.5µm).  The recovery for both formulations is similar.  We believe that the loss of the delivered 
dose of the formulation containing G3NH2-21PEG1000-3DOX is mainly from small particles with 
exhalable size range (aerodynamic diameter < 0.5 µm).  It is noted that micronized particles are 
formed from pseudo solution pMDI formulation of nano-sized particles with propellant molecule 
Table 4.1 Median mass aerodynamic diameter (MMAD), geometric standard deviation (GSD), 
respirable fraction (RF) and fine particle fraction (FPF) of the pMDI formulations containing 
acid-labile G3NH2-21PEG1000-3DOX conjugate and LA46-EO23-LA46 triblock copolymer 
surfactants, as determined by Andersen Cascade Impactor (ACI).  The formulations were 
prepared with Method A (no ethanol) and contained 0.2 mg DOX equivalent per mL HFA227 
propellant and varying concentrations of LA46-EO23-LA46 copolymer (0, 0.12 and 0.53 mM).  
Statistical significance was performed with respect to the pMDI formulation with 0 mM LA46-
EO23-LA46 prepared by Method A using one-way ANOVA Dunnett’s test with *p<0.05, 
**p<0.01, and ***p<0.001.  † denotes the formulation was prepared by the Method B, 
formulations containing anhydrous ethanol at 0.37% v/v relative to HFA227 propellant. 
LA46-EO23-LA46  MMAD (µm) GSD (µm) RF (%) FPF (%) Recovery (%) 
0†   1.2±0.1 1.8±0.1 82.0±4.8 78.1±4.3  86.9±4.7 
0 1.3±0.1 1.9±0.1 85.2±5.8 81.9 ±4.5 84.0±5.9 
0.12  2.3±0.3** 1.9±0.1 82.4±6.6 68.7±5.8* 84.5±7.2 
0.53  3.0±0.5*** 2.2±0.1 79.2±8.9 58.4±6.1** 78.7±6.4 
 
101 
 
vaporizing.  A phase separation mechanism for micronized particle formation is proposed in 
Chapter 2.  
In summary, the pseudo solution of formulation of highly PEGylated dendrimer-DOX 
conjugates can be also prepared with a facile cosolvent-free method.  The formulation prepared 
with this method shows superior aerosol properties and is conducive to deep lung deposition.   
4.4.6 Deposition-tunable pMDI formulation of G3NH2-mPEG-nDOX conjugates by the 
addition of triblock copolymer LAn-EOm-LAn 
It is observed in Figure 4.7 (b) that ca. 70% of the G3NH2-21PEG1000-3DOX conjugate 
deposited on Stage 5 to 7 which corresponds to deep lung areas including terminal bronchioles and 
alveolar sacs.  Therefore, the formulation tends to deliver chemotherapeutics to peripheral lung 
cancers.[270]  However, some primary and secondary airway malignancies occur on upper (e.g. 
trachea) and lower respiratory (bronchi, primary and secondary bronchioles) tracts.[271, 272]  As 
is well known, the addition of non-volatile excipients to pMDI formulations can increase their 
MMADs due to reduced vapor pressure of the propellant, thus leading to  increased deposition of 
particles in central lung area.[78, 273]  In this work, we selected triblock copolymer LAn-EOm-
LAn as nonvolatile excipients to adjust aerosol characteristics as experimental work and 
computational simulation has shown biocompatible polylactide homopolymers and copolymers 
are soluble excipients in HFA propellant,[58, 274, 275] which won’t change the nature of pseudo 
solution of highly PEGylated dendrimer-DOX conjugates.  Wu and da Rocha reported the 
copolymers with longer lactide (LA) repeat units are more capable of partitioning interaction 
between drug molecules.[58]  Therefore, the LAn-EOm-LAn copolymer with long PLA block was 
synthesized via ring opening polymerization of D, L-lactide (LA) with hydroxyl PEG (HO-
PEG1000-OH) as macromolecular initiator.[258]  The 1HNMR and MALDI-TOF of resulting 
102 
 
LAn-EOm-LAn copolymer (Figure 4.8) show the ratio of LA unit to PEG chain is 92:1 and the 
molecular weight is 7561.61Da.  The triblock copolymer will be denoted as LA46-EO23-LA46 from 
here.  The G3NH2-21PEG1000-3DOX conjugate was mixed with LA46-EO23-LA46 copolymer and 
then heated slightly before HFA227 filling.   
We studied the effect of PLA46-PEG-PLA46 concentration on the solvation diameters of 
the pMDI formulations by LS.  The results show the SDs of the formulations range from ca. 26 to 
31 nm (PLA46-PEG-PLA46 concentration — 0 mM: 26.1±7.8 nm; 0.12 mM: 30.3±10.9 nm; 
28.6±7.8 nm) and are not affected by the concentration of PLA46-PEG-PLA46 within 0 – 0.53 mM.  
This reflects the addition of LAn-EOm-LAn copolymer does not affect the nature of solution 
formulation.  The solvation diameter of LA46-EO23-LA46 copolymer in HPFP is not detected with 
LS, possibly due to the random coiled conformation of linear polymer.  It is thus believed that 
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Figure 4.8 1H NMR and MALDI spectra of LA46-EO23-LA46 triblock copolymer.. 
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LAn-EOm-LAn copolymer is not able to form strong interaction with PEGylated dendrimer 
conjugate. 
The effect of the concentration of LA46-EO23-LA46 on the aerosol characteristics of the 
pMDI formulations is determined with ACI and the lung deposition is plotted in Figure 4.9.  It is 
obviously observed that the deposition of G3NH2-21PEG1000-3DOX on lower stages increases 
as the concentration of PLA46-PEG-PLA46 copolymer increases.  The ratio of the deposition of 
conjugates on Stage 2-4 to Stage 5-7 (F2-4/5-7) was 0.22 (15.0%:67.0%) for 0 mM, 1.24 
(40.0%:32.1%) for 0.12 mM, and 1.94 (51.9%:26.7%) for 0.53 mM.  According to the correlation 
of ACI stage to anatomical lungs, Stage 2 to 4 corresponds to lung anatomical regions such as 
trachea, primary and secondary bronchi, while Stage 5 to 7 corresponds to deep lung area including 
terminal bronchioles and alveoli.  The shift of lung deposition to lower stages of ACI reveals the 
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formulation with LA46-EO23-LA46 as excipient is capable of delivering PEGylated dendrimer 
conjugates to upper respiratory tract.   
The aerosol parameters of these pMDI formulations are summarized in Table 1.  
As the concentration of PLA46-PEG-PLA46 increases, the RF of these pMDI formulations 
decreases slightly, while the FPF decreases with statistical significance.  However, the lowest FPF 
is still greater than that of commercial HFA-based pMDI formulations (30-55% on average).[82]  
The MMAD of these formulations increases from 1.3 µm to 3.0 µm with the concentration of 
LA46-EO23-LA46 increasing from 0 to 0.53 mM, which remain in the optimal range of particle size 
for oral inhalation (5-0.5 µm).  The trend of change of FPF and MMAD with the addition of 
nonvolatile soluble excipient is in accordance with published results.[78]     
In summary, the pseudo solution formulation of PEGylated dendrimer-DOX conjugate is 
tunable in terms of cancerous sites in the lungs by adjusting the concentration of PAL-PEG-PLA 
copolymer.  For broad relevance, the PEGylated PAMAM dendrimers via oral inhalation can be 
used as a platform for delivering therapeutics of interest to treat other pulmonary disorders. 
4.5 Conclusion 
In this work, a series of PEGylated PAMAM dendrimers with acid-labile DOX conjugated 
have been synthesized.  The conjugates were maintained stable at physiological condition (e.g. 
blood circulation), while were capable of releasing free DOX at acidic compartment (e.g. lysosome) 
causing comparable cytotoxicity to free DOX against lung cancer epithelial cell line (calu-3).  In 
vitro transport of G3NH2-mPEG-nDOX conjugates across polarized lung epithelia model 
indicated the apparent transport of apical to basolateral side increased as PEG density increased, 
whereas cellular uptake rate declined due to attenuated interaction upon PEGylation.  The 
significant reduction in TEER showed paracellular pathway played a vital role in sending the 
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conjugates across epithelial monolayer.  Different from other epithelial cells (e.g. intestinal or 
colorectal epithelia), mucus gel layer secreted by airways epithelial cells withheld a large amount 
of conjugates.  However, high degree of PEGylation can help the conjugates effectively escape 
from mucus entrapping—thus enhancing transcellular transport rate.  The G3NH2-mPEG-nDOX 
conjugates can be readily formulated into HFA-based pMDIs with two different methods: heating 
method and co-solvent aiding method, forming solution formulations.  The pMDI solution 
formulations prepared by the two methods had very excellent physical stability and aerosol 
characteristics (high RF and FPF, and low MMAD and GSD).  Considering cancerous lesions of 
the lungs and respiratory tract, the aerosol deposition was tunable by adjusting the concentrations 
of biodegradable LAn-EOm-LAn triblock copolymers.  Therefore, all combined results 
demonstrated that the acid-labile PEGylated PAMAM-DOX conjugates administered locally by 
oral inhalation are promising for treating lung adenocarcinoma.  Broadly, the pMDI solution 
formulation containing PEGylated PAMAM dendrimers is also promising platform for treating 
other pulmonary disorders.                              
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CHAPTER 5 — Conjugation to Poly(amidoamine) Dendrimers and 
Pulmonary Delivery Enhances the Antitumor Activity of Doxorubicin in 
Lung Metastasis 
5.1 Introduction 
Cancer is the second most common cause of death for both men and women in the United 
States, second only to heart diseases.[276]  Amongst the many malignant tumors, lung cancers are 
the leading cause of death.  More patients die from lung cancers than breast, pancreatic, and 
prostate cancers combined.[2]  Although curative surgery is the first choice in the clinic for treating 
primary lung tumors, chemotherapy plays a vital role in inhibiting tumor growth after surgery, 
partly due to the high rates of recurrence.[277, 278]  Additionally, the lungs are the most common 
site for metastasis for almost all other primary tumors.[279]  Metastatic tumors are also associated 
with more than 90% of cancer-related deaths.[280]  The development of new strategies that can 
help improve chemotherapeutic outcomes during the treatment of lung metastasis have, therefore, 
a significant potential societal impact. 
One of the major challenges limiting the success of chemotherapeutic treatment in lung 
metastasis is the low concentration of anticancer agents in the lung tissue and lung tumor.  Upon 
systemic administration, such as intravenous injection (i.v.), only a few percent of the total dose 
(TD) (< 4%) actually reaches the tumor site.[8]  Because of typical systemic toxicity of anti-cancer 
therapeutics, increasing the overall administered dose so as to reach therapeutic local concentration 
of chemotherapeutics is usually not a viable strategy.[9]  The study of the effectiveness of new 
chemotherapeutic strategies that consider local lung delivery are, therefore, also of great potential 
relevance as they promote local drug concentration while decreasing systemic exposure. 
Doxorubicin (DOX) is one of the most effective anti-cancer therapeutics available in the 
clinic today [281] and has been widely used alone or in combination to treat a variety of malignant 
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cancers including lung tumors.[56, 57]  DOX induces the apoptosis of cancer cells by intercalating 
itself to DNA double helix and thus inhibiting the progression of enzyme topoisomerase II.  Other 
mechanisms include the production of high level reactive oxygen species (ROS) and cellular 
membrane disruption.[95]  The applicability of DOX is to some extent limited, however, due to 
its damage to the cardiac tissue.[21]  The accumulation of DOX in the heart results in increased 
oxidative stress, down-regulated protein function, decreased cardiac gene expression, and up-
regulated apoptosis of cardiomyocytes, which eventually leads to lethal cardiomyopathy.[22] 
There are, therefore, tremendous opportunities in the development of strategies that will 
enhance the local concentration of DOX in the lung tissue, while maximizing its intracellular 
delivery to lung tumor cells, and at the same time minimizing the systemic concentration of free 
DOX.   Nanocarriers are uniquely suited in this aspect, as they can be used to modulate the 
pharmacokinetics (PK) and biodistribution of therapeutic agents.[282]  Dendrimers are 
particularly interesting drug carrier systems as they are highly monodispersed (predictable 
PK/biodistribution) and can be easily functionalized with therapeutic agents through linkages that 
allow for temporal and spatial control of drug release.  Dendrimer can also be modified with 
various ligands to control their interaction with the physiological environment and can also 
promote their cellular internalization.[31, 167, 212]  
Based on the challenges and opportunities discussed earlier, the goal of this study was to 
investigate the effect of the conjugation of DOX to dendrimer and of the local administration of 
the carrier system to the lung tissue on the efficacy of DOX in reducing the metastatic lung tumor 
burden.  We conjugate DOX to carboxyl-terminated, generation 4, poly(amidoamine) dendrimer 
(G4COOH) nanocarriers through an intracellularly-triggered (pH-responsive) drug release linker.  
We evaluated the impact of pH on the release kinetics of the conjugates – both at extracellular 
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physiological pH (7.4) and intracellular pH (lysosomal, 4.5).  The ability of the conjugates gain 
access to and to kill B16F10 mouse melanoma cells was also investigated using flow cytometry 
and MTT assay.  A mouse model of lung metastasis (from melanoma B16F10 cells) was 
established and the efficacy of the G4COOH-DOX conjugates in reducing the metastatic lung 
tumor burden and rate of survival was investigated.  The effect of conjugation was assessed by 
comparing the results of the studies above to free DOX, while the impact of the local lung delivery 
was determined by comparing the effectiveness of the conjugates and free DOX delivered via 
pharyngeal aspiration (locally) and intra venous (i.v.).  The potential of the conjugation of DOX 
to G4COOH and the pulmonary delivery route are also discussed in terms of the tissue distribution 
of the carriers, particularly to the lungs (target) and the cardiac tissue (to be avoided).   
5.2 Materials   
Generation 4, carboxyl-terminated, poly(amidoamine) dendrimer (G4COOH) was 
purchased from Dendritech, Inc (Miland, MI, USA).  Doxorubicin hydrochloride (DOX) was 
purchased from LC Laboratories (Woburn, MA, USA).  N-methylmorpholine (NMM) and isobutyl 
chloroformate (IBCF) were purchased from VWR Internationals (Radnor, PA, USA).  Tert-butyl 
carbamate (TBC), trifluoroacetic acid (TFA), triethylamine (TEA), 2, 5-dihydroxybenzoic acid (2, 
5-DHB), and 4% paraformaldehyde PBS solution were purchased from Sigma-Aldrich (St Louis, 
MO, USA).  Phosphate buffer saline (PBS, 1X), Dulbecco’s Modified Eagle’s Medium (DMEM), 
penicillin (10,000 U/mL)-streptomycin (10,000 µg/mL), and trypsin-EDTA solution (0.25% 
trypsin and 0.53 mM EDTA) were purchased from Life Technologies (Grand Island, NY, USA).  
Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA, USA).  
Deuterated dimethylsulfoxide (DMSO_d6) was purchased from Cambridge Isotope Laboratories 
(Andover, MA, USA).  Ultrapure deionized water (DI H2O, Ω=18.0-18.2) was sourced from a 
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Barnstead NANOpure DIamond System (D11911), equipment purchased from Thermo Fisher 
Scientific (Waltham, MA, USA).  All anhydrous organic solvents including dimethylsulfoxide 
(DMSO), dimethylformamide (DMF), dichloromethane (DCM), and methanol (MeOH) were 
bought from VWR International (Radnor, PA, USA).  Spectra®Por dialysis membrane 
(MWCO=3kDa) was purchased from Spectrum Laboratories, Inc (Rancho Dominguez, CA, USA).  
Amicon® Ultra 15 centrifugal filter device (MWCO=10kDa) was purchased from EMD Millipore 
(Billerica, MA, USA).  Thin layer chromatography (TLC) Silica gel 60 F254 plastic sheet was 
purchased from Merck KGaA (Darmstadt, Germany).  All reagents were used as received unless 
otherwise noted. 
5.3 Methods 
5.3.1 Cell culture   
Mouse melanoma cell line (B16F10), passage 5 to 10, was kindly gifted by Dr. Haipeng 
Liu, Department of Chemical Engineering and Materials Science at Wayne State University.  
B16F10 cells were seeded in a Corning® 75 cm2 U-Shaped Canted Neck Cell Culture Flask 
(Corning Life Sciences.  Tewksbury, MA, USA), and cultured with DMEM supplemented with 
10% FBS and penicillin (100 U/mL)-streptomycin (100 µg/mL) (Pen-Strep).  The cells were 
grown in a Thermo Scientific™ CO2 incubator (Thermo Fisher Scientific) at 37 oC and 5% CO2.  
The medium was exchanged every two days and the cells were split as they reached ca. 70-80% 
confluence. 
5.3.2 Animals for in vivo experiments  
All animal experiments were performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee at Wayne State University.  Male C57BL/6 mice 
(6-8 weeks, 20-22 g) were purchased from Charles River Laboratories (Wilmington, MA, USA).  
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The mice were housed under a 12 h light/dark cycle, allowed food and water ad libitum, and 
acclimatized for 1 week prior to any experiment.   
5.3.3 Synthesis and characterization of dendrimer-DOX conjugates with an acid-labile 
bond (G4COOH-nDOX)  
The synthetic route of the G4COOH-nDOX conjugate is shown in Figure 5.1.  All the 
intermediates and final products were characterized with proton nuclear magnetic resonance (1H 
NMR) for chemical composition and mass-assisted laser desorption/ionization-time of flight 
(MALDI-TOF) for molecular weight.  The hydrodynamic diameter (HD) and zeta potential () of 
the intermediates and final products were measured with light scattering (LS).  The methods for 
instrumentation can be found in Supporting Information in Appendix 4. 
G4COOH (78.3 mg, 3.80 µmol) was mixed with NMM (117.98 µL, 1.07 mmol) and IBCF 
(133.64 µL, 1.02 mmol) in 8 mL DMSO/DMF (v/v, 10/90).  The system was stirred at 0 oC for 5 
min, and then TBC (32.1 mg, 0.243 mmol) was added to the above mixture.[113]  The reaction 
was further stirred at 0 oC for 30 min and continued at room temperature for 48 h.  The organic 
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Figure 5.1 Synthesis of the generation 4, carboxyl-terminated PAMAM dendrimer 
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solvent was completely removed under reduced pressure.  The product was redissolved in 0.1 M 
phosphate buffer solution with pH value being adjusted to around 10.  The product (G4COOH-
mTBC) was purified with centrifugal filtration (MWCO=10kDa) and the product collected in filter 
was lyophilized for 24 h.  1H NMR (ppm, DMSO_d6):  δ 9.52 (s, 32.30H, -NHBoc in TBC), 8.67 
(s, 29.58H, -NHCO- in TBC), 7.89-7.70 (m, 156.84H, -NHCO- in G4COOH), 3.06 (m, 372.38H, 
-CONHCH2- (He) in G4COOH), 2.63-2.56 (m, 328.45H, -NCH2- (Hd) and -COCH2CH2CO (Hjr3) 
in G4COOH), 2.41 (m, 126.38H, -CH2N- (Hb,c) in G4COOH), 2.29 (m, 150.53H, -
CH2CH2CONHNH- (succinic methylene, Hjr2) in G4COOH), 2.18 (m, 248.00H, -CH2CO- (Ha) in 
G4COOH), 1.36 (m, 305.54H, -(CH3)3 in TBC).  MALDI-TOF m/z (Da): 20531.79. 
The resulting G4COOH-mTBC (84.34 mg, 4.10 µmol) was dissolved in 5 mL TFA/DCM 
(80/20, v/v) and stirred at 0 oC for 30 min.  The TFA was immediately removed under reduced 
pressure.  The product was treated with 0.1 M phosphate buffer solution (pH 10).  The product 
(G4COOH-mHyd) was purified with centrifugal filtration (MWCO=10kDa) and the conjugate 
collected in the filter was lyophilized for 24 h.  1H NMR (DMSO_d6, ppm): δ 9.02 (s, 19.06H, 
NH2NHCO- in hydrazide), 8.03 (m, 175.56H, -NHCO- in G4COOH), 3.05 (m, 258.24H,  -
CONHCH2- (He) in G4COOH), 2.620 (m, 188.96H, -NCH2- (Hd) and -COCH2CH2CO- (Hjr3) in 
G4COOH), 2.41 (m, 87.18H, CH2N- (Hb,c) in G4COOH), 2.23 (m, 151.22H, -CH2CONHNH2 
(succinic methylene (Hjr2) in G4COOH), 2.18 (m, 248.00H, -CH2CO- (Ha) in G4COOH).  
MALDI-TOF m/z (Da): 17780.33. 
DOX (20 mg, 34.48 µmol) was dissolved in 40 mL anhydrous MeOH with a trace amount 
of TFA as catalyst (1.32 µL, 17.32 µmol).  The G4COOH-mHyd (18.67 mg, 1.05 µmol) was added 
to the above organic mixture and the reaction was monitored with TLC until the reaction was 
completed.  The MeOH was completely removed under reduced pressure.  The product was 
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purified with centrifugal filtration (MWCO=10kDa) and the solution was monitored repeated for 
ending of centrifugal process.  The product (G4COOH-nDOX) was lyophilized for 24 h.  1H NMR 
(DMSO_d6, ppm): δ 9.02 (s, 20.41H, NH2NHCO- in hydrazide), 8.05 (m, 167.13H, -NHCO- and 
Ar-H in G4COOH and DOX), 5.26 (s, 11.99H, -CH- in DOX), 4.89 (d, 12.72H, -CH- in DOX), 
4.570 (m, 24.72H, -CH2OH in DOX), 4.17 (s, 11.02H, -CH- in DOX), 3.94 (s, 35.23H, -OCH3 in 
DOX), 3.05 (m, 255.54H,  -CONHCH2- (He) in G4COOH), 2.620 (m, 217.26H, -NCH2- (Hd) and 
-COCH2CH2CO- (Hjr3) in G4COOH), 2.41 (m, 109.82H, CH2N- (Hb,c) in G4COOH), 2.29 (m, 
152.93H, -CH2CONHNH2 (succinic methylene (Hjr1, jr2) in G4COOH), 2.18 (m, 248.00H, -
CH2CO- (Ha) in G4COOH), 1.86 and 1.65 (d, 23.96H, -CH2- in DOX), 1.12 (s, 36.10H, -CH3 in 
DOX).  MALDI-TOF m/z (Da): 23860.59.   
5.3.4 In vitro release of DOX from the G4COOH-nDOX conjugate   
In vitro release of DOX was determined at both pH 7.4 and 4.5 that represent extracellular 
physiological pH and the lysosomal pH, respectively.  A 2.0 mL of PBS (10 mM, pH 7.4) or citrate 
buffer (10 mM, pH 4.5) containing free DOX or G4COOH-12DOX conjugate (both with 1 µmol 
DOX or equivalent) was added to a dialysis bag (MWCO=3kDa), and the dialysis bag was 
immersed in 30 mL same medium as inside the bag.  The in vitro release was performed by gently 
shaking the system at 37.0 ± 0.2 °C and in darkness.  A 0.1 mL buffer solution from outside the 
dialysis bag was sampled at predetermined time points, and the absorption of DOX was determined 
using a Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek Instruments, Inc.  Winooski, VA, 
USA), at 490 nm and the amount of DOX was calculated with respect to an established calibration 
curve.  These experiments were run in triplicate.  The samples were returned after each 
measurement.  The cumulative release of DOX from the conjugate was plotted as a function of 
time. 
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5.3.5 Cell kill (in vitro) of the G4COOH-nDOX conjugate  
The ability of the G4COOH-12DOX conjugate to kill B16F10 melanoma cells was 
assessed using the MTT assay.  The results benchmarked against free DOX as control.  Briefly, 
sample-laden DMEM (no phenol red) was sterilized through 0.22 µm syringe filter (VWR 
Internationals).  10,000 B16F10 cells were seeded in each well of tissue culture treated 96-well 
plate (VWR Internationals) 24 h ahead of the experiment.  The DMEM in each well was replaced 
with a 100 µL of the sample-laden DMEM (no phenol red).  The medium was removed after 48h, 
and the cells were washed twice with 100 µL PBS (10 mM, pH 7.4).  100 µL of fresh DMEM (no 
phenol red) and 10 µL of MTT (5 mg/mL in PBS) were added to each well.  After 4 h incubation 
at 37 oC and 5% CO2, 75 µL medium was removed and 60 µL DMSO was then added.  The cells 
were allowed to sit in the incubator (37 oC, 5% CO2) for another 2 h.  Finally, the absorbance of 
each well was recorded at 570 nm.  The cell viability of B16F10 cells was plotted as a function of 
free- or dendrimer-conjugated DOX concentration (n=8 per concentration). 
5.3.6 Cellular internalization of the G4COOH-nDOX conjugate by B16F10 cells   
3×105 B16F10 cells/well were seeded in Costar® 24-well cell culture plate (Corning Life 
Science.  Tewksbury, MA, USA) 24 h prior to the experiment.  A 0.5 mL sterile Hanks Balanced 
Salt Solution (HBSS, 1X, pH 7.4) containing free DOX or G4COOH-12DOX (1 µM DOX or 
equivalent) was added to each well and then incubated with cells for different times (0.5, 1, 1.5, 2, 
3, 4 and 5 h. n=3 per time point).  The cellular internalization was terminated at each time point 
by washing the cells with cold HBSS (1X, pH 7.4).  The cells were detached with 0.2 mL trypsin-
EDTA and were then pelletized by centrifugation at 350 g.  The collected cells were resuspended 
in 0.5 mL cold HBSS and immediately analyzed for DOX fluorescence with BD LSR II Analyzer 
with excitation/emission=488/590 (BD Bioscience. San Jose, CA, USA).  At least 10,000 events 
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were counted for statistical significance.  Median fluorescence intensity (MFI) was plotted as a 
function of time to evaluate the cellular internalization of free DOX and dendrimer conjugates.  
5.3.7 Efficacy of free and dendrimer-conjugated DOX in treating lung metastasis  
A 200 µL PBS containing 2×105 B16F10 cells were implanted to each mouse through tail 
vein to develop the lung metastasis model.  At 5, 7 and 9 days post tumor implantation (DPI5, 
DPI7 and DPI9), 50 µL PBS containing free DOX or G4COOH-nDOX (20 µg of DOX equivalent 
per dose) was administered to each mouse via either pharyngeal aspiration (p.a. = lung delivery) 
or i.v. injection, which served as the control in terms of route of administration.  The mice were 
deeply anesthetized with 2.5% v/v isoflurance/oxygen and then placed on a slant board in a supine 
position.  The tongue was gently extended and a 50 µL sample-laden PBS was gradually dripped 
in the pharynx region with a Hamilton®900 series syringe (Hamilton Company.  Reno, NV, USA).  
The tongue was not returned until after a few breaths.  The mice were gently returned to the cage 
and monitored during a few minutes for recovery.  The mice were observed daily for behaviour 
(e.g. diet, drinking, and motion) and body weight.  The mice were euthanized at DPI17 or prior to 
terminal point if necessary.  The terminal point criteria include weight loss of 20% or more, 
obvious signs of illness in addition to the tumor, inability to move freely or significant quivering, 
and inability to eat/drink properly.  The nodule numbers in the lungs of each mouse were carefully 
counted (The lung metastases at late stages are characterized by large patches of nodules, so it’s 
inappropriate/unlikely to count nodule number exactly at that phase).  Kaplan-Meier survival 
curves were drawn by plotting survival rate as a function of DPI.  The lungs of each mouse were 
also weighed out to evaluate tumor burden.  These combined parameters are used to evaluate 
antitumor efficacy of free DOX and DOX-conjugated dendrimer conjugates.  The cohort given 
with PBS was used as positive control group.  We used 6 mice per cohort for statistical analysis. 
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5.3.8 Systemic distribution of the G4COOH-nDOX conjugate   
As the mice were euthanized, the blood was collected by cardiac puncture and principle 
organs were excised for quantifying systemic distribution of DOX.  The excised tissues are lungs, 
heart, liver, spleen, kidneys, stomach, brain, thymus, auxiliary lymph nodes (ALN), bronchial 
lymph nodes (BLN), cervical lymph nodes (CLN), mesenteric lymph nodes (MLN).  The tissues 
were homogenized in 3 mL Triton X-100 (0.5% by weight) in PBS (0.5 M, pH 7.4) with D1000 
Hand-held Homogenizer (Thermo Scientific) and DOX were extracted into the PBS at 37 oC for a 
period of 72 h in darkness.  For liver, 5 mL solution was needed instead.  The homogenate was 
pelletized by centrifugation (22,000 g, 4 oC, 10 min) and a 200 µL of the supernatant was taken to 
measure DOX fluorescence using Biotek Synergy 2 Multi-Mode Microplate Reader 
(excitation/emission=480±20/595±20 nm).  The amount of DOX in each tissue was determined 
with respect to an established calibration curve, which was measured by spiking predetermined 
amount of DOX or dendrimer-DOX conjugate directly into corresponding tissue.  The 
determination was performed in triplicate. 
5.3.9 Statistical analysis   
GraphPad Prism 5 software was used for data analysis.  The statistical analysis between 
two systems was performed by Student’s t test, while that among multiple systems by one-way 
analysis of variance (ANOVA) with either Dunnett’s test or Tukey post hoc test.  A P-value of 0.05 
or less was considered to be statistically significant. 
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5.4 Results and discussion 
5.4.1 Synthesis and characterization of the dendrimer-DOX conjugates (G4COOH-
nDOX)  
PAMAM dendrimers have been widely used as drug delivery nanocarriers in cancer 
chemotherapy due to highly controlled size, low toxicity, non-immunogenicity, and multiple 
functionalizable surface groups.[167]  Hydrazone bonds have been recognized as one of the most 
promising acid-labile spacers in covalently bonding DOX to polymer due to its high sensitivity to 
mild acidity and relatively straightforward chemistry.[113, 283]  In the study, DOX was 
conjugated G4COOH via hydrazone bonds.  G4COOH was firstly modified on surface with Boc-
protected hydrazide.  The successful modification of -COOH groups was evidenced by two peak 
shifts –NHNH2 in TBC: 7.83 ppm (-NH-) to 9.52 ppm (-NHBoc) and 3.89 ppm (-NH2) to 8.67 
ppm (-NHCO- adjacent to G4COOH).  The protective Boc groups were subsequently removed to 
give rise to hydrazide groups (-NHNH2), which was evidenced by the shift of -NHCO- (adjacent 
to G4COOH) peak from 8.67 to 9.02 ppm and disappearance of the peak at 9.52 ppm.  The 
resulting –NH2 groups of hydrazides were further reacted with carbonyl group of DOX, leading to 
formation of the hydrazone bonds, which are cleavable at mild acidic condition (pH≤5; e.g. 
intracellular lysosomal pH), but stable at near neutral condition (e.g. extracellular physiological 
pH).  The detailed 1H NMR and MALDI spectra of dendrimer-DOX conjugates and important 
intermediates are shown in Figure 5.2.  DOX payload and molecular weight of dendrimer 
conjugate are quantified and summarized in Table 1.  Approximately 12 DOX molecules are 
attached to each dendrimer according to 1H NMR spectra, which was in agreement with MALDI 
results.  
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Size and surface charge and chemistry are some of primary parameters to be considered in 
the design of drug delivery systems as they strongly affect the interaction with the physiological 
environment, including the bioavailability, pharmacokinetics and pharmacodynamics of the 
conjugates.  It can be seen that the hydrodynamic diameter (HD) of the dendrimer slightly 
decreased upon surface modification with hydrazides (4.7 to 3.6 nm), whereas it dramatically 
increases upon conjugation of DOX (4.7 to 9.7 nm).  The partial conversion of negatively charged 
Conjugates MW 
DOX content (n) 
HD ± s.d. (nm) ζ ± s.d. (mV) 
1HNMR MALDI 
G4COOH 17104 0 0 4.7 ± 1.8 -6.6 ± 4.1 
G4COOH-30Hyd 17780 0 0 3.6 ± 0.9 -0.5 ± 2.6 
G4COOH-12DOX 23861 12.2 11.5 9.7 ± 3.5 +13.8 ± 7.0 
 
Table 5.1 Molecular weight (MW), number of conjugated doxorubicin (DOX) (n), 
hydrodynamic diameter (HD), and zeta potential (ζ) of generation 4, carboxyl-
terminated PAMAM dendrimer (G4COOH) conjugate.  DOX was conjugated 
through an acid-labile hydrazone linker.  Results obtained by 1H NMR, MALDI, 
and light scattering (LS) at 25oC.  s.d. = standard deviation. 
10.0 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0
G4COOH
ppm
G4COOH-30TBC
G4COOH-30Hyd
G4COOH-12DOX
15 20 25 30 35
  
 
m/z (kDa)
 G4COOH = 17104
 G4COOH-TBC = 20532
 G4COOH-Hyd = 17780
 G4COOH-12DOX=23861
(a) (b)
Figure 5.2 (a) 1H NMR spectra of acid-labile G4COOH-12DOX conjugate.  Inset: 
chemical structure of G4COOH-12DOX.  Spectral shifts for all compounds are 
provided in Section 2.4 and (b) MALDI spectra of G4COOH-12DOX conjugate and 
intermediates. 
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carboxylates to neutral tert-butyl groups (G4COOH-mTBC) attenuates the repulsion of peripheral 
carboxylates.  Additionally, hydrophobic tert-butyl group will tend to be less solvated by the 
aqueous environment.  Both effects lead to more collapsed architecture with respect to G4COOH.  
In contrast, the HD increase upon DOX attachment is mainly due to large number of bulky and 
rigid DOX molecules bonded onto the dendrimer surface.  The dendrimer structure is expanded to 
some extent by the rigid DOX molecule through the interaction including hydrogen bonding and 
electrostatic force. It is also observed that the  increased from a negative value of -6.6±4.0 mV 
for bare G4COOH, to a moderately high positive charge of +13.8±7.0 mV upon DOX conjugation.  
The remaining hydrazides (ca. 18) on surface and primary amines of DOX (ca. 12) are protonated 
at physiological pH (7.2-7.4), which cannot only offset negative charges from carboxylates, but 
provide extra positive charges.  Therefore, the overall surface potential of dendrimer-DOX 
conjugate is positive, which may potentially enhance cellular internalization and promote 
interaction with the local epithelia.[49] 
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5.4.2 Sustained in vitro release of acid-labile G4COOH-12DOX conjugate   
The ability of DOX release from dendrimer-DOX conjugate was determined at two pH 
values — mild acidic (e.g. lysosomal pH 5~4.5) and physiological (e.g. pH 7.4~7.2) 
conditions.[113, 115]  The results are summarized in Figure 5.3. 
As shown in Figure 3, the release of DOX from G4COOH was shown to be dependent on 
pH.  A negligible (<4%) amount of DOX was released at pH 7.4, while in an acidic medium over 
80% DOX was released from the conjugate at 48 h.  In contrast, free DOX diffused out of dialysis 
membrane at a fairly rapid rate (over 90% release at approximately 7 h) for both pH values.  Based 
on the release profile of free DOX, approximately 7% of DOX cannot be recovered likely due to 
interactions of DOX with the dialysis bag and photobleaching.  Similar losses can be expected for 
the conjugates, indicating a recovery of over 86% from the “viable” DOX. 
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Figure 5.3 In vitro release profiles of DOX from acid-
labile G4COOH-12DOX at (i) lysosomal pH = 4.5 and 
physiological pH = 7.4, both at 37 oC.  Results represent 
mean ± s.d. (n=3 per group).  s.d. = standard deviation.  The 
diffusion of free DOX out of dialysis membrane 
(MWCO=3000Da) is used as control. 
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The acid-labile dendrimer-DOX conjugate demonstrates high stability at extracellular 
physiological pH, while a sustained DOX release at pH similar to that in acidic compartment.  The 
high sensitivity of the dendrimer-DOX conjugates merely to acidic condition is of great relevance 
as it potentially decreases the concentration of free DOX in plasma by promoting intracellular 
release of DOX – spatial control.  The decreased DOX concentration in plasma mitigates acute 
and chronic cardiac toxicity of DOX which limits long-term use as well as application in certain 
patient population.[284, 285]  In lung tumor chemotherapy, only a few percent of dose of DOX 
can reach tumor lesion upon systemic administration.[8]  The incidence of fatal myelosuppression 
(decreased bone marrow activity) and cardiomyopathy is significantly increased when cumulative 
dose is over a certain limit (e.g. 400-550 mg/m2 of body surface area).[286] Therefore, spatially 
controlled DOX release — intracellularly — could potentially reduce the access of free DOX to 
systemic bloodstream and bone marrow.  
5.4.3 Cell kill of B16F10 melanoma cells lines by the G4COOH-12DOX conjugates   
The cytotoxicity of free DOX and G4COOH-12DOX against B16F10 cells was assessed 
by MTT assay.  As shown in Figure 5.4, the G4COOH-12DOX (IC50=6.01 µM) conjugate was 
slightly less toxic (2.3-fold less potent) than free DOX is against B16F10 melanoma cells at 48 h 
incubation.  The difference in toxicity can be mainly ascribed to sustained release of conjugated 
DOX (see discussion in Section 3.2), differing cellular uptake extent and different subcellular 
trafficking pathways of free and conjugated DOX.  Free DOX can directly diffuse through cellular 
membrane and reach the nucleus,[216] while the trafficking of conjugated DOX to nucleus is more 
complex.  That is, dendrimer-bound DOX is internalized through endocytic pathways, followed 
by DOX release from dendrimers upon the cleavage of hydrazone in acidic compartments.  The 
diffusion of released DOX out of lysosome is a time-consuming process as the internal membrane 
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of lysosomes is permeable to the base form of weak bases.[219]  Mild acidity in lysosomes 
protonates a substantial majority of DOX ([DOX+H]+) which need to be converted to free base for 
outflow.  The forward conversion of cationic DOX to free base (both forms are at equilibrium) is 
driven by DOX efflux from lysosomes.[219]  
It is also important to note that the therapeutic efficacy in vivo depends on the ability of the 
payload to reach the tumor site first and foremost (before it can be internalized), and nanocarrier 
systems are expected to perform better than the free therapeutic.[34, 287]  Therefore, while less 
cytotoxic at a certain time point, the expectation is that the nanocarrier conjugates will outperform 
the free drug. 
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Figure 5.4 Cell kill of acid-labile G4COOH-12DOX as 
determined by MTT assay after 48 h incubation with 
B16-F10 melanoma cells.  Free DOX is used as control.  
Results represent mean ± s.d. (n=8 per group). s.d. = 
standard deviation.  IC50 was calculated based on non-
linear regression Log(inhibitor) vs. Response (variable 
slope) with G4COOH-12DOX being 6.0 µM and free 
DOX being 2.6 µM. 
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5.4.4 Enhanced cellular internalization of DOX by its conjugation to dendrimer conjugate   
The cellular internalization of free DOX and G4COOH-12DOX conjugate by B16F10 cells 
was investigated as a function of time by flow cytometry (a period of 5 h at early stage of 
internalization).  The early kinetics was evaluated by a plot of median fluorescence intensity (MFI) 
of DOX internalized within the cells as a function of time, as shown in Figure 5.5.  
It is observed that the rate and extent of internalization of DOX were enhanced upon the 
conjugation to dendrimer nanocarriers.  The conjugated DOX had a rate of internalization of 268.7 
a.u.h-1 within early times, which was approximately 7.5 fold greater than that of free DOX (35.7 
a.u.h-1).  The overall extent of internalization of conjugated DOX was significantly different from 
that of free DOX, at least within the time frame of the experiment - 5h.  However, the difference 
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Figure 5.5 Cellular internalization of the acid-labile G4COOH-
12DOX in B16-F10 melanoma cells as a function of time, as 
determined by flow cytometry.  Results denote mean ± s.d. (n=3 per 
group).  Statistical significance is calculated with respect to free 
DOX by Student’s t test (*p<0.05, **p<0.01, and ***p<0.001).  The 
rates of internalization of G4COOH-12DOX (conjugated DOX) 
and free DOX are 268.7 a.u.h-1 (R2 = 0.963) and 35.7 a.u.h-1 (R2 = 
0.981), respectively.  The rate is calculated by linear fitting of 3 
initial time points. 
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narrowed down over time — the overall uptake of G4COOH-12DOX was 7.8, 4.1, and 2.5 times 
as high as free DOX at 0.5, 2, and 5 h incubation, respectively.   
Earlier works show passive diffusion is responsible for cellular uptake of hydrophobic 
DOX, which is determined by concentration gradient and hydrophobicity of DOX,[216, 224]  
while dendrimers are internalized via various endocytosis including macropinocytosis,[226] 
receptor-mediated endocytosis,[217, 225, 226] and non-specific, adsorptive endocytosis.[225, 227, 
228]  The endocytosis is dictated by size, shape and surface chemistry.  The significantly enhanced 
rate and extent of internalization of G4COOH-12DOX by B16F10 cells can be attributed to its 
positive charged surface upon DOX attachment.  G4COOH-12DOX conjugate with a  of +13.8 
mV is readily adsorbed on negative plasma membrane and quickly saturates the membrane,[227] 
which results in rapid internalization and uptake plateau (found at 1.5 - 2 h incubation).  The non-
specific, adsorptive endocytosis is faster and less energy-dependent than other endocytic pathways 
due to its electrostatic interaction.[217] 
The apparent paradox between weaker in vitro potency and enhanced uptake of the 
conjugates, which has been also observed for other polymer-DOX systems conjugated through 
acid-labile bonds[34, 130]  could be interpreted in the following way: (1) incubation time has a 
stronger effect on cell kill of acid-labile conjugates than free DOX due to sustained release from 
the conjugate.  The ability of dendrimer-DOX conjugates to kill cancer cells in vitro is very close 
to that of free DOX as incubation is prolonged; (2) to a lesser extent, dendrimers are likely to 
disrupt endosomes and lysosomes due to the protonation of tertiary amines as their concentration 
in acidic compartments increases; The disruption of acidic compartment fails to release DOX from 
dendrimer conjugates, resulting in an underestimation of cell kill of the dendrimer-DOX conjugate 
by MTT assay when  the concentration of conjugate is relatively high ; (3) dendrimer conjugates 
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are internalized through various endocytic pathways, including those whose vesicles do not evolve 
into acidic compartments.[166, 230]  For instance, caveolae-mediated endocytosis ends up in 
neutral caveosomes, where DOX will have a lesser change to be released from dendrimers. 
In summary, the cellular uptake of DOX is significantly enhanced upon its conjugation to 
the dendrimer nanocarriers discussed here.  This is relevant as greater intracellular concentration 
of DOX may be achieved while also minimizing also potentially decrease plasma concentration, 
which in turn is expected to mitigate systemic adverse effect, especially to the cardiac tissue. 
5.4.5 Effect of the G4COOH-12DOX conjugates in treating lung metastasis 
We investigated the impact of conjugation and route of delivery (p.a. and i.v.) on the 
efficacy of DOX in reducing the metastatic lung tumor burden.  As shown in Figure 5.6, the 
development of numerous black nodules in the lungs showed that neither free nor conjugated DOX 
suppressed the proliferation of lung tumors when administered i.v. – note, however, that the 
intensity of tumor nodules appears to be slightly less in the case of G4COOH-12DOX compared 
to the free DOX group.  Because the density of nodules is so high, it is hard to clearly count them 
and thus only a qualitative assessment can be achieved by visually inspecting the lung tissue. 
In contrast, only a small number of lung nodules were observed in the treatment groups 
where DOX was administered via pulmonary route, revealing that either free or conjugated DOX 
delivered directly to the lungs significantly inhibits the growth of metastatic tumor in the lungs, 
and it is thus a superior route of administration when compared to i.v. .  Additionally, the number 
of lung nodules in the G4COOH-12DOX p.a. group was also significantly fewer than that of DOX 
p.a. group (6.8±0.5 : 10.3±1.0; p=0.0063), demonstrating that conjugation further enhances 
treatment efficacy.  While the counting of lung nodules can be employed to qualitatively evaluate 
tumor burden, it is somewhat limited as it is difficulty to delineate single nodules, especially when 
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nodules are numerous and are of different sizes.  Therefore, other methods should be also 
employed to further assess the effectiveness of therapeutics in reducing tumor burden.  We selected 
the overall weight of lungs as a complementary parameter to the counting nodules protocol.  The 
results are summarized in Figure 5.7 as a function of delivery route and conjugation.  
The lung weights of two positive control groups — PBS i.v. (213±24 mg, p=0.0098) and 
PBS p.a. (201±30 mg, p=0.0177) — were significantly greater than those of healthy mice (142±11 
mg).  Among all treatment groups, neither DOX i.v. nor G4COOH-12DOX i.v. altered overall 
lung weights (DOX: 202±22 mg and G4COOH-12DOX:195±26 mg; both were not significant) 
compared to their positive group (PBS i.v.).  In contrast, the tumor-bearing mice treated with either 
Figure 5.6 Images of lungs collected from C57BL/6 mice bearing lung metastases 
(n=6 per group).  PBS, free DOX or G4COOH-12DOX is administered through i.v. 
or p.a. route.  i.v.: intravenous injection; p.a.: pharyngeal aspiration (pulmonary route).  
The lungs excised from normal mice are used as negative control (top row). “+” in 
tumor column denotes mice bearing lung tumors from metastatic melanoma and “–” 
represents the lungs excised from negative control group. 
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DOX p.a. (159±18 mg, p=0.0336) or G4COOH-12DOX p.a. (152±15 mg, p=0.0259) significantly 
reduced lung weights compared to PBS p.a. positive group.  We also observed that the groups 
treated with same therapeutics but different routes showed significant difference in lung tumor 
burdens.  That is, DOX group: i.v. : p.a. = 202±22 mg : 159±18 mg (p=0.0415); and G4COOH-
12DOX group: i.v. : p.a. = 194±26 mg : 152±14 mg (p=0.0489).  
The Kaplan−Meier survival curves (Figure 5.8) showed that 100% of mice were alive when 
treated with either DOX p.a. or G4COOH-12DOX p.a., which represents a significant 
improvement in treatment (p=0.0185 for both groups) compared to no treatment group (PBS p.a.), 
with only 1 mouse alive (16.7% survival rate) at terminal point.  In contrast, the treatments via i.v. 
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Figure 5.7 Weight of lungs excised from healthy C57BL/6 
mice (negative control group; n=3 per group) and tumor-
metastases bearing mice treated with different therapies (n=6 
per group) at 17 days post implantation (DPI17).  Results 
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one-way ANOVA Tukey’s test.  *p<0.05, **p<0.01, and 
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route were ineffective — neither DOX i.v. (16.7% survival rate) nor G4COOH-12DOX i.v. group 
(33.3% survival rate) showed significant difference with respect to their positive control group 
(PBS i.v.=16.7% survival rate). 
In summary, the results discussed above show that lung metastatic tumors can be 
significantly inhibited by pulmonary delivered DOX, thus leading to an improved survival rate.  
The results also show that metastatic lung tumor burden is further relieved upon conjugation of 
DOX to dendrimer nanocarriers. 
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Figure 5.8 Survival rate of mice bearing lung metastases over 17 days, as plotted on a 
Kaplan-Meier survival curve.  The survival rate of each group is analyzed using Log-rank 
(Mantel-Cox) test (*p<0.05) with respect to the positive control of same administration route 
(PBS).  n.s. = not significant.   
128 
 
5.4.6 Impact of administration route and DOX conjugation on systemic biodistribution 
 Our in vitro results have showed that conjugation of DOX to dendrimer nanocarriers 
enhances the cellular uptake of DOX, while promoting intracellular release, demonstrating the 
potential to reduce systemic toxicity of DOX.  However, the in vivo fate and distribution of DOX 
free or in conjugate form is much more complex as it is impacted by several factors, such as various 
in vivo barriers, which vary as a function of the delivery route.  We investigate, therefore, the 
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Figure 5.9 Systemic distribution of DOX and G4COOH-12DOX delivered via (a) p.a. 
and (b) i.v..  Mice bearing lung metastases were euthanized at 17 days post implantation 
(DPI17) or terminal point prior to DPI17.  Results represent mean ± s.d. (n=6 per 
group).  The groups of same administration (p.a. or i.v.) are analyzed using one-way 
analysis of variance (ANOVA) with Tukey’s post hoc test.  *p<0.05, **p<0.01 and 
***p<0.001.  % of TD = % of total dosage.  p.a. = pharyngeal aspiration; i.v. = 
intravenous injection; s.d. = standard deviation. 
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distribution of systemically and locally (lung) delivered DOX (free or in conjugate form) in major 
organs.  The systemic distribution results are summarized in Figure 5.9. 
The results show that the DOX tissue distribution is strongly impacted by the route of 
administration and conjugation.  The amount of DOX in the lungs at DPI17 (8 days after last 
dosing) followed the sequence: G4COOH-12DOX p.a. (26.8±5.0% of total dose - TD) > DOX p.a. 
(9.8±4.3% of TD) >> G4COOH-12DOX i.v. (1.1±0.4% of TD) ≈ DOX i.v. (0.5±0.1% of TD).  
These results demonstrate that pulmonary delivery can potentially increase drug dose and prolong 
drug retention in lungs compared to systemic administration.  This can be seen as an extra 
advantage compared to free DOX, which was not captured on the results presented while 
discussing number of tumor nodules or lung weight.  It suggests that upon further optimization of 
dosages (concentration and number), there is the potential to either decrease total dosage or the 
number of dosages.  For comparison, it is worth noticing that previous studies have shown that a 
large amount of DOX-loaded PLGA nanoparticles remained in the lungs one week after inhalation, 
and a detectable amount of DOX was still found up to 14 days post treatment.[142]  Similarly, 
PEI-conjugated DOX could be still clearly seen 7 days after i.t. administration.[143] 
We further analyzed the statistical difference of drug retention among all groups at DPI17.  
As shown in Figure 5.10 (a), one-way ANOVA Tukey’s test showed the amount of DOX in the 
lungs of G4COOH-12DOX p.a. group was significantly greater with respect to that of all other 
groups — DOX p.a. group (p=0.0194), G4COOH-12DOX i.v. (p<0.0001), and DOX i.v. 
(p<0.0001).  Additionally, the amount of DOX in the lungs of DOX p.a. group was also much 
greater than that of G4COOH-12DOX i.v. (p=0.0038) and DOX i.v. group (p=0.0050).  However, 
no statistical difference was found between DOX i.v. and G4COOH-12DOX i.v. group.   
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Our recent results demonstrated that the fate of PAMAM dendrimer nanocarriers 
administered to the lungs is greatly impacted by their surface charge — positively charged 
PAMAM dendrimers tent do reside locally (lungs) for longer, while neutral dendrimers have tend 
to more effectively translocate into systemic circulation.[168]  The HD of G4COOH-12DOX is 
ca. 10 nm, which is larger than the fenestration of the endothelial lining of vascular vessels (4-5 
nm).[175]  Compared to small molecule drugs, reverse diffusion of dendrimer conjugates into 
vascular vessels for clearance is thus reduced.[175]  In the meantime, the reabsorption of interstitial 
dendrimer conjugates through lymphatics is also much attenuated in tumor tissues due to a lack of 
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Figure 5.10 (a) Accumulation of DOX (free/conjugated form) in the lungs at terminal 
point (DPI17).  Therapeutics were given through i.v. or p.a. route.  Statistical analysis 
is performed with one-way analysis of variance (ANOVA) with Tukey’s post hoc test.  
(b) Temporal effect on accumulation of DOX in the lungs.  Therapeutics were given 
through p.a..  The mice were euthanized at DPI13 (n=3 per group) and DPI17 (n=6 per 
group).  Statistical analysis is performed in 2 different ways: (i) all groups at DPI13 or 
DPI17 are analyzed with one-way analysis of variance (ANOVA) with Tukey’s post hoc 
test; (ii) same therapy groups (e.g. DOX p.a.) at DPI13 and DPI17 are analyzed with 
Student’s t test.  *p<0.05, **p<0.01 and ***p<0.001.  Results represent mean ± s.d..  % 
of TD = % of total dosage.  i.v. = intravenous injection; p.a. = pharyngeal aspiration; 
DPI = days post implantation; s.d. = standard deviation. 
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effective lymphatic drainage.[287, 288]  These conditions thus lead to a preferred retention of 
dendrimer-bound DOX in the lungs compared to free DOX. 
Due to the enhanced local concentration of drug upon pulmonary administration, we 
investigated the temporal effect on pulmonary retention of locally delivered DOX and G4COOH-
12DOX.  We compared the content of DOX in the lungs at DPI13 (4 days after last dosing) and 
DPI17 (8 days after last dosing).  The results are summarized in Figure 5.10 (b).  At DPI13, the 
amount of DOX in the lungs was 39.1±8.5% of total dose (TD) for G4COOH-12DOX p.a. and 
25.2±5.3% of TD for free DOX p.a. (p=0.0765).  At DPI17, the % of TD decreased for both free 
and conjugated DOX.  However, the elimination of free DOX from the lung tissue was much more 
substantial, decreasing at almost twice the rate when compared to conjugated DOX, being at 
26.8±5.0% of TD for G4COOH-12DOX p.a. and 9.8±4.0% TD for free DOX p.a. (p=0.0089) at 
DPI17.  Therefore, a higher DOX retention and a much greater p value between DPI13 and DPI17 
demonstrates that conjugation to the dendrimer nanocarriers slow down the elimination of DOX 
from the lungs.  The processes responsible for dendrimer-DOX and DOX clearance may include 
mucociliary escalator, pulmonary alveolar macrophage phagocytosis, translocation to systemic 
circulation and enzymatic degradation.[39, 72, 152, 201] 
Interestingly, the groups treated with either DOX p.a. or G4COOH-12DOX p.a. showed 
lower cardiac accumulation of DOX compared to the distribution upon i.v. administration.  No 
statistical difference was found between the two p.a. groups.  Noticeably, intravenous injection of 
free DOX was the system that resulted in the greatest accumulation of DOX in the cardiac tissue 
compared to all other groups— Figure 5.11 (a).  Considering the limited accumulation of DOX in 
heart upon pulmonary administration, the cardiac content of locally delivered DOX as a function 
of time (sampled at DPI13 and DPI17) was further investigated.  As shown in Figure 5.11 (b), we 
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observed that at DPI13, the cardiac content of DOX in the groups treated with either DOX or 
G4COOH-12DOX were statistically greater than that of no treatment group, whereas they 
decreased slightly at DPI17 and only DOX p.a. group showed significant difference with respect 
to no treatment group at that terminal point.   Comparing with i.v. injection route, however, the 
cardiac accumulation of DOX (even in DOX p.a. group) was still much less at DPI17.   
The results show that the distribution of DOX to the heart tissue can be mitigated upon 
pulmonary delivery, and further upon conjugation to dendrimers.  This is of great relevance as 
major adverse effects, including lethal cardiomyopathy, are known to limit the applicability of 
DOX in the treatment of a variety of cancers including lung metastasis.[289] 
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Besides the ability to modulate the distribution of DOX in the lungs and heart, the results 
shown here demonstrate that the route of elimination of DOX is also impacted by the choice of 
delivery route and conjugation.  As shown in Figure 5.9 (a) and (b), higher 
concentrations/percentage dosage of DOX was found in spleen and liver upon their conjugation to 
dendrimers independent of routes of administration.  The clearance of polymeric delivery systems 
is dictated mainly by surface charge and particle size.[49]  Positively charged nanocarriers (e.g. 
G4COOH-12DOX in our case) can be cleared and processed by mononuclear phagocytic system 
(MPS), whose targets are opsonized by plasma proteins and subsequently captured by 
phagocytes.[290, 291]  Phagocytes, such as macrophages, mainly reside in or migrate to bone 
marrow, lymph nodes, liver and spleen.[292]  It is also reported that dendrimer nanocarriers are 
cleared by glomerular filtration in kidneys.[193]  In this work, small amounts of DOX in the case 
of G4COOH-12DOX conjugate (i.v.: 0.84±0.37% of TD and p.a.: 0.60±0.29% of TD) was found 
in kidneys at DPI17 (8 days after last dosing).  This may be to some extent due to the fat that the 
time for observing renal accumulation of DOX is too long.  Previous research has shown that 
PAMAM dendrimers can be detected in urine 2 h after i.v. injection.[199]  On the other hand, it is 
also possible that renal pathway may not play a vital role in clearing these dendrimer-DOX 
conjugates.  Renal glomeruli have round pores of approximately 6 nm in diameter.  Therefore, the 
nanocarriers with diameter < 6 nm are rapidly to be cleared by glomerular filtration.  The 
hydrodynamic diameter of G4COOH-12DOX (9.7±3.5 nm) is greater than the size threshold for 
glomerular filtration.[49, 291]  Additionally, nanocarrier-biomolecule coronas are instantaneously 
formed when nanocarriers are exposed to physiological fluids, since plasma proteins are readily 
adsorbed on positively charged nanocarriers with formed,[293, 294] leading to much greater 
physiological diameters than as light scattering measured.[291]  
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5.5 Conclusion 
In this work, we demonstrated the potential of PAMAM-DOX conjugates upon pulmonary 
delivery for lung cancer treatment using an in vivo lung metastasis model.  DOX was conjugated 
to G4COOH through an acid-sensitive bond, which has shown to provide a sustained intracellular 
release of DOX, but to be stable at extracellular physiological conditions.  Upon conjugation to 
dendrimer, significant increase has been observed on the rate and extent of internalization of DOX 
by B16F10 cells at short times (up to 5 h).  Nuclear colocalization study indicated that DOX can 
rapidly colocalize with nucleus, after being released from the conjugates.  The dendrimer-DOX 
conjugates showed similar ability to kill cancer cells as free DOX did.  The acid-labile dendrimer-
DOX conjugates administered via pulmonary route remarkably reduced the mass and nodule 
number of lung tumors derived from metastatic B16F10 melanoma, thus significantly increasing 
survival rate of tumor-bearing mice.  A high amount (ca. 30% of TD) of locally delivered 
dendrimer-DOX conjugates remained in the lungs 8 days after last dosing, significantly higher 
than that through i.v. injection.  Interestingly, little DOX accumulated in heart tissues upon 
pulmonary delivery compared to systemic injection, which implicates greatly reduced risk of acute 
and chronic cardiac toxicity.  Therefore, the dendrimer-based chemotherapeutic delivery system 
in combination with pulmonary administration technology (e.g. oral inhalation) is a potentially 
promising strategy for lung cancer treatment.  
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CHAPTER 6 — CONCLUSIONS AND FUTURE DIRECTIONS  
6.1 Conclusions and future directions 
Lung cancer is the leading cause of cancer death among both men and women in the United 
States.  Adenocarcinoma accounts for more than 40% of all lung cancer cases.  Doxorubicin (DOX) 
is an FDA-approved chemotherapeutic that has been widely used as primary anticancer drug in the 
treatment of a variety of cancers including lung cancers.  However, rapid elimination, uncontrolled 
release, and life-threatening cardiotoxicity, has hindered the applicability of DOX and other potent 
anti-cancer agents.  The treating efficacy for lung adenocarcinoma is also limited by low 
accumulation of DOX in the lungs which is generally administered through systemic route, and by 
severe cardiac toxicity.  The development of polymeric carriers for the modulation of transport, 
targeting and controlled release of potent anti-cancer agents and their aerosol formulation for local 
lung delivery is of great relevance in the treatment of lung adenocarcinoma. 
The main conclusions drawn from our studies and suggested future directions are discussed 
here: 
(i). We have characterized the effect of PEGylation and route of administration on systemic 
and local distribution of PAMAM dendrimer.  Our pharmacokinetic results show that dendrimers 
with high density of surface modification with PEG not only present long circulation times upon 
I.V. administration, but they also reach systemic circulation much faster and are found at much 
greater concentrations (ca. 13% of administered dose) than the non-PEGylated counter parts (2% 
of administered dose) upon pulmonary administration at tmax.  PEGylation and route of 
administration also have profound effects on systemic and local (lung cell) distribution.  While ca. 
83% of G3NH2 is found in the lungs upon pulmonary delivery at 6.5 hours post administration, 
only 2% reaches the lungs upon I.V. delivery.  Interestingly, pulmonary delivery provide 
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dendrimers with ability to accumulate in lymph nodes, while no measurable concentration of 
neither bare dendrimers nor highly PEGylated dendrimers is found in the lymph nodes upon I.V. 
administration.  Moreover, PEGylation also increased the transport of dendrimers to the lymph 
nodes upon lung delivery.   The findings are valuable for the design of new dendrimer-based 
nanovaccines.  No statistical difference was observed in terms of the overall percentage of cells 
found to take up the unmodified vs. PEGylated dendrimers in the lung.  Myeloid and epithelial 
cells from the alveoli and airway internalized dendrimers effectively, independent of chemistry, 
with myeloid cells being responsible for most of the uptake.  The biggest impact of the dendrimer 
chemistry was observed regarding uptake in endothelial cells, where PEGylated dendrimers were 
observed to be taken up by a large extent.  This observation is in agreement with the idea of the 
fast transport across extracellular barriers and the lung epithelium leading to enhanced endothelial 
internalization en route to systemic circulation.  The results shown here suggest that the pulmonary 
route of administration in combination with dendrimer chemistry can be used to passively target 
tissues of interest for treating a variety of medically relevant diseases of the lungs and other target 
tissues of tissues outside the lungs.  
As the results show significantly higher local concentration of dendrimer nanocarriers in 
the lungs and potential to passively target various lymph nodes.  The suggested further studies may 
focus on the following aspects: (1) the concentration of PAMAM dendrimers in lungs and lymph 
nodes as a function of time should be studied in details; (2) the mechanism for the accumulation 
of pulmonary delivered PAMAM dendrimers in various lymph nodes should be further elucidated 
— activation of antigen-presenting cells or passively leaking into draining lymph nodes; (3) One 
of major challenges that may limit the delivery of polymeric nanocarriers (e.g. PAMAM) 
to/through the lungs is the potential acute and chronic toxicological issues caused by delivered 
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particulates.  To evaluate the acute toxicity PAMAM dendrimers caused in the lungs, inflammatory 
cytokines and immune response elicited in animal models should be studied with 
immunochemistry staining and flow cytometry.  Tumor damage may be screened by histological 
staining; (4) in this work, PAMAM is used as model dendrimer to exploit the feasibility of 
dendrimers as anticancer drug carriers delivered to/through the lungs.  Due to its non-degradable 
nature, potential chronic toxicity and biocompatibility may limit its clinical application.  The 
transition from PAMAM to biodegradable dendrimers (e.g. hyperbranched polyester) are helpful 
to expand biomedical application of dendrimer.   
(ii). We have developed PEGylated, acid-labile dendrimer-DOX conjugates which can 
achieve spatially and temporally sustained release of DOX.  The conjugates upon pulmonary 
delivery can significantly inhibit tumor growth in vivo and improve survival rate.  In detail, 
PEGylated poly(amidoamine) dendrimer nanocarriers with acid-labile DOX conjugates were 
synthesized.  Due to hydrophobicity of DOX, dendrimer may crash out of aqueous solution when 
high payload DOX are attached.  Aqueous solubility of dendrimer-DOX conjugates can be 
increased upon PEGylation of dendrimer nanocarriers.  We developed direct PEGylation to 
synthesize dendrimer conjugates with low DOX payload and varying PEGylation degree, and two-
step PEGylation especially for dendrimer conjugates with high drug payload and high PEGylation 
degree.  The resulting PEGylated, acid-labile dendrimer-DOX conjugate released DOX only in 
acidic medium, and also intracellularly.  The release can be modulated by PEG density on 
dendrimer surface.  We also observed that the kinetics of cellular entry of the nanocarrier with 
DOX increased significantly compared to free DOX.  At the highest PEGylation density, the rate 
of internalization of the nanocarrier containing DOX was even higher than that of free DOX.  
PEGylation density also affects cytotoxicity as seen by an increase in IC50 for DOX-conjugated 
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dendrimer compared to free DOX, due to the controlled release of the therapeutic.  PEGylation 
significantly helped dendrimer nancarriers escape mucus trapping compared to bare dendrimer, 
aiding their transport to the basolateral side.  It is in accordance with in vivo pharmacokinetics. 
Reduced transepithelial electrical resistance (TEER) and limited cellular internalization 
demonstrated that paracellular transport plays a vital role in transporting dendrimer-DOX 
conjugates across airway epithelium.  Upon pulmonary delivery of the acid-labile dendrimer-DOX 
conjugate, lung tumor burdens were significantly reduced and survival rate of mice were 
considerably improved, while i.v delivered therapeutics showed a very limited efficacy.  The 
results can be correlated to significant greater concentration of therapeutics in the lungs — the 
observation extended to 8 days showed approximately 30% of total DOX remained in the lungs. 
On the other hand, less DOX were accumulated in heart tissues upon lung delivery, which can 
potentially mitigate cardiac toxicity. 
The acid-labile dendrimer-DOX conjugates delivered to the lungs showed great promise in 
lung tumor treatment in this work, it thus deserves continuing studies in the following aspects: (1) 
combination therapy are believed to be an more effective way to fight cancers including lung 
tumors, it is potentially relevant to develop dendrimer conjugates for co-delivery of two or more 
therapeutics at the same time; (2) The acid-labile dendrimer-DOX conjugates are able to release 
DOX intracellularly.  Although systemic toxicity of DOX can be significantly reduced by local 
delivery, the dendrimer conjugates are incapable of targeting to lung tumor cells.  Therefore, next 
step may be focused on designing dendrimer conjugates with ability to selectively enter tumor 
cells. For example, the conjugation of MUC1 aptamer to dendrimer, whose receptors are 
overexpressed on lung cancer cells;[295] (3) gene therapy and immunotherapy are gaining more 
and more attention due to their significantly reduced side effects and high ability to kill cancer 
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cells.  The conjugation of nucleic acid or antigens to dendrimers can significantly may prevent 
them from enzymatic degradation and increase their cellular uptake as well.  Therefore, the 
combination of dendrimer-based immunotherapy/gene therapy in conjunction with dendrimer-
based chemotherapy may be a potent therapy against lung cancers, while reduces systemic/local 
side effects; (4) we used pharyngeal aspiration to perform lung delivery, which may make 
difference in terms of aerosol deposition in the lungs compared to aerosolization.  Therefore, 
further study may focus on the use of real aerosolizer such as Penn-Century Microsprayer.   
(iii) Oral inhalation is well known for its high efficiency of lung deposition and non-
invasive nature.  The development of oral inhalation formulations for lung cancer treatment is 
potentially beneficial to millions of lung cancer patients.  Our PEGylated, acid-labile dendrimer-
DOX conjugates can be directly formulated in the propellant-based metered-dose inhalers (pMDIs) 
with a trace amount of ethanol (ca. 0.4% v/v), forming a solution aerosol formulation.  The pMDI 
formulations containing high PEGylated dendrimer-DOX conjugates can also be readily 
formulated into propellant with a co-solvent free method.  It is for the first time, to our best 
knowledge, that polymer nanocarrier drug delivery system is formulated into a solution aerosol 
formulation.  The stability and aerosol characteristics increased significantly as PEG density 
increased and DOX payload decreased.  The formulation of highly PEGylated dendrimer-DOX 
conjugates showed superior aerosol characteristics.  The pMDI formulation is suitable for 
delivering drug to deep lung area such as alveolar region and terminal bronchi.  Furthermore, the 
lung deposition position of dendrimer-DOX conjugates can be further modulated by adding 
biodegradable surfactants, in order to treat tumors in different pulmonary regions.  Broadly, the 
PEGylated dendrimer conjugate in combination with metered dose inhalers showed great 
potentials to deliver therapeutics to/through the lungs. 
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Although the pMDI formulations containing PEGylated dendrimer-DOX conjugates 
showed superior aerosol properties, the drug dose in these formulations is still low (ca. 0.2 mg/mL). 
A few attempts can be made in future to address the low dose issue: (1) a simple method to increase 
DOX dose is to increase concentration of the conjugates in propellant.  The aerosol properties 
could be compromised as the concentration is over a certain limit.  Therefore, the guideline to 
improve drug dose is to maximize DOX payload in dendrimer nanocarriers, while minimize the 
fraction of other components (dendrimer+PEG).  To achieve this goal, thorough studies on the 
effect of PEG density and DOX payload on aerosol performance should be performed to find the 
highest DOX payload and lowest PEG density, as well as optimal concentration without aerosol 
properties compromised.  The smaller size of PEG (e.g. 750 Da or 550 Da) may be attempted for 
this purpose.  However, the consequent alterations of in vivo pharmacokinetics and biodistribution  
are also needed to be taken into account and evaluated; (2) previous computational work showed 
ester and ether bonds have strong interaction with HFA propellant, enhancing the 
solubility/dispersibility of these bonds-containing molecules in HFA propellant. Hyperbranched 
polyester contains an abundance of ester bonds.[237]  Much lower PEG density on surface are 
needed to solvate polyester dendrimer in HFA propellant.  Therefore, a much higher concentration 
of PEGylated dendrimer-DOX can be reached; (3) a significant advantage DPI formulations hold 
over pMDI formulations is much higher dose of drug delivered to the lungs.  Therefore, 
development of DPI formulations containing acid-labile dendrimer-DOX conjugates may also be 
considered. 
.
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APPENDIX A  
SUPPLEMENTAL INFORMATION OF CHAPTER 2 
S1. Proton magnetic nuclear resonance spectra (1H NMR) and peak assignment 
1H NMR spectra were recorded with a 400 MHz Agilent Mercury spectrometer (Santa Clara, CA).  
Proton chemical shifts were reported in ppm (δ) and the peak of deuterated DMSO (DMSO_d6) at 
2.483 ppm was set as the reference peak. 1H NMR (DMSO_d6, ppm) of G3NH2-3Cy3: δ 7.972-
7.772 (m, 50.27H, NHCO of G3NH2), 7.614 (m, 3.28H, aromatic H of Cy3), 7.427 (m, 6.07H, 
aromatic H of Cy3), 7.163 (m, 17.94H, aromatic H of Cy3), 6.476 (d, 5.73H, =CH of Cy3), 3.104 
(m, 139.92H, CONHCH2 of G3NH2), 2.599 (m, 86.75H, NCH2 of G3NH2), 2.391 (m, 58.50H, 
CH2N of G3NH2), 2.161 (m, 120H, CH2CONH of G3NH2), 1.658 (s, 32.97H, CH3 of Cy3), 1.509 
(m, 5.88H, CH2 of Cy3), 1.353 (m, 6.03H, CH2 of Cy3).  
1H NMR (DMSO_d6, ppm) of G3NH2-
24PEG1000-3Cy3: δ 7.907-7.784 (m, 40.82H, NHCO of G3NH2), 7.609 (m, 3.49H, aromatic H 
of Cy3), 7.431 (m, 6.34H, aromatic H of Cy3), 7.179 (m, 18.32H, aromatic H of Cy3), 6.481-6.444 
(s, 5.51H, =CH of Cy3), 4.014 (m, 47.64H, CH2NHCO of G3NH2), 3.647-3.402 (m, 2043.61H, 
CH2CH2O of PEG1000), 3.216 (69.95H, OCH3 of PEG1000), 3.056 (m, 153.05H, CONHCH2 of 
G3NH2), 2.622 (m, 87.78H, NCH2 of G3NH2), 2.396 (m, 63.38H, CH2N of G3NH2), 2.157 (m, 
120H, CH2CONH of G3NH2), 1.664 (s, 32.48H, CH3 of Cy3), 1.537 (m, 6.02H, CH2 of Cy3), 
1.341 (m, 5.80H, CH2 of Cy3). 
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Figure S1. 1H NMR spectra of G3NH2-Cy3 (pink line) in deuterated oxide (D2O) and G3NH2-
24PEG1000-3Cy3 (black line) in deuterated dimethylsulfoxide (DMSO_d6).   Detailed chemical 
shifts discussed above.  The inset is chemical structure of G3NH2-24PEG1000-3Cy3.  
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S2. Mass-assisted laser desorption/ionization-Time of Flight (MALDI-TOF) 
MALDI-TOF mass spectra were performed on a Bruker Ultraflex spectrometer equipped with a 
pulsed nitrogen laser (337 nm) under positive ion reflector mode.  10 μl of sample (1.0 mg/ml) in 
DI H2O was mixed with 10 μl of DHB (10 mg/ml) in methanol.  2 μl of the sample was spotted on 
a Bruker Daltonics MALDI plate.  The spotted sample was dried gently by air flow.  MALDI: 
G3NH2-3Cy3 (m/z, 8285) and G3NH2-24PEG1000-3Cy3 (m/z, 33312). 
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Figure S2. MALDI-TOF spectra of G3NH2-3Cy3 and G3NH2-24PEG1000-3Cy3.   
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S3. Single cell staining of pulmonary cellular populations 
Lung cell populations tagged by fluorescent probe-labeled antibodies includes myeloid cells 
tagged by Percp-Cy5.5, endothelial cells tagged by PE-Cy7, surfactant protein C-secreted alveolar 
type II cells tagged by AF647 and ciliated airway epithelial cells tagged by pacific blue. These 
cells were prepared according to a preceding reported method [296] with slight modification as 
described below.  
Primary Antibodies 
Rat anti-mouse CD16/CD32 (Fc-Block; BD Biosciences. San Jose, CA, USA), 1:100 dilution in 
0.15 or 0.3% saponin buffer. (Preparation: 1 µl Fc-Block + 99 µl 0.15 or 0.3% saponin buffer)  
Rabbit polyclonal anti-mouse pro-surfactant protein-C (pro-SPC) antiserum, reactive with human 
and mouse proSPC (Abcam. Cambridge, MA, USA), 1:500 dilution in 0.15 or 0.3% saponin buffer. 
(Preparation: 1 µl + 499 µl0.15% or 0.3% saponin buffer) 
Rat anti-mouse β-tubulin (BD Biosciences. San Jose, CA, USA), 1:500 dilution in 0.15 or 0.3% 
saponin buffer. (Preparation: 1 µl + 499 µl saponin buffer) 
Rat anti-mouse CD45-PerCP/Cy5.5, clone 30-F11 (BioLegend. San Diego, CA, USA), 1:50 
dilution in 0.15 or 0.3 % saponin buffer. (Preparation: 2 µl + 98 µl saponin buffer) 
Rat anti-mouse CD31-PE/Cy7, clone MEC13.3 (BioLegend. San Diego, CA, USA), 1:100 dilution 
in 0.15 or 0.3% saponin buffer. (Preparation: 1 µl + 99 µl saponin buffer) 
Secondary antibodies 
F(ab’)2-goat anti-rabbit IgG(H+L) secondary antibody, Alexa Fluor®647 conjugate (Life 
Technologies. Grand Island, NY, USA) 1:500 dilution in 0.15 or 0.3% saponin buffer. (Preparation: 
1 µl AF647 + 499 µl saponin buffer) 
146 
 
F(ab’)2-goat anti-mouse IgG(H+L) secondary antibody, Pacific Blue conjugate (Life 
Technologies. Grand Island, NY, USA), 1:500 dilution in 0.15 or 0.3 saponin buffer solution. 
(Preparation: 1 µl + 499 µl saponin buffer). 
2. Incubated lungs connected with trachea in an additional 3 ml dispase per lung for 30 min at 
37°C in a 6-well plate. 
3. Placed the lungs into a 6 cm petridish filled with 6 ml DMEM containing 100 U/ml DNase and 
25 mM HEPES. Removed the lung tissue from the trachea by gentle tapping with the back of a 
pair of tweezers. 
4. Incubated for 10 min at room temperature with slight agitation. 
5. Added 4 ml medium with a 10 ml serological pipet. 
6. To further disarticulate the tissue, homogenize by pipetting up and down with a 1 ml pipet.  
7. Pipetted the lung homogenate up and down again with a 10 ml serological pipet and transferred 
it to a 100 µm nylon cell strainer placed on a 50 ml tube. Added 5 ml medium without DNase and 
processed the tissue through the cell strainer. 
8. Passed the lung homogenate through the 40 m cell strainer into a fresh 50 ml tube. 
9. Centrifuged the single cell suspension for 10 min at 350 g. 
10. Discarded the supernatant and resuspended the pellet in 5 ml fresh medium. 
11. To determine the amount of cells, dilute the suspension 1:2,000 in 10 ml CasyTon™ and 
count the cells using a Casy TT cell counter. 
12. Centrifuged the single cell suspension for 10 min at 350 g. 
13. Discarded the supernatant and resuspended the pellet in 4 ml fresh 1% paraformaldehyde 
solution and incubate for 15 min on ice. 
14. Centrifuged the fixed cells for 10 min at 350 g. 
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15. Discarded the supernatant and resuspended in 5 ml wash buffer. 
16. Centrifuged cells for 10 min at 350 g. 
17. Discarded the supernatant and resuspended the pellet in 4 ml wash buffer. 
18. Transferred about 200,000 cells per lung sample into FACS tubes. 
19. Prepared additional samples as blank controls. 
20. Centrifuged the aliquots of 200,000 cells per FACS tube for 10 min at 350 g. 
21. Discarded the supernatant, added 100 µl 0.15% saponin buffer per sample for permeabilization, 
mix, and incubated for 20 min at 4 °C. 
22. Centrifuged FACS tubes for 5 min at 350 g. 
23. Discarded the supernatant, added 10 µl diluted Fc-block, added 20 µl of the appropriate 
dilutions of the antibodies against CD45, CD31, and pro-SPC and β-tubulin. Vortexed, and 
incubated for 25 min at 4°C in the dark. 
24. Centrifuged the stained cells for 5 min at 350 g. 
25. Discarded the supernatant, washed with 100 µl 0.15% saponin once, and centrifuged the cells 
for 5 min at 350 g. 
26. Discarded the supernatant, added 20 µl of the appropriate dilution of the secondary antibody 
to pro-SPC and β-tubulin group. Mixed, and incubate for 25 min at 4°C in the dark. 
27. Centrifuge the stained cells for 5 min at 350 g. 
28. Discarded the supernatant, wash with 100 µl 0.15% saponin buffer once and centrifuged the 
cells for 5 min at 350 g. 
29. Discarded the supernatant, wash with 100 µl once with wash buffer, centrifuged the cells again 
for 5 min at 350 g, and resuspended them in 200 µl wash buffer. 
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30. Gated the cells to exclude debris and cell clumps using flow cytometer. 160,000 events were 
at least counted. 
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Examples of FACS cellular biodistribution results for control groups, G3NH2-3Cy3 and 
G3NH2-24PEG1000-3Cy3 
(a) Control 
  
Myeloid cells Endothelial cells 
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(b) G3NH2 
    
 
Epithelial cells Ciliated cells 
Myeloid cells Endothelial cells 
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(c) G3NH2-24PEG1000K 
Epithelial cells Ciliated cells 
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Figure S3. Dot plot of antibody-dye vs. Cy3-dendrimer, determined by flow cytometry. 
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Biodistribution of the conjugates in a per tissue mass basis. 
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Figure S4. Effect of the PEGylation and route of administration on the whole body distribution of 
the conjugates.  The statistical analysis was performed between G3NH2 and G3NH2-24PEG1000 
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with Student t-test (*p<0.05, **p<0.01, and ***p<0.001).  Panel (a) pharyngeal aspiration and (b) 
intravenous administration, 6.5 h post administration.  n=3 per group.
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APPENDIX B 
SUPPLEMENTAL INFORMATION OF CHAPTER 3 
S1. Characterization 
S1.1. Electrospray ionization (ESI) 
A trace of sample (a few µg) was dissolved in methanol (mass spectrometry grade), and 
then diluted 50 times, also with methanol.  The methanolic solution was injected into ZQ-Waters 
TERS/Micromass spectrometer (Waters) for determining the m/z value of the analyte. 
S1.2. Mass-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-
TOF) 
MALDI-TOF was performed on a Bruker UltrafleXtreme mass spectrometer (Bruker) 
equipped with a pulsed nitrogen laser (337 nm) under positive ion reflector mode.  The conjugates 
were dissolved in deionized water at a concentration of 1.0 mg/mL.  2, 5-dihydroxybenzoic acid 
(2, 5-DHB) in methanol (10 mg/mL) was used as matrix.  10 μL of conjugate solution was mixed 
with equal volume of 2, 5-DHB solution and 2 μL of the mixed solution was spotted on a Bruker 
Daltonics MALDI plate.  The spotted sample was dried gently by air flow. 
S1.3. Proton magnetic nuclear resonance (1H NMR) 
1H NMR spectra were recorded on a Varian Mercury 400 (400 MHz) spectrometer (Agilent 
Technologies) using deuterated DMSO (DMSO_d6).  Proton chemical shifts were reported in ppm 
(δ) and DMSO_d6 at 2.48 ppm was set as reference peak. 
S1.4. Light scattering (LS) 
Sample (1.0 mg/mL) was dissolved in phosphate buffer saline (PBS, pH 7.4).  pH test 
indicated all sample solutions were neutral.  Hydrodynamic diameters and zeta potentials were 
measured using Zetasizer Nano ZS (Malvern Instruments).  The average and standard deviation 
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for hydrodynamic diameters and zeta potentials were calculated based on at least three 
measurements. 
S2. Synthesis of PEGylated PAMAM dendrimer conjugates with acid-labile DOX (G3NH2-
mPEG-nDOX) and acid-nonlabile DOX (G3NH2-mPEG-nDOXNL) 
 
Figure S1. Protons in cis-aconityl DOX and succinic DOX. 
S2.1. Synthesis of cis-aconityl DOX 
The synthesis of cis-aconityl DOX was performed using a similar strategy to that reported 
in the literature,[297] with modifications.  Briefly, 3 mL anhydrous p-dioxane solution of cis-
aconityl anhydride (188.4 mg, 0.60 mmol) was added dropwise to a 6 mL DI H2O DOX solution 
(86.7 mg, 0.15 mmol).  The pH value of the aqueous solution was immediately adjusted to 9.0-9.2.  
The reaction was vigorously stirred for 20 min at 0-5 oC, and additionally 15 min at room 
temperature.  The product was precipitated by acidifying the solution to pH 2.0 with 1 M 
hydrochloric acid (HCl aq) at 0 oC and then collected by centrifugation.  The precipitate was 
redissolved in cold DI H2O and the pH was adjusted to 9.0 with 1 M sodium hydroxide solution 
(NaOH aq).  The precipitation-dissolution process was repeated twice.  Finally, the red powder 
was lyophilized and stored at 4°C for future use.  Yield: 61.7%.  TLC (chloroform/methanol/acetic 
acid = 17/3/1 v/v, retention factor (Rf): 0.05 (DOX), 0.33 (cis-aconityl DOX)).  ESI (m/z): 
700.2016 ([cis-aconityl DOX + H]+), 722.1509 ([cis-aconityl DOX + Na]+), 738.1769 ([cis-
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aconityl DOX + K]+).  1H NMR (DMSO_d6, ppm) δ: 7.947 (s, 1.03H, Ar-H (H-2) in DOX), 7.771 
(s, 0.97H, Ar-H (H-3) in DOX), 7.443 (s, 0.94H, Ar-H (H-1) in DOX), 6.397 (s, 0.96H, -CH=C- 
(H-16) in cis-aconitic acid), 5.263 (s, 0.99H, -CH- (H-9) in DOX), 4.890 (d, 1.02H, -CH- (H-5) in 
DOX), 4.570 (m, 1.95H, -CH2OH (H-6) in DOX), 4.173 (s, 1.02H, -CH- (H-13) in DOX), 3.936 
(s, 3.03H, -OCH3 (H-15) in DOX), 3.575 (s, 1.03H, -CH- (H-12) in DOX), 2.986 and 2.807 (d, 
1.95H, -CH2- (H-4) in DOX), 2.161 and 2.054 (d, 2.05H, -CH2- (H-7) in DOX), 1.859 and 1.647 
(d, 1.96H, -CH2- (H-10) in DOX), 1.122 (s, 3.10H, -CH3 (H-14) in DOX).  The sequence of all 
protons for cis-aconityl DOX was shown in Figure S1. 
S2.2. Synthesis of succinic DOX  
DOX (53.8 mg, 92.7 µmol) and TEA (32.6 µl, 0.23 mmol) were dissolved in 2.2 mL 
anhydrous DMSO.  To the mixture a 1.0 mL anhydrous p-dioxane solution of succinic anhydride 
(13.9 mg, 0.14 mmol) was added dropwise.  The reaction was stirred and monitored with TLC for 
completion.  The purification for succinic DOX was same as that of cis-aconityl DOX described 
above.  Finally, the precipitate was lyophilized until constant weight and stored at 4 °C for future 
use.  Yield: 67.2%.  TLC (chloroform/methanol/acetic acid = 17/3/1 v/v, Rf: 0.07 (DOX), 0.79 
(succinic DOX)).  ESI (m/z): 666.1815 ([succinic DOX + Na]+), 682.1591 ([succinic DOX + K]+).  
1H NMR (DMSO_d6, ppm) δ: 7.942 (s, 0.99H, Ar-H (H-2) in DOX),  7.739 (m, 1.04H, Ar-H (H-
3) in DOX), 7.441 (s, 0.97H, Ar-H (H-1) in DOX), 5.263 (s, 0.97H, -CH- (H-9) in DOX), 4.896 
(d, 2.08H, -CH2- (H-5) in DOX), 4.566 (m, 1.88H, -CH2OH (H-6) in DOX), 4.195 (s, 0.95H, -CH- 
(H-13) in DOX), 3.922 (s, 3.06H, -OCH3 (H-15) in DOX), 3.575 (s, 1.00H, -CH- (H-12) in DOX), 
2.989 and 2.807 (d, 2.01H, -CH2- in DOX), 2.732 (m, 4.14H, -CH2- (H-17, 18) in succinic linker), 
2.161 and 2.046 (d, 2.02H, -CH2- (H-7) in DOX), 1.859 and 1.647 (d, 1.99H, -CH2- (H-10) in 
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DOX), 1.125 (s, 3.09H, -CH3 (H-14) in DOX).  The sequence of all protons for succinic DOX was 
shown in Figure S1. 
S2.3. Synthesis of acid-labile G3NH2-mPEG-nDOX conjugates 
Direct PEGylation  
S2.3.1. Synthesis of acid-labile G3NH2-nDOX conjugates (n=3) 
Cis-aconityl DOX (23.6 mg, 33.6 µmol), EDC (6.4 mg, 33.5 µmol) and NHS (5.6 mg, 40.2 
µmol) were dissolved in 1 mL anhydrous DMSO and stirred for 1.5 h.  To the mixture, a 2.2 mL 
solution of G3NH2 (22.8 mg, 3.3 µmol) and p-toluenesulfonic acid monohydrate (p-TSA) (5.6 mg, 
29.7 µmol) in anhydrous DMSO were added.  The reaction was stirred for 48 h in darkness.  The 
product was dialyzed against PBS (0.1 M pH 7.4) for 48 h, followed by DI H2O for 24 h.  The 
precipitate was removed by 0.45 µm nylon syringe filter (VWR Internationals) and then 
lyophilized for 48 h.  MALDI-TOF (m/z): 9133.32.  1H NMR (DMSO_d6, ppm) δ: 8.053-7.689 
(m, 57.61H, -NHCO- in G3NH2 and Ar-H (H-2, 3) in DOX), 7.429 (s, 2.95H, Ar-H (H-1) in DOX), 
6.397 (s, 3.10H, -CH=C- (H-16) in aconityl linker), 5.252 (s, 3.12H, -CH- (H-9) in DOX), 4.896 
(d, 3.19H, -CH- (H-5) in DOX), 4.560 (m, 5.82H, -CH2OH (H-6) in DOX), 4.175 (s, 2.85H, -CH- 
(H-13) in DOX), 3.938 (s, 9.88H, -OCH3 (H-15) in DOX), 3.054 (m, 128.66H, -CH2- in G3NH2), 
2.620 (m, 119.14H, -CH2- in G3NH2), 2.380 (m, 52.09H, -CH2- in G3NH2), 2.181 (m, 120H, -
CH2- in G3NH2), 1.647 (d, 5.66H, -CH2- (H-10) in DOX), 1.126 (s, 9.69H, -CH3 (H-14) in DOX).  
S2.3.2. Synthesis of acid non-labile G3NH2-nDOXNL conjugates (n=3)  
The synthesis and purification of G3NH2-3DOXNL was similar as to that for G3NH2-
3DOX.  MALDI-TOF (m/z):  8914.62.  1H NMR (DMSO_d6, ppm) δ: 8.119-7.653 (m, 60.34H, 
-NHCO- in G3NH2 and Ar-H (H-2, 3) in DOX), 7.437 (s, 2.91H, Ar-H (H-1) in DOX), 5.249 (s, 
3.38H, -CH- (H-9) in DOX), 4.902 (d, 3.10H, -CH- (H-5) in DOX), 4.560 (m, 6.38H, -CH2OH 
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(H-6) in DOX), 4.173 (s, 3.12H, -CH- (H-13) in DOX), 3.968 (s, 10.63H, -OCH3 (H-15) in DOX), 
3.078 (m, 114.72H,  -CH2- in G3NH2), 2.673 (m, 101.63H, -CH2- in succinic linker (H-17, 18) 
and -CH2- in G3NH2), 2.430 (m, 57.37H, -CH2- in G3NH2), 2.183 (m, 120H, -CH2- in G3NH2), 
1.653 (d, 6.16H, -CH2- (H-10) in DOX), 1.123 (s, 10.14H, -CH3 in DOX). 
S2.3.3. Synthesis of acid-labile G3NH2-mPEG-3DOX and acid non-labile G3NH2-mPEG-
3DOXNL conjugates (m=9 or 21)  
The G3NH2-mPEG-3DOX and G3NH2-mPEG-3DOXNL conjugates were synthesized in 
the same way.  G3NH2-21PEG-3DOX: a 0.3 mL anhydrous p-dioxane of PEG1K-SE (35.5 mg, 
33.0 µmol) was added to G3NH2-3DOX (5.2 mg, 0.58 µmol) which was in 2.0 mL PBS (0.1 M, 
pH 8.6).  The reaction was stirred at 4 °C for 1 h and at room temperature for another 5 h.  MALDI-
TOF (m/z): 31219.72.  1H NMR (DMSO_d6, ppm) δ: 8.053-7.689 (m, 57.61H, -NHCO- in G3NH2 
and Ar-H (H-2, 3) in DOX), 7.429 (s, 3.19H, Ar-H (H-1) in DOX), 6.393 (s, 2.93H, -CH=C- (H-
16) in aconityl linker), 5.252 (s, 3.32H, -CH- (H-9) in DOX), 4.896 (d, 3.07H, -CH- (H-5) in DOX), 
4.560 (m, 6.27H, -CH2OH (H-6) in DOX), 3.996 (m, 52.82H, -OCCH2O- in PEG and -OCH3 (H-
15) in DOX), 3.431 (m, 1587.3H, -OCH2CH2- in PEG and -CH- (H-12) in DOX), 3.215 (s, 64.49H, 
-OCH3 in PEG), 3.054 (m, 128.66H, -CH2- (H-4) in DOX and -CH2- in G3NH2), 2.667 (m, 
119.14H, -CH2- in G3NH2), 2.410 (m, 52.09H, -CH2- in G3NH2), 2.181 (m, 120H, -CH2- in 
G3NH2), 1.659 (d, 4.95H, -CH2- (H-10) in DOX), 1.123 (s, 9.33H, -CH3 (H-14) in DOX). 
Two-step PEGylation 
S2.3.4. PEGylation of G3NH2 (G3NH2-xPEG) (x = 7) 
A 0.5 mL anhydrous p-dioxane of PEG1K-SE (65.7 mg, 56.7 µmol) was added dropwise 
to a 5 mL PBS (0.1 M, pH 8.6) of G3NH2 (48.8 mg, 7.1 µmol).  The reaction was stirred at 4 °C 
for 1 h and then at room temperature for another 5 h.  The product was purified by dialysis against 
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DI H2O for 48 h, and then lyophilized for 48 h.  MALDI-TOF (m/z): 13979.13.  1H NMR 
(DMSO_d6, ppm) δ: 8.047-7.769 (m, 52.86H, -NHCO- in G3NH2), 4.025 (m, 14.29H, -OCCH2O- 
in PEG), 3.461 (m, 714.9H, -OCH2CH2- in PEG), 3.215 (s, 21.09H, -OCH3 in PEG), 3.057 (m, 
112.43H, -CH2- in G3NH2), 2.676 (m, 100.17H, -CH2- in G3NH2), 2.419 (m, 47.23H, -CH2- in 
G3NH2), 2.181 (m, 120H, -CH2- in G3NH2). 
S2.3.5. Synthesis of G3NH2-xPEG-nDOX (x = 7, n = 7) 
Cis-aconityl DOX (17.9 mg, 22.0 µmol), EDC (5.1 mg, 26.4 µmol) and NHS (3.1 mg, 26.4 
µmol) were reacted in 1.0 mL anhydrous DMSO at room temperature for 1.5 h.  To the cis-aconityl 
DOX solution was added a 5 mL solution of G3NH2-7PEG (20.5 mg, 1.7 µmol) in anhydrous 
DMSO.  The reaction was stirred for 48 h at room temperature.  The product was dialyzed against 
DI H2O for 48 h and then lyophilized for 48 h.  MALDI-TOF (m/z): 18705.66. 
S2.3.6. Synthesis of G3NH2-mPEG-nDOX (m = 21, n = 7)     
A 0.6 mL anhydrous p-dioxane solution of PEG1K-SE (57.4 mg, 49.6 µmol) was added 
dropwise to a 7.0 mL PBS (pH 8.6, 0.1 M) of G3NH2-7PEG-7DOX (22.6 mg, 1.2 µmol).  The 
reaction was stirred at 4 °C for 1 h and room temperature for another 5 h.  The product was purified 
by dialysis against DI H2O for 48 h and then lyophilized for 48 h.  MALDI-TOF (m/z): 33844.20.  
1H NMR (DMSO_d6, ppm) δ: 8.130-7.811 (m, 67.26H, -NHCO- in G3NH2 and Ar-H (H-2, 3) in 
DOX), 7.421 (s, 7.07H, Ar-H (H-1) in DOX), 6.399 (s, 6.4H, -CH=C- (H-16) in aconityl linker), 
5.284 (m, 6.99H, -CH- (H-9) in DOX), 4.896 (d, 6.19H, -CH- (H-5) in DOX), 4.547 (m, 15.82H, 
-CH2OH (H-6) in DOX), 4.033 (m, 68.92H, -OCCH2O- in PEG and -OCH3 (H-15) in DOX), 3.453 
(m, 1928.8H, -OCH2CH2- in PEG and -CH- (H-12) in DOX), 3.214 (s, 65.37H, -OCH3 in PEG), 
3.068 (m, 135.78H, -CH2- (H-4) in DOX and -CH2- in G3NH2), 2.658 (m, 76.09H, -CH2- in 
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G3NH2), 2.424 (m, 59.28H, -CH2- in G3NH2), 2.182 (m, 120H, -CH2- in G3NH2), 1.659 (d, 
11.96H, -CH2- (H-10) in DOX), 1.118 (m, 21.26H, -CH3 (H-14) in DOX).  
Table S1. IC50 (µM) of free DOX and acid-labile G3NH2-mPEG-nDOX conjugates calculated 
from Figure 3 (c) and (d). The cell viability profiles were fitted with a non-linear regression 
Log(Inhibitor) vs Response (variable slope). 
Conjugates 72 h  144 h 
DOX 0.52  0.45 
G3NH2-3DOX 21.80  1.41 
G3NH2-9PEG-3DOX 29.94  1.73 
G3NH2-21PEG-3DOX 48.53  2.38 
G3NH2-21PEG-7DOX 56.95  2.91 
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Table S2. Aerosol mass deposition (µg) of the pMDI formulation containing G3NH2-mPEG-
nDOX on stages of Andersen Cascade Impactor (ACI).  The results was represented with mean±s.d. 
(n=3).  AC, IP, 0-7, and F denote actuator, induction port, stage 0-7 and filter, respectively. 
Stage G3NH2-3DOX G3NH2-9PEG-3DOX G3NH2-21PEG-3DOX G3NH2-21PEG-7DOX 
AC 65.7 ± 22.3 92.1 ± 26.9 155.1 ± 17.4 163.3 ± 25.6 
IP 389.1 ± 45.6 909.9 ± 58.0 368.4 ± 28.7 185.6 ± 7.9 
0 61.6 ± 29.2 26.8 ± 9.9 31.9 ± 9.0 11.3 ± 6.6 
1 23.6 ± 14.7 26.2 ± 17.4 27.1 ± 9.0 20.6 ± 1.2 
2 19.3 ± 8.2 26.4 ± 4.6 19.6 ± 18.1 34.3 ± 5.2 
3 16.5 ± 6.5 20.4 ± 13.5 18.1 ± 25.1 10.3 ± 10.8 
4 14.9 ± 14.7 76.6 ± 37.5 129.3 ± 7.6 76.3 ± 6.9 
5 16.7 ± 8.2 120.0 ± 25.1 939.8 ± 115.3 494.8 ± 57.5 
6 16.3 ± 13.2 96.3 ± 12.9 689.8 ± 91.9 317.4 ± 28.8 
7 19.5 ± 14.0 84.8 ± 10.6 508.2 ± 39.9 100.3 ± 12.1 
F 24.1 ± 22.9 41.1 ± 4.8 201.3 ± 72.4 13.7 ± 8.2 
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APPENDIX C 
SUPPLEMENTAL INFORMATION OF CHAPTER 5 
S1. Characterization 
S1.1 Mass-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-
TOF) 
MALDI-TOF mass spectra were performed on a Bruker UltrafleXtreme mass spectrometer 
equipped with a pulsed nitrogen laser (337 nm) under positive ion reflector mode. The conjugates 
were dissolved in deionized water at a concentration of 1.0 mg/mL.  2, 5-DHB in methanol (10 
mg/mL) was used as matrix.  10 μL of conjugate solution was mixed with equal volume of 2, 5-
DHB solution and 2 μL of the mixed solution was spotted on a Bruker Daltonics MALDI plate.  
The spotted sample was dried gently by air flow.  
S1.2 Proton magnetic nuclear resonance (1H NMR) 
1H NMR spectra were recorded on a Mercury 400 (400 MHz) spectrometer using 
deuterated DMSO (DMSO_d6).  Proton chemical shifts were reported in ppm (δ) and DMSO_d6 
at 2.48 ppm was set as reference peak.  
S1.3 Light scattering (LS) 
Sample (1.0 mg/mL) was dissolved in phosphate buffer saline (PBS, pH 7.4).  pH test 
indicated all sample solutions were neutral.  Hydrodynamic diameters and zeta potentials were 
measured using Zetasizer Nano ZS.  The average and standard deviation for hydrodynamic 
diameters and zeta potentials were calculated based on at least three measurements.  
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Lung cancers are leading cause of cancer death for both men and women in the world.   Lungs 
are also one of the primary organs to which almost all cancer can spread.  Chemothepray plays a 
crucial role in the fight against both primary lung cancers and lung metastases.  Doxorubicin (DOX) 
is a potent anticancer drug that has been approved for treating many cancers including lung cancers.  
However, only a few percent of systemically administered DOX can be found in the lungs.  The 
issue is further complicated by dose-limiting toxicity of DOX.  Another major challenge in the use 
of DOX is its cardiac toxicity.  Free DOX in bloodstream can accumulate in cardiac tissues, thus 
leading to fatal heart damages.  On the other hand, the lungs are considered as a portal to external 
environment and suitable for local delivery.  Additionally, oral inhalation (OI) has long been 
accepted as the preferred mode of administration of therapeutics to the lungs.  To address these 
discussed challenges, we used a strategy — polymeric nanocarriers (PNCs) to achieve the spatial 
and temporal drug release and local delivery of drug to the lungs.  In this work, we desgined 
polyamidoamine dendrimer (PAMAM) conjugates which can only release DOX intracellularly, 
while being stable in physiological environment.  We observed the PAMAM-DOX conjugates 
upon local delivery to the lungs can significantly inhibit tumor growth both in vitro and in vivo.  
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We also successfully prepared the PAMAP-DOX conjugates into propellant-based aerosol 
formulations which is conducive to deep lung areas.  To our knowledge, it is for the first time that 
polymeric nanocarrier-based drug delivery system has been formulated into propellant-based 
aerosol formulations.
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